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Abstract 
Financial toxicity (FT) is the impact that out of pocket (OOP) costs of cancer care have 
on patients’ well-being, leading to lower quality of life, less compliance with prescribed 
therapy, and poorer outcomes, including increased mortality. The purpose of this study 
was to understand the impact of FT on advanced cancer patients’ lives and their health 
care decision-making. Fuzzy trace theory provided the framework for examining how 
patients use gist and verbatim when making health care decisions while experiencing FT. 
Gist refers to main ideas that are often infused with emotional overlays that people use to 
make risky decisions, while verbatim thinking involves the recall of precise facts and 
figures to make decisions. The research method was case study that included conducting 
13 in-depth interviews, collecting artifacts, and scoring of FT using the Comprehensive 
Score for Financial Toxicity tool. Findings from two-cycle coding and cross-case analysis 
indicated that FT and OOP costs have significant impacts on patients’ lives and how they 
make decisions about their cancer care. Participants considered cost as a risk in cancer 
treatment decisions and encoded this information using verbatim rather than gist, which 
they used for other dimension of risk in these decisions. Participants reported they would 
decline care if OOP costs were high and FT was present. When OOP costs were low, 
participants relied on gist decision-making and generally followed their physicians’ 
recommendations. Findings may assist cancer experts who are investigating FT and its 
impact on cancer care as well as those who are developing support programs for patients 
who experience FT. 
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Chapter 1: Introduction to the Study  
Cancer is one of the most impactful diseases in the United States; it is the cause of 
one in four deaths, with 609,640 expected cancer-related deaths in 2018 (Siegel, Miller, 
& Jemal, 2018). There are now 14.5 million Americans living with cancer (NCI, 2016a). 
Since President Nixon declared war on cancer in 1971, the United States invested in 
prevention, detection, and treatments in an attempt to reduce deaths and morbidity 
associated with the disease (Drake, 2011). Although billions of dollars were invested in 
research and treatment, advances in cures have not been forthcoming. Cancer continues 
to cause mortality with men, women, and children in the United States and globally each 
year. The impact of this disease is far reaching, with nearly 40% of Americans having a 
cancer diagnosis at some point in their lives (NCI, 2016b).  
Although cancer research produced some advances, the cure that many hoped 
would come from the 40-year war on cancer has yet to be achieved; cancer has proven to 
be a strong foe (Drake, 2011). Nevertheless, cancer patients are surviving longer with the 
disease (NCI, 2016c; Siegel et al., 2018) due to advances in early detection 
methodologies, surgical options, radiation, chemotherapy, and advanced biologic 
treatments (Masters et al., 2015). Overall mortality rates have improved 20% compared 
to the rate in 1991 (Masters et al., 2015). Mass screenings for colon, breast, cervical, and 
prostate cancer yielded improved survival results (NCI, 2016c). Early detection means 
that treatment options can include surgery or less invasive options, and newer therapeutic 
options give some metastatic patients extended survival (Masters et al.,2015; Seiden, 
2016). For example, new infused immunotherapy options offer remarkable new survival 
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benefits to metastatic cancer patients where previously few efficacious options existed 
(Seiden, 2016). Therapeutic options have expanded, but not all patients are equally 
benefiting from the scientific advances (IOM, 2009; NIH, 2007;  Siegel, Ward, Brawley, 
& Jemal, 2011). These advances in care and technology come at a price; research in 
cancer and the delivery of cancer care is expensive, and not all access the benefits (Goss, 
Lopez, Brown, Wollins, Brawley, & Raghavan, 2009). Moreover, cancer patients are 
increasingly bearing a larger share of costs (Balfe et al., 2016; Chang et al., 2004). 
There is a growing body of literature addressing the impact of the costs of care 
that cancer patients bear for their treatment and the resultant financial distress that it 
causes. A new term, financial toxicity (FT), emerged to describe the financial and 
emotional distress that the direct out of pocket (OOP) costs of cancer care have on 
patients. Despite this, few researchers have addressed the patient perspective of how FT 
is impacting patients and their decision-making processes about treatments and cancer. 
This qualitative case study provided a perspective on how advanced cancer patients 
experienced FT and making decisions about cancer care.  
The findings from this study may contribute to a deeper understanding of how 
patients seek to incorporate costs and financial responsibilities into their decision-
making, and how these costs can become a source of distress and can create access 
barriers. Health care providers can use this information to be more responsive to signs of 
FT and to have support resources available to assist patients before FT becomes severe. 
Researchers may benefit from the current study findings to identify additional ways to 
incorporate the patient perspective into treatment decisions and decision support tools.  
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In Chapter 1, I describe the problem of FT and how it may impact decision-
making in advanced cancer patients, the purpose of the research, and the research 
questions addressed in the study. I outline the theoretical basis for the inquiry and 
describe how the theory may be applied to decision-making in patients experiencing FT. I 
also provide an overview of the study’s scope, methodology, assumptions, and 
delimitations. Finally, I address the importance of the study to social change and provide 
a transition to Chapter 2. 
Background of the Study 
 With over 14.5 million Americans living with cancer (NCI, 2016b) and 
approximately 50% of Medicare beneficiaries spending at least 10% of their income on 
OOP costs of cancer care (Davidoff et al., 2013), patients’  costs of cancer are a growing 
challenge. Patients’ OOP cancer care costs are increasing to the point that it is creating a 
new side effect of cancer care called FT (Zafar & Abernethy, 2013a). FT is the mental 
and physical distress that is felt by cancer patients who are coping with both the disease 
and the impact of the OOP costs of the disease treatment (Zafar & Abernethy, 2013a). 
This distress is linked to poorer outcomes, poorer quality of life, and greater risk of 
mortality in cancer patients (Delgado-Guay et al., 2015; Khera, 2014; Ramsey et al., 
2016; Ubel, Abernethy, & Zafar, 2013). Researchers are working to characterize, report, 
and grade this potential side effect of cancer care so that appropriate strategies may be 
developed to combat it (de Souza et al., 2014; Khera, 2014).  
The distress that FT causes is a major source of anxiety and suffering for cancer 
patients and their families and creates greater disparities in cancer outcomes (Carrera, 
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Kantarjian, & Blinder, 2018); the IOM has called for solutions to this issue (IOM, 2009; 
Zafar & Abernethy, 2013b). The issue has emerged as a major topic of debate in 
academic and public health forums, especially with the increased scrutiny that drug costs 
are receiving (Morrison, 2015; IOM, 2009; Ubel et al., 2013). Although drug and other 
medical services costs are increasing, there are associated improvements in length of 
survival for cancer patients. Nevertheless, disparities exist, especially for those who are 
not accessing these advanced care options (Howard et al., 2016). These increased costs 
create an anguishing dilemma for some patients who seek to survive their cancer, but find 
paying for the services to be extremely difficult. In particular, there is a lack of 
understanding of patients’ needs and experiences with FT and how it impacts medical 
decision-making (Zafar, Ubel, Tulsky, & Pollak, 2015). 
As patients progress in cancer care, they are often presented with a bewildering 
series of treatment choices between options that offer a wide variety of outcomes, risks, 
and costs (Reyna, Nelson, Han, & Pignone, 2015a). These decisions are typically made 
with their physician, but must be made without a full understanding of the costs 
associated with the treatment because medical oncologists and radiation oncologists do 
not always know what the exact costs will be for a patient. Costs depend on many factors 
(Peddie et al., 2012; Zafar et al., 2015). Estimating costs for care include factoring in the 
type of insurance; the probable coverage provided by the insurer for the proposed 
treatment; the deductible, and a patient’s coinsurance or copayment requirement 
(Reinhardt, 2013; Sinaiko & Rosenthal, 2011). Although costs of care may be discussed, 
it can be a difficult discussion with many uncertain factors, and satisfaction with 
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decision-making may be eroded when too much uncertainty is introduced into the patient-
physician relationship (Politi, Clark, Ombao, Dizon, & Elwyn, 2011).  
Most patients remain willing to discuss their treatment options and the costs of 
their cancer care with their providers so long as the physician is making therapy 
selections that support their disease treatment plan (Bullock, Hofstatter, Yushak, & Buss, 
2012), but many providers are not eager to discuss difficult social or emotional issues 
(Bestvina et al., 2014). In a recent survey of medical oncologists, 76% either felt it was 
not their responsibility to discuss costs or rarely did so with patients (Altomare et al., 
2016).  
Many cancer patients develop deep trusting relationships with their oncologists 
and have cost discussions with their physicians, particularly when they are experiencing 
distress associated with FT (Abbott, Curley, Hanseman, & Sohn, 2014; Hillen, de Haes, 
& Smets, 2011). These physicians work to develop treatment plans for their patients 
based on the cancer’s response to therapy, sometimes working for years with patients to 
treat and retreat the cancer as it undergoes metastasis and moves throughout the body. 
Some researchers suggested that improving patient and physician cost-related health 
literacy is a key strategy to reduce the impact of FT on cancer patients (Zafar et al., 
2015). This will involve additional research to better understand the patient perspective 
on FT.  
Problem Statement 
Cancer is the second largest killer of Americans, and as the baby boomer 
generation continues to age, epidemiologists expect even greater incidence and 
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prevalence of the disease in the United States (Masters et al., 2015; NIH, 2016). Through 
research and prevention strategies, advances in overall survival have improved, but not 
all people are able to access these benefits (Goss et al., 2009). Although researchers have 
examined many of the factors related to cancer outcome disparities for race and 
socioeconomic status (Freedman et al., 2011; Grubbs et al., 2013; Parise & Caggiano, 
2013; Walker et al., 2014) and the barriers resulting from FT (de Souza & Wong, 2013; 
Delgado-Guay et al., 2015; Ramsey et al., 2016; Zafar et al., 2015), there is a gap in 
knowledge about how patients who are experiencing FT make decisions about their 
cancer care (Abbott et al., 2014; Bullock et al., 2012; Ó Céilleachair et al., 2012; Zafar, 
2016). My study may help to create a better understanding of advanced cancer patients’ 
experiences and medical decision-making while experiencing FT.  
Purpose of the Study 
The purpose of this qualitative case study was to understand the experiences of 
advanced cancer patients who are under financial distress and FT to understand how OOP 
cancer care costs impacted these patients’ experiences and decision-making. The study 
focused on understanding how patients feel and think while experiencing FT and making 
decisions about their care. Knowledge about how FT impacts patients’ experiences and 
decision-making may be used to develop strategies to address the declines in health 
outcomes and decreased quality of life for patients with FT.  
Research Questions 
Several research questions guided this research: 
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1. What was the experience of advanced cancer patients who experienced 
financial distress stemming from OOP costs of the disease treatment? 
2. How did financial toxicity manifest in patients’ lives, and how did patients use 
gist and verbatim as they made medical decisions?  
3. How, if at all, did financial toxicity factor into treatment decisions in patients 
with advanced cancer? 
Theoretical Framework 
I used fuzzy trace theory (FTT), a cognition theory proposed by Reyna and 
Brainerd (1995), as the theoretical basis for exploring advanced cancer patients’ 
experiences and decision-making while experiencing FT and financial distress associated 
with treatment. This theory explains how patients may use mental shortcuts or heuristics 
and gist, which are core mental conceptual representations of an idea or concept, in 
making risky medical decisions (Reyna & Brainerd, 2011). The theory also provides an 
explanation for how the use of cognitive approaches can lead to bias (Reyna & Brainerd, 
2011). Reyna et al. (2015) applied FTT to cancer decision-making and underscored how 
adults develop their reliance on gist-based decision-making. Reyna et al., (2015) use FTT 
to understand how advanced cancer patients create meaning in challenging, risky, and 
stressful decisions. 
Nature of the Study 
The research design was a qualitative case study. A method should fit with the 
researcher’s proposed research questions and subject of inquiry (see Creswell, 2013). A 
case study design was an appropriate choice because it was consistent with gathering the 
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patients’ perspectives and gaining an in-depth understanding of their thoughts, underlying 
considerations in decision-making, and experiences. Case study research creates an deep 
understanding of a person’s or group’s experiences and lives; the case study includes in-
depth observations and understanding of respondents’ perspectives using secondary 
artifacts and data collection means (see Creswell, 2008). I used in-depth interviews 
triangulated with secondary data to answer the research questions.  
To ensure protection for the research respondents and to gain access to an 
appropriate sample of individuals, a researcher must identify a recruitment and access 
strategy and pass the institutional review board (IRB) evaluation and approval process 
(HHS, n.d.). Researchers use these processes to ensure that the study does not harm the 
participants and that their privacy is protected (HHS, n.d.). Researchers cannot contact a 
vulnerable population such as advanced patients without first gaining access to the 
patients either via their health care provider or some other means. Before contacting 
patients, researchers must create an informed consent form that details the key reasons for 
the study, the potential benefits of participation, the potential risks, and the assurances of 
confidentiality (Patton, 2015).  
The size of the sample should be consistent with the method (see Creswell, 2013), 
and interviews should be conducted and data analyzed until a point of saturation or 
consistency is met (see Patton, 2015). I determined that 12 in-depth interviews with 
patients, supplemented with secondary data artifacts, would be a large enough sample to 
answer my research questions. To access potential participants, I approached a 
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community oncology practice in Colorado. Physicians own these practices, and their 
consent and support required a second IRB approval process.  
Definition of Terms 
Advanced cancer: Cancer that has spread from its primary origination site or 
organ to nearby or distant organ sites; treatments generally focus on controlling the 
growth of these cancers and are not curative (NCI, 2015). 
Biological therapy: A large-molecule therapy that is grown in a living cell line in 
a biotechnology production center and is infused to treat a disease (Morrow & Felcone, 
2004). 
Cancer: A collection of associated diseases having unmitigated cellular growth in 
which the cells invade from a tumor site to nearby tissues or distant organs (NCI, 2015). 
Chemotherapy: A form of treatment that may be given as an injection, infusion, or 
oral treatment to destroy targeted cancer cells (NCI, 2015). 
Copayment: A form of cost sharing in a health insurance plan that requires the 
patient to pay a flat dollar amount to the provider who is rendering a service at the time 
the service is given (KFF, 2016). 
Cost: Resources or dollars spent directly or indirectly to attain a good or service 
(NIH, 2007). 
Deductible: The dollar amount of covered services that a consumer must pay 
before the insurance will begin to pay for covered services (KFF, 2016). 
Direct cost: Resources spent for the prevention or provision of health care 
services (NIH, 2007). 
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Disparities: Inequalities that result when one group does not enjoy the equivalent 
health benefits or health status as another group (NIH, 2007). 
Financial toxicity (FT): The financial burden caused by OOP costs and the 
financial distress that it can cause patients and their families. FT is associated with lower 
adherence to therapy, poorer quality of life, and potentially worse health outcomes, 
including lower survival (Zafar & Abernethy, 2013a). 
Gist: The mental process of organizing facts and concepts into a simplified and 
core set of mental representations (Reyna & Brainerd, 1995). 
Health literacy: An ability to read, assess, interpret, and understand health-related 
concepts and constructs so a person can function in a health care environment as a patient 
(Morris et al., 2013).  
Infused therapy: A drug or biologic treatment that is provided to a patient via a 
venous port or needle, typically delivered slowly over a period of an hour or more and 
may be administered in an outpatient setting (NCI, 2015). 
Medicaid insurance: A state and federal jointly run health insurance program for 
low-income Americans (Shi & Singh, 2011). 
Medicare insurance: A federal governmental insurance program for Americans 
age 65 and older or those qualifying via disability (Shi & Singh, 2011). 
Metastatic cancer: A cancer that has spread from its original site to nearby tissues 
or distant organs. This can also be referred to as advanced cancer (NCI, 2015). 
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Out of pocket costs (OOP): Direct costs borne by a patient for the provision of 
health care services and are not covered by insurance (Gordon, Merollini, Lowe, & Chan, 
2016). 
Patient Assistance Program (PAP): A program to provide free drug supply to 
uninsured or underinsured individuals as part of a pharmaceutical company’s 
philanthropic effort to improve access to their products (Fein, 2017; Zafar & Peppercorn, 
2017a). 
Quality of life: A measure of several dimensions of well-being and health 
including emotional, psychological, and physical measures (NIH, 2007). 
Radiation therapy: A form of treatment in which high energy beams of radiation 
are targeted and delivered to destroy cancer tumors (NCI, 2015)  
Tumor stage: The categorization of the size, extent, and presence or lack of 
presence of metastasis of the initial cancer tumor at diagnosis. A cancer is staged at initial 
diagnosis, and even if it worsens or improves, the tumor staging categorization does not 
change (NCI, 2015). 
Assumptions 
There were several assumptions that I acknowledged prior to the beginning of this 
study. First, I assumed that advanced cancer patients who are undergoing treatments for 
their cancer want to access care that extends their survival while balancing the risks and 
adverse effects of that care. I also assumed that patients can self-identify the distress that 
FT causes them and can describe what they consider when making medical decisions. 
Finally, I considered that patients may be reluctant to participate in the research if they 
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believe that discussing financial concerns, limitations, or FT could make their physician 
less likely to treat their cancer or impact the care that they receive in any way.  
Scope 
The scope of this study was advanced cancer patients’ experiences, perceptions, 
and decision-making about cancer treatments while experiencing FT. The study provided 
perspective from patients, an area of research where there were little data. Researchers 
and cancer care providers may be better able to develop strategies and support programs 
to address the specialized needs that patients with FT have if providers have more 
understanding of the patient perspective.  
Delimitations 
I chose to delimit the research with advanced cancer patients from several 
dimensions. First, I included only adults older than 18 years because children may not 
have similar experiences with financial responsibility or FT. I explored the patient 
experiences in decision-making and living with FT and cancer, but I did not seek to 
demonstrate health outcomes associated with FT or measure the clinical impact of 
adherence to prescribed therapy. These may be important dimensions for additional 
research, but this study was not designed to address these outcomes.  
An important delimitation was the setting for the study. I recruited and 
interviewed cancer patients who were receiving care in a community-based ambulatory 
setting, not those receiving care in a hospital. Although several of the patients were 
unwell during the interview, they were not critically ill or impaired to the extent that their 
communication and conversation was impeded. The research was also limited to cancer 
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patients with some form of health insurance who were experiencing FT. This was a 
subpopulation of people for whom there is a paucity of published research relating to 
their experiences with FT. 
Limitations 
There were several limitations that stemmed from the qualitative case study 
method and from me. First, the research method included in-depth interviews during 
which I asked patients to describe their thinking, decision-making processes, and 
experiences after the fact. This may have introduced bias as the patient sought to recall 
the previous situation and thought processes and articulate them for me. What the patient 
felt and thought at the time may have been altered by the time that elapsed or by 
additional experiences that influenced how the patient recalled and described a particular 
decision or experience (see Patton, 2015).  
I was an important part of the research because it was my job to develop trust 
during the interview with the patient, synthesize the findings, interpret them, and report 
on them as objectively as possible (see Janesick, 2011). I did not have first-hand 
experience as a cancer patient, so I may have misinterpreted the participants’ meaning 
and may have inadvertently added my own bias. To guard against this, I identified my 
biases as best I could, and during the research and analysis phases I attempted to insulate 
the work from my biases. Another limitation of the study was that findings are not 
generalizable to the entire population of advanced cancer patients with FT. The sample 
size was small and limited to cancer patients who were well enough to have ambulatory 
care and who had health insurance. 
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Cancer is a collection of many subforms of the disease, and the treatment 
experience, costs, side effects, and intensity of care varies widely between the many types 
of cancer. This study included cancer patients with different forms of the disease such as 
breast, colon, prostate, or lung, and this variety impacted the patient experiences and 
costs. Moreover, the variety of cancer types led to a variety of experiences and decision-
making criteria that could have complicated interpretation of the data and achieving 
saturation of data.  
Significance 
This study focused on understanding patients’ perceptions and decision-making 
while experiencing FT, a phenomenon that is increasing in scale and scope for cancer 
patients (Zafar, 2016). FT erodes a patient’s access care and it decreases his or her quality 
of life (Barber, Bensen, Snavely, Gehrig, & Doll, 2016; Delgado-Guay et al., 2015). To 
eliminate barriers to care and decrease disparities in cancer outcomes, access to standard 
services and support of a patient’s psycho-social needs for decision-making must be 
considered.  
Using FTT, I sought to understand how gist and verbatim are intertwined in 
decision-making for patients with FT, and the ways in which health care providers and 
health care systems may better support patients and reduce barriers to care and improve 
quality of life. The knowledge gained from this study may help policymakers and health 
care administrators understand patient reactions and decisions to improve access to care 
and to support quality medical decision-making.  
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Summary 
Although tremendous advances in cancer care have extended lives and improved 
outcomes, FT has emerged as a major challenge to care provision in the United States 
(Carrera et al., 2018; Head, Harris, Kayser, Martin, & Smith, 2018). There are over 14.5 
million cancer patients in the United States (NCI, 2016b), and despite access to insurance 
through both governmental and private sources, the costs of cancer care to individuals is 
increasing so substantially that is the leading cause of medical bankruptcy (Ramsey et al., 
2013) and increased mortality (Ramsey et al., 2016). A major priority of the IOM and 
other major professional societies is to reduce the impact of FT and the disparities in 
outcomes that it produces (IOM, 2009; Meropol, 2009). Research on this challenge and 
the physician perspective is available, but there is little known about how patients 
experience FT and make decisions about their care while under duress. I sought to 
understand the advanced cancer patient perspective and decision-making while 
experiencing FT.  
In Chapter 1, I provided a summary of the challenges in cancer care, including 
how FT is contributing to access and disparities in care and outcomes. I addressed the 
theoretical basis for the inquiry and outlined the methodology, constraints, and 
assumptions of the study in Chapter 1. In Chapter 2, I review the current literature on FT 
and define the need for the study. Chapter 3 presents a detailed overview of the 
methodology used to conduct the fieldwork, analyze the data, and support conclusions 
from the study to answer the research questions. Chapter 4 provides an in-depth 
discussion of the research findings, and Chapter 5 provides analysis, interpretation, and 
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conclusions from the research. Further, I recommend additional research that may flow 
from the study conclusions, and provide insights into the implications for social change.  
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Chapter 2: Literature Review 
Metastatic cancer patients have to battle the disease from at least two 
perspectives. First, they must physically and emotionally fight cancer, and second they 
must cope with paying for their OOP costs of care created by treatment. Both of these 
battles create mental distress (Delgado-Guay et al., 2015). Therapeutic approaches and 
early diagnosis are improving cancer patients’ chances of survival, but there are 
significant costs associated with treatment and care (CDC, 2010). New therapies are 
extending patients’ lives: FT is an unintended consequence of these therapy advances 
(Meropol et al., 2009; Meropol & Schulman, 2007; Tangka et al., 2010; Zafar & 
Abernethy, 2013a). FT is a term that researchers define as the strain and distress borne by 
cancer patients as a result of coping with perceived high OOP costs for therapy and loss 
of income resulting from reduced participation in the workforce (Ubel et al., 2013; Zafar 
et al., 2013; Zajacova, Dowd, Schoeni, & Wallace, 2015). The impact of FT is significant 
and extends beyond the mental health and financial aspects of the disease (Carrera et al., 
2018; Chatterjee et al., 2017; Head et al., 2018).  
Cancer Costs Can Reduce Access for Patients 
The costs of cancer care can be high, and cost sharing for the consumer is 
significant in many insurance plans, resulting in many patients, both insured and 
uninsured, being unable to afford the costs for cancer care (Jagsi et al., 2014; Zafar et al., 
2015). New infused biologic therapies can cost over $150,000 per year, in addition to the 
costs of diagnostic testing and imaging, radiation therapy, doctor visits, and hospital care 
(Newcomer, 2012; Seiden, 2016; Staton, 2014). The costs of drugs and testing have 
18 
 
increased, and insurance products have changed to shift more costs on the consumer, with 
high deductibles and the requirements for patients to pay coinsurance versus flat copays 
for many medical services (Goldman, Joyce, Lawless, Crown, & Willey, 2006; Lo Sasso, 
Helmchen, & Kaestner, 2010; Wharam, Ross-Degnan, & Rosenthal, 2013). As these 
costs increase, cancer patients are bearing a significant portion of the costs, called OOP, 
which can ultimately reduce their access to services if the patients cannot afford the 
services and elect not to receive them (Himmelstein, Thorne, & Woolhandler, 2011). 
For patients fighting cancer, there are many OOP costs to pay. There is the cost of 
surgeries and hospitalizations, OOP costs for both medical services and prescription 
drugs, coinsurance payments for medical imaging, and radiation treatments. Other 
indirect costs such as loss of income from time away from work, transportation, or child 
care costs also impact patients (Chang et al., 2004; Tsimicalis et al., 2013). A diagnosis 
of cancer typically will reduce a patient’s ability to work, further reducing income and 
the ability to afford the costs of care (Meropol & Schulman, 2007; Zajacova et al., 2015).  
Inflation in the cost of health care services has eroded real income gains for most 
Americans over the last decade, which decreases patients’ ability to afford OOP costs 
(Auerbach & Kellermann, 2011). Additionally, cancer disproportionately affects older 
Americans who generally have more limited incomes after retirement and cannot afford 
extra costs (Davidoff et al., 2013). Although Medicare and Medicare supplemental 
insurance can afford these patients with more protection from OOP costs, cancer patients 
are bearing more costs than patients with other diseases. As a result more of these 
patients are falling into medical debt, which can lead to bankruptcy, loss of homes, and 
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severe distress, all of which can limit the ability to have the social and physical support 
necessary to fight a difficult disease (Davidoff et al., 2013; Himmelstein et al., 2011; 
Ramsey et al., 2013). 
For many cancer patients, insurance no longer holds the protective effect it had a 
decade ago; the OOP costs of cancer care are resulting in FT for patients (Zafar & 
Abernethy, 2013a). FT is the mental and physical distress that is felt by cancer patients 
who are coping with both the disease and the impact of the OOP costs of the disease 
treatment. Factors such as race, low socioeconomic status, and the ability to afford care 
(even with insurance) are linked to poorer outcomes, worse quality of life, and greater 
risk of mortality in cancer patients (Delgado-Guay et al., 2015; Khera, 2014; Ramsey et 
al., 2016; Ubel et al., 2013). Researchers are working to characterize, report, and grade 
the factors that are creating disparities in cancer care so that appropriate strategies may be 
developed to combat them (de Souza et al., 2014; Khera, 2014). A cancer diagnosis is 
one of the leading factors in predicting medical bankruptcy (Ramsey et al., 2013). New 
data published by Ramsey et al. (2016) indicated that cancer patients who experience 
severe FT resulting in bankruptcy have significantly higher mortality rates than those 
who are more protected from costs, after controlling for potentially confounding factors 
such as age, gender, race, severity of disease at diagnosis, and tumor type. FT can worsen 
a patient’s likelihood to survive cancer. 
Sometimes there is help available to patients who have large OOP costs to pay for 
care and who, despite their insurance coverage, cannot afford care. This assistance comes 
from foundations that provide financial grants to qualified individuals (Rajurkar, Presant, 
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Bosserman, & McNatt, 2011; Zafar & Peppercorn, 2017a; Zullig, Wolf, Vlastelica, 
Shankaran, & Zafar, 2017). Patients also may qualify for free drugs or reduced copays 
via patient assistance programs or copay card programs. Although these programs can be 
extremely helpful for some patients, not all who need help will qualify, and many 
programs exclude federally funded Medicare and Medicaid patients due to anti-kickback 
legislation (Nicolla, Friedman, Manners, & Zafar, 2017; Zafar, Peppercorn, Asabere, & 
Bastian, 2017; Zafar & Peppercorn, 2017b).  
The emotional strain and distress of FT can be severe; Delgado-Guay et al. (2015) 
found that 30% of advanced cancer patients rated the financial stress resulting from their 
disease as worse than the physical symptoms, the emotional distress, and the family 
distress. FT can cause deep emotional anguish for cancer patients and their families. 
Although researchers are beginning to understand the depth of the problem for patients, 
little is known about how patients make decisions while under stress from FT. 
Use of Decision-Making Theory in Cancer Decisions 
Reyna, Nelson, Han, and Pignone (2015) used FTT to explain how cancer patients 
made decisions involving complex treatment options. This work included important 
dimensions of regime safety and efficacy and gave a solid perspective on how patients 
apply gist and other recall mechanisms in this decision-making. Gist is defined as the 
individual’s ability to distill a complex concept into an essential qualitative conceptual 
block of information that may be ordered into hierarchical frames of reference for 
decision-making (Reyna & Brainerd, 1995). No researchers have explored how a third 
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dimension of decision-making, OOP costs and the financial distress that these cause, can 
influence how patients make decisions. 
My study focused on understanding advanced cancer patients’ medical decision-
making while experiencing FT. I applied FTT as a theoretical construct. In addition, I 
examined how cancer treatment impacted patients’ financial stability and the extent to 
which OOP costs have contributed to distress in their lives. In Chapter 2, I provide a 
review of the literature on FT and the decision-making theory, FTT.  
Purpose of the Research 
The purpose of the study was to understand the experiences of advanced cancer 
patients who are under financial stress and to understand how cancer care costs impacted 
patients’ experiences and decisions. FT is a growing area of oncology research; however, 
most of the literature published to date addressed the size and scope of FT (de Souza et 
al., 2014; de Souza & Wong, 2013; Delgado-Guay et al., 2015; Jagsi et al., 2014; Khera, 
2014; Zafar et al., 2013). These researchers used a quantitative methodology to examine 
patient expenditures and measure associated distress experienced by patients. Few 
researchers studied patient experiences, decision-making, and thought processes of 
patients under financial duress in the United States. These experiences and the decisions 
that patients make during times of stress impact not only the patient’s cancer journey, but 
also the costs that the family bears. 
Literature Search Strategy 
The literature on FT and OOP costs in cancer is still emerging. Zafar and 
Abernethy (2013a) coined the phrase, financial toxicity, and they detailed the complex 
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emotional and physical distress that FT caused. They stated that the distress caused by 
OOP costs in cancer care was so great that it deserved to be named and managed as 
aggressively as the other major adverse events or toxicities of cancer treatment (Zafar & 
Abernethy, 2013a). Other researchers examined the cost borne by patients, including loss 
of income and total costs of care including ancillary costs, but these researchers did not 
link these to financial toxicity. Some of these studies included focused subpopulations 
such as patients with colon cancer, breast cancer, renal cell carcinoma, and other tumors. 
The search terms that I used for this study focused on the foundational literature on costs 
of care, total costs, and the economic impact of cancer on patients and families. The 
search also included the terms financial distress and financial toxicity. I combined these 
search terms with cancer, metastatic, and oncology, and I included searches for medical 
bankruptcy and cancer. I attempted to limit all searches to articles published in 2010 or 
later.  
I also searched for journal articles that included a qualitative methodology to 
investigate patient’s experiences with costs and cancer care. To identify qualitative 
methodologies for investigating FT in cancer, I searched the terms qualitative research 
and cancer costs, case study and cancer costs, cost and case study in cancer, and a 
combination of insurance, cancer, and qualitative study. To identify the relevant 
literature on FTT, I searched FTT and cancer, FTT and gist, decision-making in cancer, 
gist in cancer decisions, and heuristics in patient cancer decisions. 
I used the Google Scholar search engine and Walden University’s databases. I 
also searched industry databases including the American Society of Clinical Oncology 
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(ASCO) publication databases and those of the Kaiser Family Foundation to identify 
additional sources of evidence. These databases were extensive and returned consistent 
literature for the key terms searched. To ensure a complete literature review, I examined 
the reference lists of recently published work and checked key terms that were listed in 
the online versions of articles to see if I had missed any relevant journal articles.  
Theoretical Foundation 
I used FTT to support the investigation. FTT helps researchers explain how two 
decision-making processes (verbatim and gist) work in tandem, and researchers applied it 
to help explain how people make decisions in medical and health related contexts (Reyna 
& Brainerd, 1995; Reyna et al., 2015). Verbatim refers to the precise encoding of 
information such as numbers, risk ratios, or other facts that humans can recall and apply 
in a logical way to sort through a decision (Reyna & Brainerd, 1995). Verbatim is 
generally used when a situation calls for factual precision. Gist is a process in which 
people construct essential concepts and remember these key qualitative features and 
functions of information to use efficiently and logically in decision-making (Reyna & 
Brainerd, 1995). FTT includes the approaches from previous decision-making theory. 
Researchers applied the constructs of why and how people are imperfect decision-makers 
and how decision-makers apply many shortcuts and have weaknesses in information 
processing that may yield inconsistent decisions and less than optimal choices, 
particularly under stress (Reyna et al., 2015). In health care decision-making, researchers 
found that people use heuristics, make inconsistent estimates of risk, and lack training 
and application experience when using numbers, statistics, and numerical relationships to 
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make decisions (Peddie et al., 2012; Peters, McCaul, Stefanek, & Nelson, 2006). These 
factors reduce the effectiveness of decision-making by people (Puts et al., 2015).  
FTT and Cancer Decisions 
When patients with cancer face decisions about their therapy choices and end-of-
life options, these are important decisions that can produce life-changing consequences. 
For example, a breast cancer patient may need to select between options involving 
postsurgical drug therapy, and each option has significant potential adverse effects 
(Zikmund-Fisher, Fagerlin, & Ubel, 2008). These decisions involve trading potential 
high-risk side effects for higher probability of cure, duration of therapy, or period of 
remission (Reyna et al., 2015). Reyna et al. (2015) found that patients making therapy 
choices use gist to recall and process risk information and apply it as a flexible and 
efficient process to evaluate alternatives. The gist of the risk, not the verbatim numerical 
representation of the risk, is how cancer patients encode the options available to them and 
process the information in decision-making. Reyna et al. (2015) also observed other 
factors that could mediate these decisions. Patients often must apply their morals and 
judgment in the situation, making choices that are consistent with their values. In these 
cases, patients’ gist is infused with emotional and moral considerations and is accessed 
by memory and processed efficiently in decision-making (Reyna et al., 2015). The fuzzy 
nature of applying conceptual frameworks is the foundation of the FTT.  
Researchers found that the recommendations by physicians are some of the most 
important influencers in patient decision-making in cancer (Puts et al., 2015). The 
significant influence of physicians in cancer care increases the importance of the patient’s 
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assessment and decision-making based on physician recommendations. Applying FTT to 
the examination of physician recommendations and patient decision-making, researchers 
found that patients will listen and encode or remember key conceptual gist 
representations from their discussions with physicians about treatment options. Rarely are 
verbatim data recalled by patients; instead, patients hold imprecise gist representations of 
their options as presented by their physicians and use these as flexible and simple 
building blocks accessed by their memory and imbued with emotion and moral judgment 
to make choices (Reyna & Brainerd, 1995; Reyna et al., 2015). 
The U.S. Preventive Services Task Force (USPTF) recommendations for breast 
cancer screening list the need to tailor evidence based recommendations to individual 
patient’s situations (USPSTF, 2016). Helping patients to understand their risk, especially 
for those patients with low health literacy or lower understanding of comparative risk 
information, was significant to cancer decision-making and FTT (Reyna et al., 2015). 
Although decision-making in cancer used data and recommendations from trusted 
sources, patients with cancer made decisions that were emotionally charged. For those 
with cancer, there was a high degree of emotion during decision-making. Patients also 
had to make projections of preferred states of emotional well-being. These two elements 
form the decision-making process called dual processing (Reyna & Brainerd, 2011). Dual 
processing decision-making is a way to synthesize the emotional and cognitive aspects of 
how patients approach a decision. FTT uses these decision-making approaches and the 
theory includes moral values and mental shortcuts of verbatim and gist. FTT also 
provides researchers with a way to explain how patients mentally interpret statistics 
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associated with a proposed decision’s risk. Researchers showed that FTT used the two 
processes of decision-making, but extended cognition and emotion by adding the 
elements of gist and verbatim (Reyna & Brainerd, 2011). 
The concepts of gist and verbatim stemmed from research in psychology and 
developmental linguistics (Corbin, Reyna, Weldon, & Brainerd, 2015). Verbatim and gist 
worked together like two ends on a scale. Exact recall, verbatim, is on one end of the 
scale. Gist, a simple, bottom-line, essential meaning of a concept, is on the other end of 
the scale. People remember gist and verbatim in context to a person’s entire experience, 
including culture and emotions. As one develops and gains experience, researchers found 
that gist was important to making risky medical decisions because gist can help one 
discern between various states of risk (Reyna & Brainerd, 2011). When applied to 
complex decision-making such as in selecting between treatment options in cancer, 
decision-makers used gist to give meaning to the options and distill the most important 
elements relative to that individual. These processes occurred in a fuzzy, inexact manner 
as the patient ordered his or her gist representations of the states of risk (Reyna & 
Brainerd, 1995; Reyna et al., 2015) Retrieval and use of gist is a core process that 
patients use in cancer decision-making by applying their essential feelings and choices 
between therapies or actions given their situation. Researcher have also applied FTT to 
cancer decision-making and risk communication strategies (Brewer, Richman, DeFrank, 
Reyna, & Carey, 2012). The researchers studied how patients made decisions when 
presented with complex future risks such as the potential for development of breast 
cancer for those women who carry genetic mutations. In this evaluation, researchers 
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prepared a series of vignettes describing the risk of developing cancer and surveyed 
women who had undergone testing to understand their comprehension of risk (Brewer et 
al., 2012). The study results showed that women rely on gist in applying genetic testing 
results to the likelihood of developing breast cancer. The researchers found that simpler 
graphics depicting risk were better accepted by patients and improved decisions by 
patients (Brewer et al., 2012). This approach fits with the use of fuzzy gist 
representations. It was shown to assist patients with making sound risk-based decisions 
because providing incremental verbatim information to patients was less helpful in 
patients’ decision-making.  
When selecting therapy options, patients with cancer can become overloaded with 
verbatim facts and risk ratios, which reduces the efficacy of decision-making, especially 
when stress and emotions are high (Reyna et al., 2015). When patients use online therapy 
risk decision tools, such as one for selecting adjuvant therapy in breast cancer, Zikmund-
Fisher et al. (2008) found that simplified graphics support use of gist decision-making 
and improved patients’ understanding of the risks. These studies demonstrated the utility 
of gist in helping patients to make therapy decisions in cancer. The use of FTT was also 
established in other medical decision-making processes including vaccination decisions 
and health prevention activities.  
Use of Fuzzy-Trace Theory in My Study of Financial Toxicity 
 The FTT theory fits my study of how FT impacts cancer patients’ decision-
making when there are risk and efficacy options for consideration. Researchers studied 
FTT in a several applications of medical decision-making including cancer and found 
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FTT to be reliable and valid (see Reyna et al., 2015). These studies showed that by 
including verbatim and gist, researchers may better understand how patients made life-
changing decisions. While these researchers have reliable knowledge of the application of 
FTT to cancer patients’ decision-making, none examined how OOP costs and FTT may 
create gist that are not discussed in risk communications but are important to patients in 
their decision-making.  
I applied FTT to evaluate advanced cancer patients’ perspectives with fuzzy gist 
in medical decision-making and how FT impacted these choices.  My study showed how 
FTT can extend to include verbatim costs and how financial costs can be risks that 
patients consider in decision-making. The research may extend knowledge to identify 
how FT may be incorporated into decision support tools. This may help patients who are 
experiencing financial distress to make better decisions while undergoing cancer 
treatment.  
Literature Review Related to Financial Toxicity 
Cancer was a top cause of mortality and a major cause of overall health care 
spending due to the increases in incidence, prevalence, and costs of care in the United 
States (Mariotto, Yabroff, Shao, Feuer, & Brown, 2011). Epidemiologists expect the total 
costs of cancer care to increase by approximately 40%, exceeding $173 billion by 2020. 
Innovative new drugs have higher costs than older chemotherapy (Howard et al., 2016; 
Mailankody & Prasad, 2015). Over the last decade, new biotechnology drugs entered the 
market with higher prices compared to previous periods with the average cancer drug 
costing about $100,000 per year (Mailankody & Prasad, 2015). At the same time, there 
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were advances in radiation technologies and imaging that increased overall costs of 
cancer care (Lievens & Grau, 2012; Nguyen et al., 2011; Patel et al., 2016). Community 
oncology practices began to join the hospitals which increased the cost to deliver the 
same care in communities around the United States (Association of Community Cancer 
Centers, 2013). Drug costs increased; radiation and imaging technology improved, but 
increased costs of radiation treatment and more patients were treated in higher cost 
hospital outpatient settings. These all increased the total cost of care and the OOP cost to 
cancer patients.  
In response to these and other costs, employers and public insurers made changes 
to the design of insurance products, which shifted more of the risk to the individual and 
increased patient cost sharing (Lo Sasso et al., 2010; Samuel, Raleigh, Hower, & 
Schwartz, 2003; Wharam et al., 2013). Physicians and public health advocates voiced a 
new concern about the ability of the cancer patients to afford care and the concept of 
financial distress emerged, particularly in cancer patients (KFF, 2006).  
Cancer Disparities Exist 
In cancer care, there are health outcome disparities and lack of access to 
nationally recognized standards of care. People of color, those of lower socioeconomic 
status and lower health literacy, and those without health insurance consistently have less 
access to cancer standards-of-care, early detection, and, as a result, have poorer survival 
(Freedman et al., 2011; IOM, 2009; Parise & Caggiano, 2013; Walker et al., 2014). 
While cancer is a disease that affects all types of people irrespective of gender, age, race, 
or socio-economic status, there are distinct disparities in cancer outcomes despite efforts 
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to increase access and reduce barriers to screening (Freeman & Rodriguez, 2011; R. 
Siegel et al., 2011). 
Disparities in cancer outcomes stem from many factors including lack of access to 
services (Freeman & Rodriguez, 2011). Other barriers to care stem from language, lower 
health literacy, and cultural barriers to routine health screening services. Those without 
access to routine prevention and screening are more likely to have cancers diagnosed at 
later stages of disease when the disease is more advanced and has spread to other parts of 
the body (Parise & Caggiano, 2013). The treatments for late stage cancer are more 
intensive, invasive, and can have significant health and financial consequences to the 
patient (Freedman et al., 2011; Walker et al., 2014). Researchers have identified the 
complex interplay of factors that increase mortality in cancer; those who more money, 
more education, better insurance, and are white, generally have more favorable outcomes 
that those who are not part of those groups (National Academies Press, 2009; R. Siegel et 
al., 2011; Walker et al., 2014). 
In cancer, lower socioeconomic status and lack of insurance are key factors 
contributing to poorer health outcomes (Bittoni, Wexler, Spees, Clinton, & Taylor, 2015; 
Bleyer, Ulrich, & Martin, 2012). When controlling for other factors including tumor site, 
size, and stage, researchers found that those without insurance and with lower incomes, 
had more mortality and shorter survival. For people who have lower incomes, there is a 
high correlation to having Medicaid insurance. Medicaid insurance is a notoriously low 
paying insurance plan for doctors and hospitals and many providers refuse to accept 
Medicaid (Bittoni et al., 2015; Walker et al., 2014). When few specialists in an area 
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accept the plan, it creates access barriers for patients with Medicaid. Cancer patients with 
private or Medicare insurance have more financial protection because the insurance  
insulates them from some of the OOP costs associated with care and does not require a 
means test to qualify for it (IOM, 2009).  
Cost Can Decrease Compliance to Therapy 
A deeper understanding of financial distress caused by cancer treatment costs led 
researchers to investigate the correlation between costs and treatment compliance and 
outcomes. Researchers began to study the impact of OOP cost on adherence and patient 
concordance with prescribed regimens, in particular,  in patients who were prescribed 
oral therapy treatments requiring daily medication ingestion at home (Eliasson, Clifford, 
Barber, & Marin, 2011; Gebbia, Bellavia, Ferraù, & Valerio, 2012; Hede, 2009; 
Verbrugghe, Verhaeghe, Lauwaert, Beeckman, & Van Hecke, 2013). Investigators found 
that patients did not comply with oral therapy regimens in cancer care and this effect was 
more pronounced amongst older patients and those who experienced side effects 
(Verbrugghe et al., 2013). Hede (2009) found that the costs and complexities of oral 
cancer therapy decreased compliance in cancer patients. Patient cost was cited as a 
contributing factor, but Verbrugghe et al. (2013) and Hede (2009) called for more 
qualitative research to explore why and how patients think about these regimens and their 
decisions to act in concordance with their physicians’ prescriptions for care.  
Relationship Between High OOP Costs and Distress 
As the evidence mounted on the impact of financial distress, researchers began to 
focus their work on quantifying and qualifying the costs that were borne by patients, and 
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to the extent possible, identifying compliance challenges and other accommodations or 
deprivations made by patients and their families. FT can cause severe emotional distress 
and this can lead to poorer outcomes as patients continue therapy and accrue higher debt. 
Delgado-Guay et al. (2015) reported that in a cohort of advanced cancer patients, greater 
than 30% believed that the stress caused by their cancer cost was more severe than other 
disease-related stress including their family’s reactions and distress, their symptoms, and 
their personal emotional reaction associated with the disease. 
Impact of Insurance, Age, and Race on OOP Costs 
There is a correlation between insurance status and the affordability of cancer 
services in specific cancer types and by insurance type. (Weaver, Rowland, Bellizzi, & 
Aziz, 2010). Weaver et al. (2010) found that lack of insurance increased the likelihood of 
patients bearing significantly higher OOP costs. In gastric cancer, for example, patient 
costs exceeded $40,000 over approximately 50 days for first -line therapy and were 
similar for subsequent lines of treatment (Hess et al., 2015). In a cohort of racially diverse 
early stage breast cancer survivors, Jagsi et al. (2014) found that greater than 15% of the 
cancer patients experienced personal financial costs greater than $5,000 and 12% of 
survivors were managing debt four years post-diagnosis. Women of color, Latinas and 
Blacks, were more likely than those who were White to experience a degradation of the 
ability to pay for essentials of life such as rent or food (Jagsi et al., 2014). Younger 
patients who are working full-time and are then diagnosed with cancer experience greater 
distress compared retirees. For younger patients, treatments can interfere significantly 
with patients’ ability to provide income for their family (Gordon et al., 2016). This leads 
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to significant distress and more privation. In a study of Medicare patients with private 
supplemental and Medicaid insurance, more patients with private insurance received 
chemotherapy treatment consistent with national guidelines than those with Medicaid 
supplemental insurance, a lower paying plan (Warren et al., 2015). Because of these 
studies and other large reviews of costs of care and impact on cancer outcomes, 
professional associations formed committees to respond to the challenges that OOP costs 
were creating for patients (Goss et al., 2009).  
In 2009, the ASCO issued a statement focusing on elimination of disparities of 
care within cancer, including reductions in financial barriers for patients (Goss et al., 
2009). The study identified that racial disparities exist that documented poorer outcomes 
for Blacks and Hispanics, but these are exacerbated when the patient is underinsured or 
uninsured. In 2015, ASCO issued a list of diagnostic services and interventions that 
oncologists should avoid to prevent high costs with low clinical utility (Schnipper et al., 
2015). This effort to focus on preventing use of low utility services does not address the 
OOP costs for services that do have utility. Cancer care costs were increasing, patient 
OOP spending for care was mounting, and patients were experiencing financial, 
emotional, and health-related distress. Rather than focus on measuring these costs, some 
health scientists began to study the effect of prolonged exposure to OOP costs and the 
resultant distress. A new concept in cancer care emerged, FT.  
OOP Costs Lead to FT 
FT emerged as an important consideration for oncologists in managing cancer 
patients (Zafar & Abernethy, 2013a). Through the use of quantitative data analysis, 
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industry and professional association studies demonstrated that costs of cancer care are 
increasing and the patient OOP portion are becoming significant.(Mariotto et al., 2011; 
Schnipper et al., 2015; Tangka et al., 2010) In addition, researchers correlated cancer 
costs, FT and decreased mental and physical well-being (de Souza & Wong, 2013; 
Delgado-Guay et al., 2015; Smith, Nicolla, & Zafar, 2014; Timmons, Gooberman-Hill, & 
Sharp, 2013; Tsimicalis et al., 2013). 
The patient voice began to emerge around the experience of living with FT. 
Researchers published on OOP cancer costs and the impact on well-being, financial 
stability and the trade-off between cancer care and essentials of living including home 
mortgage payments, food, clothing, and children’s education cost. Head et al. (2018) 
found that cancer survivors applied a series of coping strategies to adapt to the financial 
consequences of cancer costs. Delgado-Guay et al. (2015) used interviews and self-
reported surveys with cancer patients receiving care in a public hospital and a private for- 
profit hospital to assess both the presence of FT and its associated distress. This mixed 
method research study identified that patients treated in the public hospital were far more 
susceptible to the physical and emotional impacts of FT than those who had insurance 
that enabled them to seek care in a private cancer center. In another study, the 30% of 
cancer survivors who experienced FT had lower quality of life, higher rates of 
depression, and the worry of cancer recurrence was worse for these individuals (Kale & 
Carroll, 2016). While measuring the distress with scales was important, other researchers 
delved into the qualitative aspects of cancer and FT. 
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Ó Céilleachair et al. (2012) researched the impact of FT on newly diagnosed 
colorectal cancer patients in Ireland and found that the emotional impact of the disease to 
be equally stressful as the financial impact. They found that the stress of the cost of the 
disease reduced the cancer patients’ ability to cope well with the disease. Ó Céilleachair 
et al. (2012) concluded that the emotional impact of colorectal cancer and the financial 
impact were intricately intertwined; there is the potential for one to worsen the other. The 
authors concluded that family relationships and support, and a strong self-caring 
approach by the patient, can mitigate the exacerbation of these factors (Ó Céilleachair et 
al., 2012). While this study provided insights into the inter-relationships of financial and 
emotional health in colorectal cancer patients, it did not focus on decision-making around 
privations or other considerations.  
In 2013, de Souza & Wong (2013)(2013) published a review of the reasons for 
the emerging financial burdens that cancer patients were experiencing including higher 
costs for emerging treatments, shifts in insurance products that expose consumers to 
higher cost sharing, and imaging. They defined the term financial distress, financial 
toxicity, and financial burden as the terms that the oncology community used to refer to a 
patient’s experiences when treatment costs consume a high proportion of income (de 
Souza & Wong, 2013). Using other disease states as metrics, de Souza and Wong (2013) 
estimated that if a patient were to spend greater than 20% of their income on OOP costs, 
the patient could be termed as experiencing FT. These authors linked FT to poorer health 
outcomes including skipping drug doses and indicated that a dearth of quantitative 
metrics of FT hindered better understanding of the implications on patients and 
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outcomes. A year later, (de Souza et al., 2014) began to publish early results from the 
development of a validated instrument that would help assess the patient outcomes 
associated with quantitative measures of the costs borne by the patient.  
Evaluation of how care givers, health professionals, and patients were coping with 
FT is important. The amount of OOP dollars and its proportion to total income may be 
less relevant to those with low income or greater financial responsibilities to children and 
family since these patients may experience the same amount of financial OOP cost to be 
far more distressing than others (Timmons et al., 2013). Timmons et al. (2013) used 
semi-structured interviews with oncology social workers and advanced cancer patients in 
Ireland to identify the strategies that these patients used to cope with financial distress 
and to understand how decisions were made about coping with the distress and tradeoffs 
that the families made to afford care. They uncovered that patients made behavioral 
changes to reduce spending and cope with lower income and higher costs while trying to 
protect children from deprivation. The emotional stress and distress reported was a strong 
indicator that despite a public and private insurance system in Ireland, most cancer 
patients are experiencing financial distress in addition to coping with disease. Timmons 
et al. (2013) describe that patients make decisions about reducing costs of care by staying 
home instead of going to the clinic when experiencing side effects from the medication. 
Patients reported delaying treatments until insurance is secured and reducing use of 
beneficial medications due to costs. Each of these causes distress, but patient reported the 
financial distress stemming from increasing costs were not as important to them as taking 
these actions. The development of the COST tool by de Souza et al. (2014) was an 
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important milestone since it marked the first cancer specific measure to assess patient-
self-reported costs and FT. Researchers published studies linking worsening health 
outcomes for cancer patients experiencing FT (Delgado-Guay et al., 2015; Kale & 
Carroll, 2016; Ramsey et al., 2016). Researchers reported that breast cancer patients with 
high deductible plans could be personally liable for $55,000 of costs and that a Medicare 
colorectal cancer patient might have an $8,800 OOP cost for a single course of biotech 
drug therapy (Ubel et al., 2013) Ubel et al. (2013) concluded that physicians should 
consider the potential costs to be borne by a patient to be as important as potential side 
effects when making a therapy selection. They recommended that physicians work to 
intervene early in treatment to mitigate FT to the extent possible.  
Communication between patients and oncologists is one way to potentially 
mitigate some of the impact of FT (Ubel et al., 2013). In 2010, Hofstatter (2010) found 
that there was little information available about cost communication preferences in 
cancer patients with their physicians. The only published study was conducted with 
physicians not patients. Hofstatter (2010) cautioned against using data from other 
diseases because of the uniqueness of cancer, its acuity, high rates of mortality, and high 
costs. He acknowledged a gap in the literature regarding patient preference and decision-
making in cancer with respect to inclusion of the cost dimension.  
Additional research began to emerge on patient preferences on cost 
communication. In a survey of cancer patients, Bullock, Hofstatter, Yushak, and Buss 
(2012) found that 68% of patients wanted to understand the cost of care upfront but fewer 
patients, 59%, wanted their physician to discuss it with them. Also, 55% of patients 
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believed that their physicians should not take cost into consideration of their treatment 
and this number was statically higher in those patients currently under therapy (Bullock, 
et al., 2012). The concept of cost communication between physician and patient is posited 
as one way to mitigate the FT experienced by patients.  
Research demonstrated that patients with FT experience changes in decisions 
about their cancer care and often make choices to skip therapy and make tradeoffs that 
may affect their activities of daily living. Barber, Bensen, Snavely, Gehrig, and Doll 
(2016)  that women diagnosed with gynecologic cancer experienced significant barriers 
to accessing health care services as a result of the patient’s ability to pay for these 
services. In this same study, younger women reported forgoing medicines and other 
services in greater proportion than an older cohort of patients. Cost can impact a patient’s 
daily decisions about remaining consistently compliant to oral chemotherapy or 
undergoing IV drug therapy.  
In a large survey of cancer survivors in the United States, Weaver et al. (2010) 
asked patients to disclose whether they had elected not to have any medical services or to 
discontinued services due to cost concerns. The results demonstrated that compared to 
those without a cancer diagnosis, cancer patients were more likely to not have medical 
care, not to use a recommended prescription, or to delay care (Weaver et al., 2010). 
Younger patients were more likely to undertake these actions than those greater than 65 
years of age. 
While some researchers have published insights into patients’ actions and 
behaviors while experiencing FT, few have explored the decision-making and thinking 
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that patients use while under FT distress. This is an important gap in knowledge because t 
it is difficult to build strategies and implement support programs without the knowledge. 
Applying FTT to the complex problem of FT will be helpful. It will improve the 
understanding of decision-making processes among those most impacted by FT, the 
cancer patients. 
Summary and Conclusions 
The study used FTT framework to help guide an analysis and investigation of 
patient decision-making while experiencing FT. There is a rich body of knowledge about 
decision-making theory and understanding how patients select between options that 
include benefits, risks, and elements that are unknown (Reyna et al., 2015). 
Understanding how people use emotion, gist, and verbatim recall when making choices 
about their cancer care and including costs as a consideration was important since it may 
expand understanding of decision-making for patients experiencing FT. These are 
concepts that are not well studied but are important for those treating and caring for 
cancer patients.  
What is well understood in the literature is that FT is a problem that is becoming 
more widespread due to increasing costs and shifts of costs to consumers (Ahuja Parikh, 
Amin, Hall, & Patel, 2017; Chino et al., 2017; Gordon, Merollini, Lowe, & Chan, 2016). 
FT is well documented to impact the lives of patients with its distress and to decrease 
access to care. When FT is severe, it can impact outcomes and decrease survival. FT is 
not a number, but a state of emotional being for cancer patients. It is important to assess 
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the mental processes that patients apply to important decisions that impact their lives and 
their cancer outcomes. 
 To study these decisions and understand the patient perspective, my research 
study utilized qualitative research design. Using case study methods and selecting 
advanced cancer patients who are living with FT and cancer in community settings 
helped to provide deeper insights into decision-making and choices. Chapter 3 will 
discuss the methodology used to evaluate the role of FTT in cancer patient decision-
making while experiencing FT associated with cancer care. 
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Chapter 3: Research Method 
The purpose of this qualitative case study was to develop a deeper understanding 
of how adult advanced cancer patients who are experiencing FT make decisions about 
their medical care and how they experience FT in their lives. FT has been reported to be 
one of the most important dimensions of cancer patients’ experiences (de Souza et al., 
2014; Delgado-Guay et al., 2015) and is causing serious distress (de Souza et al., 2016), 
yet there is a paucity of literature about how patients experience FT and how they make 
decisions about their care when FT is present (Zafar & Abernethy, 2013b; Zafar et al., 
2015). To address this gap in knowledge, I used FTT to examine the decision-making of 
advanced cancer patients who are experiencing FT. 
There is a body of research that has focused on helping patients make informed 
choices regarding their cancer care and other chronic illnesses. This literature focused on 
patient-centered decisions (Barry & Edgman-Levitan, 2012; Joseph-Williams, Elwyn, & 
Edwards, 2014; Shay & Lafata, 2015) and how to present clinical information about an 
option that may contain numbers and concepts that are not usually part of a patient’s 
everyday experience. Researchers focused on how to make health and numerical literacy 
more accessible for cancer patients and patients with chronic illnesses to select 
appropriate treatment (Chewning et al., 2012; Joseph-Williams et al., 2014; Patkar et al., 
2011). Health and numerical literacy can help patients make informed choices and 
empower them in medical decision-making. None of the studies that I reviewed included 
extensive cost information, and none of the FT literature focused on patient decision-
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making while experiencing FT (de Souza et al., 2016; Zafar et al., 2015). My study 
addressed this gap in the literature to provide the patient’s perspective.  
In Chapter 3, I give a detailed description of my research plan to gain access to 
potential respondents and to analyze the data. I describe how I designed the study and 
justified the research method. I define the core concepts that I used throughout the study 
and how the method allowed me to answer the research questions. I address threats to 
validity and explain how I controlled for bias and how I protected the participants from 
potential harm. I also provide an overview of the data analysis plan.  
Research Design and Rationale 
The research questions addressed in the study were the following: 
1. What was the experience of advanced cancer patients who experienced 
financial distress stemming from OOP costs of the disease treatment? 
2. How does financial toxicity manifest in patients’ lives, and how did patients 
use gist and verbatim as they make decisions about therapy?  
3. How, if at all, did financial toxicity factor into treatment decisions in patients 
with advanced cancer? 
The study focused on learning more about how advanced cancer patients make 
decisions about their care when FT is present in their lives. I explored how patients think 
about options, what information they rely on, and how they process that information as 
they make choices about their care and their lives while experiencing FT. 
I used qualitative methods to learn from patients how they make decisions. 
According to Patton (2015), researchers use qualitative methods to gather and analyze 
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data to identify themes. Qualitative methods can be used to describe how people act, 
think, or make decisions, and to explain the contexts and the processes by which people 
take actions or make decisions (see Maxwell, 2013). Qualitative methods include a deep 
and rich approach of collecting data that includes not only the answers to the interview 
questions but also participants’ tone of voice, observations of the setting, and other data 
artifacts that may add to the description and observation (see Janesick, 2011; Patton, 
2015).  
For this study, I used a case study method. I conducted in-depth interviews with 
patients and collected additional documents and artifacts from patients that addressed 
their FT and cancer experience. I supplemented the interviews and artifacts with field 
notes and observation memos. This design allowed for thick descriptions and rich 
contextual observations of patients regarding their decision-making processes (see 
Maxwell, 2013). Because I did not know how patients would describe their experiences 
with FT or how they would characterize their decision-making while experiencing FT, 
the case study design allowed for collection of data that included the context for their 
responses (see Maxwell, 2013). A case study method was appropriate to answer my 
research questions because the method can be used to focus on how patients who are 
experiencing FT think, act, and make decisions. This method allowed me to gain insight 
into the application of FTT to cancer decision-making in patients with FT (see Yin, 
2003). Yin (2003) stated that case studies, with appropriate structure and systemic 
processes, can enable researchers to explain behaviors, thinking, and actions through a 
theoretical framework. Case study methods are helpful to researchers who are attempting 
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to study decisions and decision-making under a set of circumstances in a naturalistic 
setting (Yin, 2003).  
Role of the Researcher 
In any qualitative inquiry, the researcher is the vital link between the experiences 
and thinking of the respondents and the analysis and reporting of results and conclusions. 
The researcher is the instrument or medium through which the data are collected and 
processed; therefore, understanding the connections, personal goals, potential biases, and 
previous experience that the researcher brings to a study is essential (see Maxwell, 2013). 
Prior to beginning the study, it was important to examine my role as a researcher and 
observer in this study.  
I have professional relationships with the community cancer center sites where I 
conducted the research, and I examined how my relationships and potential biases were 
managed to limit the power I may exert over participants and site leaders. As a consultant 
and then later in my career, I led a business that supported patients and physicians to 
navigate the complex reimbursement framework of health care. I have worked with teams 
of people focused on improving access to cancer care and novel drugs. For many years, I 
have had a deep concern for the impact of health care costs, particularly pharmaceutical 
costs, on patients’ lives and how these costs impact their health and wellness. I have 
directed my career toward helping patients, providers, and pharmaceutical companies 
find efficient ways to help underinsured and uninsured patients gain access to 
breakthrough therapies by working to advocate for coverage with payers and educate the 
payers about the benefits of providing access to these drugs or novel treatments for 
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clinically appropriate patients. In this role, I was a consultant to the innovators and 
marketers of the drugs, the pharmaceutical companies. I sought new ways to expand 
access to the therapy for as many appropriate patients as possible, usually by working to 
improve the insurance reimbursement environment for the therapy.  
That job helped me hone my expertise in how health care services, particularly 
care provided in the community care setting, is paid and the challenges patients and their 
families face when insurance denies coverage or the coverage leaves the family with 
large unaffordable OOP costs. The work sensitized me to the deep and painful challenges 
that many people face as they try to pay for necessary services and care. I have respect 
for the difficulties that severe chronic illness and costs of care can cause for patients and 
their families.  
Potential biases may have stemmed from my early career choices in which my 
work was financed by pharmaceutical companies; however, I focused on helping people 
to access care. I believed that patients should advocate for themselves, be involved, and 
be educated regarding their health. I recognized that this is an ideal and not a reality for 
all, and I understood that others do not share my perspective. I accepted that there are 
many people who choose not to be involved or who are unable or unprepared to be their 
own health advocates. I generally do not have negative feelings toward the 
pharmaceutical industry or other health care providers such as doctors or hospitals. This 
could have created a bias where I inadvertently discounted the potential distrust, anger, or 
other emotions that patients may have toward pharmaceutical companies and health care 
providers. To mitigate this potential bias, I focused on capturing the patient’s perspective 
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in my research. To the extent that personal emotions or thoughts arose in my research, I 
ensured that I recognized these and prevented them for altering how I recorded the 
patients’ experiences in my notes, analysis, and reporting.  
A third bias that I managed was my desire to repair situations for patients and 
make their lives easier, especially where costs of care are escalating. Prior to starting this 
study, I had a deep understanding of the reimbursement, billing, and coding environment 
and recognized how difficult it can be for patients. I knew that it required a fair amount of 
health literacy and more insurance literacy to be comfortable understanding claims and 
health care costs. I have years of experience leading teams focused on the mission of 
helping patients. I recognized that in this study it was my job to understand the patient 
perspective and it was not my job to be a remedy to all potential challenges for patients or 
to find ways to bail them out of FT. To do this would be to overstep the researcher-
participant relationship. To manage these biases, I used a strategy of having another 
research participant, such as chair, read a sample of transcripts. I also asked the 
respondents to read the transcripts and confirm the accuracy of my results.  
The data artifacts that patients shared with me provided another check and a 
means for triangulation (see Patton, 2015). Case study research has three potential ways 
in which bias or distortion can be managed (Patton, 2015). Patton (2015) stated that one 
the most important ways to control bias is to ensure that the data are always kept in 
context and not to yield to the temptation to extrapolate results from the sample or 
context in which the data are provided. Patton further explained that qualitative 
researchers must ensure that the data are firmly grounded in the purposeful sample and 
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situations under study, within a time bound period, and that limitations arise from the 
type of people selected for the study and the types of artifacts observed in the study. To 
control bias in my study, I ensured that I included field notes and reflective writing to 
note potential limitations during data collection and encourage myself to remain focused 
on what was observed in context.  
Another concern in research is controlling for power relationships (Patton, 2015). 
In 2015, I changed my job to work more directly with medical oncologists, radiation 
oncologists, and surgeons who provide cancer care in the community setting. My 
organization contracts with groups of cancer care providers to manage all aspects of their 
cancer center services except for the clinical care delivery. At the time of the study, I was 
in a leadership position for the team that delivers the services to practices servicing 
providers across the United States. These practices are customers of my company, and 
my team manages the employees who work in the practices. I have employees supporting 
all the services to deliver cancer care. I have relationships with the administrators who 
lead the business support services for the practice, but I do not have direct access to the 
patients. These relationships could have created power concerns for me and study 
participants as I worked to gain access to the potential sites for recruitment of advanced 
cancer patients. Potential power concerns that might have stemmed from this relationship 
included staff engaged in helping to identify patients may have feared that to not 
participate in the study may have jeopardized their pay, their annual review, or their job 
security. To reduce this concern, I ensured that I was not directly involved in any staff 
annual reviews or salary discussions for a period of 1 year after the study. Prior to the 
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study, I was not routinely involved in staff reviews at the site because it is the 
responsibility of the local leadership team. Although this power concern was a perceived 
issue, it was minimized.  
Power relationships can emerge from other sources of blurred lines between 
researchers and participants in case studies (Creswell, 2013). In a case study and other 
qualitative research, although the inquiry is structured, the participant is sharing his or her 
perspective and approach and the researcher must follow the lead of the participant and 
not attempt to compartmentalize the results into preconceived survey responses (Karnieli-
Miller, Strier, & Pessach, 2008). This distributes some power to the participants who 
construct meaning from their experiences through sharing it with the researcher. A 
researcher must put aside bias and seek to understand the respondent’s intended meaning 
as closely as possible. It is important for researchers to gather the participants’ stories and 
experiences without coloring them with personal bias (Karnieli-Miller et al., 2008). A 
researcher must create trust and rapport with the respondent in all phases of the research 
from the solicitation to participate to the data collection and through the analysis phase 
(Karnieli-Miller et al., 2008). I conducted my research in the centers where patients come 
for treatment, but I also visited a respondent at home when that was more convenient and 
when travel was problematic. In selecting the treatment center, I chose a site where the 
patients had trusting relationships and where they were being treated for cancer. The site 
was also likely to be one of the sources of costs to them, and this may have created a 
concern for patients if they perceived that any of my research would be shared with the 
center and linked to them personally. The patients may have worried that the sharing of 
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information could have interfered with the provision of care. To ease this concern, I 
ensured that I would not share individual case stories with the center and that the 
narratives and examples would not reference the individual’s name.  
Participants with advanced cancer patients and FT are considered a vulnerable 
population (HHS, n.d.).They were afforded incremental protections and care as part of 
my study. There were costs that the participants incurred to participate in my study 
including travel costs and time away from family, home, or work. To compensate the 
participants for their efforts and costs, I reimbursed each study participant with $80 cash 
or check. This is not an amount that unduly influenced or coerced a respondent to 
participant in the study, but it did recognize their contribution and repay costs for travel. I 
asked the participants to acknowledge receipt for the money. This payment to patients 
was disclosed and approved by the IRBs.  
 My study sites have researchers who conduct studies for investigational cancer 
drugs and have a culture of supporting research. The physicians in the centers participate 
in research and use a centralized IRB and their IRB became IRB of record for my study. I 
received approval from the center IRB and the Walden University IRB (Walden 
University IRB Approval 17071).  
Methodology  
A case study method must have sufficient proposed rigor such that researchers 
can replicate the research design (Yin, 2003). I selected advanced cancer patients who 
were experiencing FT as participants and I collected data by using predominantly 
interviews for my case study. The interviews were supplemented with artifacts shared by 
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the patients and the results of a validated instrument. I used this instrument to assess the 
severity of the FT and the questions served as a discussion items. Typically, case studies 
use multiple data sources to form a full rich view of a perspective or line of inquiry (Yin, 
2003). 
Participant Selection 
The target participant selection audience for my inquiry was insured advanced 
cancer patients who were receiving cancer care in a community setting. These patients 
were in either active cancer treatments or follow up care. Most participants in community 
oncology practices receive care that involves a number of therapeutic modalities 
including surgery, radiation, and chemotherapy or advanced biotechnology therapy (see 
Ubel et al., 2013). The patients in my study were adults over the age of 18; no children 
were part of this study. These patients responded to a flier that described asked for 
participants who were concerned about costs of cancer care.  Each participant had some 
form of health insurance. There is a newly validated tool called the COmprehensive 
Score for financial Toxicity (COST) tool that is available to researchers to assist with 
grading potential FT experienced (de Souza et al., 2016). With permission, I used this 
COST score to help score the current feelings of FT at the time of the interview within 
the selected participants. This served as a document used for discussion purposes, not as a 
quantitative data gathering tool.  
I used a purposeful sample of advanced cancer patients who were seeking their 
care at a community oncology practice in Colorado. Purposeful sampling helps a 
researcher to achieve several goals that add validity to the study (Maxwell, 2013). First 
51 
 
when a small number of participants are expected, purposeful sampling gives the 
researcher some assurance that the patients in the study are typical of most or average 
community cancer center patients (Maxwell, 2013). Purposeful sampling can also help a 
researcher to achieve heterogeneity and to hear opposing views, and to include variance 
that occurs within the typical population (see Maxwell, 2013). In my study, there was 
heterogeneity in the sample in age, gender, experience with treatment, types of cancers, 
employment, and marital status.  
To identify and recruit the sample, I introduced myself to the targeted centers’ 
leadership and established a relationship with the physicians and their staff. The IRB 
approved several recruitment methodologies including allowing patients to pick up the 
flier at the center. Fliers were available to patients in waiting rooms. The IRB also 
permitted me to ask center staff to disseminate the flier to invite the patients to participate 
in the study. Financial counselors and patient benefit representatives disseminated fliers. 
This sampling strategy supported purposeful sampling. It produced cases with typical 
experiences and permitted inclusion of participants who could share these experiences. 
Some use of snowball or chain recruitment was used since some patients shared the fliers 
at their support groups that take place in the community cancer centers. In this case, a 
patient referred a fellow patient who was interested and contacted me.  
Once the patients contacted me on email, via text, or by phone, I communicated 
with the patient by email or phone to introduce myself, to describe the study, and to set 
an interview date. With the participant’s permission, I emailed the informed consent form 
for review prior to the interview. I also introduced the need to bring an item with them to 
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the interview that represented how they think or feel about financial costs of cancer. At 
the interview, I further described the study, its data collection and analysis processes, and 
obtained their signature on the informed consent form (Appendix A).  
The patient sample size was 13 participants. This was a size that allowed for 
enough cases to identify homogeneity and heterogeneity in the cases and the context in 
which people make decisions about their care while experiencing FT (see Maxwell, 
2013). With this number of respondents, I gathered rich descriptions of how patients 
made decisions while experiencing FT in a community cancer setting. According to 
Patton (2015), qualitative methods rely most on the deep richness of the information 
generated from the cases to provide the insights and significance from the research. To 
determine if the sample size was adequate, I transcribed the results and conducted 
thematic analysis and began coding, and from there, determined that the sample provided 
saturation. By working with the data from each case, and understanding if new 
perspectives emerged, I identified that a point of saturation was achieved with 13 patients 
(see Patton, 2015). Saturation can occur in qualitative case study methods when the cases 
do not add new insights or additional findings (see Patton, 2015).  
Instrumentation 
There were three forms of data collection. First, there were in-depth interviews 
that I conducted, following an interview guide (Appendix B). The interviews were audio 
recorded and transcribed. These interviews were supplemented by field notes and 
observations that I made about the interview and the respondent. In addition, I asked the 
respondent to share any paperwork or artifacts that they believed to be helpful to 
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understand their experience with FT and health care decision-making. These materials 
were redacted of patient identifier information and were part of the data collection 
process. I asked the respondents to bring these items to the interview and explain to me 
why they selected the item; I sought to understand the importance of the artifacts to the 
respondents. A few questions in the discussion guide were attributed to these artifacts. A 
third way in which I collected data was asking the respondent to take a survey with a 
validated instrument called COST that grades the patient’s current level of FT (de Souza 
et al., 2016). I obtained permission for the use of this tool from the investigator, Dr. de 
Souza (2016), who developed it (Appendix C). This validated tool is available online to 
the public and allows one to receive an immediate response with a grading of the degree 
of severity for FT once the questions are answered. The COST score helped to validate 
and triangulate the degree of distress that the patient described. The survey questions also 
generated more extensive exploration of the issues of FT and how patient experienced it 
as part of the interview process. 
Recruitment, Participation, and Data Collection Procedures 
Once I received IRB approval, I began the recruitment procedures including 
working with key informants at the cancer centers. The types of individuals that I worked 
with were patient social workers, patient navigators, patient benefit representatives, and 
patient financial counselors. These staff members are responsible for assisting patients 
with understanding and planning for the costs of their care including their insurance 
benefits and their OOP costs as well. In addition, these individuals help to enroll patients 
into specialized programs that can provide cost offsets and financial support if a patient 
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qualifies for the programs. Generally, community practice employees learn about the 
patients who are struggling with FT and seek to help with assistance programs. For this 
reason, the social workers were particularly helpful in supplying the flier to patients who 
were potentially interested in becoming study participants. The protocol for explaining 
the distribution procedures for the fliers to center staff is in Appendix E. The recruitment 
flier that was posted and distributed in the center is contained in Appendix B. 
Once a patient contacted me, I emailed or called them. During the phone call or 
email, I screened them for participation. I ensured that the patient was an adult, had 
advanced cancer, had insurance, and was experiencing FT. Once these criteria were 
confirmed, I introduced the informed consent form and asked the patient to read it prior 
to the interview so that he or she might consider participation. I underscored that a patient 
may change his or her mind about participation at any point and that participation is 
voluntary. I then set a time and place for the interview. I scheduled each interview for 
approximately one hour. As I set up the time for the interview with the patient, I 
explained that the participant could bring any paperwork or artifact that they believed to 
be helpful in demonstrating the impact of cost of cancer upon them and their lives. I 
explained that I will copy or photograph the material during the interview and then return 
the originals to them. 
I conducted interviews at the cancer center, by telephone, or at the respondent’s 
home depending on the availability and convenience of the patient. With permission, 
each interview was audio recorded. Not all patients permitted audio recording. In that 
case, I took extensive notes and the patient read the notes immediately following the 
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interview for accuracy. We discussed areas where further description or explanation was 
needed. This interview and review period was over two hours with the patient’s 
permission because of the extra time it took for her to review the notes and further 
explain her thoughts. For one interview, I used a transcription service called Transcribe 
Me to create an initial transcription that I reviewed and edited with the audio source. This 
transcription service was HIPAA compliant and secure (Transcribe Me, 2017). A copy of 
the agreement with Transcribe Me that contains the company confidentiality is in 
Appendix F. I transcribed the remainder of the interviews myself by listening to the 
recordings.  
 A COST score tool was discussed using the tool on the website costofcancer.org 
(Appendix D). This tool gives patients a way to obtain a scoring of the severity of their 
current FT (de Souza et al., 2016). I followed the research protocol and read the questions 
to the patient, asking them to score each question. After the interview concluded, I 
entered responses into the COST webpage and it returned a score. I chose to delay the 
scoring of the COST tool until after the interview was complete since the result could 
distract the discussion to details of the tool. Giving a diagnostic grade of FT in the 
interview could have been emotionally distressing for the patient and may have require 
follow-up that was not in the scope of the researcher’s relationship with the patient. The 
results of the COST score was used to further triangulate and reference the experience of 
FT that the patient described in the interview.  
 After each interview, I thanked the participant and asked if he or she would 
review my written transcript of the interview to ensure I captured their responses 
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accurately. I asked if I might contact them again if I had follow up questions or needed 
additional information. At this stage of the interview, I provided them with their 
honoraria and ask for them to sign for receipt for the honoraria (Appendix H). With 
thanks, I concluded the interview.  
Data Analysis Plan 
A researcher should specify a data analysis plan in sufficient detail that others 
could follow the research and replicate it and demonstrate how each portion of the 
research connects to the proposed research questions (see Patton, 2015). The data 
analysis plan provides a guide that describes how the data was categorized and organized 
for the researcher to identify themes.  
Each interview was recorded (if the patient consented) and each was transcribed 
into a written transcript. I took field notes about the non-verbal elements of the interview 
as well as the telephone calls that I had to set up the interview. Artifacts were copied or 
photographed. I recorded the results of the COST tool and stored them electronically. 
These three forms of data were collected for each patient to the extent possible. Each of 
these data was stored and loaded into NVivo data analysis software (Version 11). This 
software assisted me in the coding of the data for each case, and in the cross-case 
analysis. 
I used an open coding method and two coding cycles in the data coding process 
(see Saldana, 2015). I made my first cycle of coding by reviewing the transcript of the 
interview and listening to the recording while using descriptive coding. I coded the 
artifact data using descriptive coding in the first cycle as well. To help guide the 
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interpretation of codes and emerging themes and concepts, I wrote analytic memos. I 
used a code book within the NVivo data analysis software (Version 11)that included the 
codes, their definitions, and links to the coded data (see Saldana, 2015). This was shared 
with my dissertation chair for review as well. Once I had collected all the data and my 
first cycle coding was complete, I reviewed the data and coding using a second cycle 
method (see Saldana, 2015). In this cycle, I used pattern coding to help to assemble the 
data toward the analysis and themes.  
For analysis, one method is to fully describe each case and develop themes from a 
full evaluation of each case, but not compare between cases (see Yin, 2003). Another 
method is to collect multiple cases and then identify the themes within each case and 
cross-connect the individual cases to analyze the data in that manner (see Yin, 2003). I 
used a cross-cases analysis plan. The key to successful data analysis in qualitative 
research is to fully examine the data and evaluate all evidence that supports and 
contradicts themes that emerge. All data must be included and rival interpretations or 
themes should be explored (see Yin, 2003). The data analysis plan for this research 
included exploration and discussion of potential rival interpretation of conclusions and 
themes. 
Issues of Trustworthiness 
Issues of trustworthiness in research are critically important since a lack of 
trustworthiness can erode the validity and reliability of the results, casting doubt on the 
conclusions and the research process (see Maxwell, 2013; Patton, 2015; Yin, 2003). The 
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trustworthiness of this study may be evaluated by its ability to meet tests that promote 
credibility, transferability, dependability, and confirmability (see Yin, 2003).  
Credibility 
In qualitative inquires, credibility increases the validity of the study by helping to 
improve the quality of the inferences that emerge when a researcher is unable to directly 
observe something (see Yin, 2003). In my study, I asked participants to recall and discuss 
what they did or thought in the past. To improve credibility, a researcher must fully 
explore potential rational and reasons why an inference could be thought of differently; 
alternatives should be explored, and either dismissed or discussed as potential future 
research (see Yin, 2003). To improve the credibility of the study, I used cross-case 
pattern matching in my data analysis to identify where emerging patterns and inferences 
may have alternative explanations. I also used reflective journals after the interview to 
record observations about the interview, the tone and demeanor of the statements by the 
patient, and any bias I may be self-observing so that I limited the entrance of bias into the 
analysis.  
Transferability 
Transferability deals with the extent to which, if at all, the findings and 
conclusions of the research may be applicable outside of the study (see Yin, 2003). The 
applicability of the results of the study beyond my cases research depends on whether 
there is logic in the FTT between the cases to help explain how patients make decisions 
while under FT, but there are likely to be important limitations. To enhance the 
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transferability, I used thick description. This provided a rich context for the analysis. 
There was variation in the types of cancer participants and their experience.  
Dependability 
In case study methods, one seeks to increase the ability of the same case to be 
replicated later by others and achieve similar results (see Yin, 2003). This means that a 
researcher must document steps and procedures within the research to provide full 
descriptions of the operations of the case study such that one could later replicate it. 
Dependability also is focused on ensuring that the research follows operational 
procedures to reduce the subjectivity of data collection, especially in case study methods 
(see Yin, 2003). In my research, I used a protocol for the data collection and a case study 
database for the collation, storage, and collection of data. I provided a detailed listing of 
my coding procedure and analysis.  
To improve dependability in this research, I used several sources of information 
including patient interviews, field notes and observations, the validated and published 
COST tool, and data artifacts supplied by the patients. The use of several types of 
information provides the researcher with opportunities to increase the convergence of the 
emerging description of the experience, from the patient’s perspective. Using this, a 
researcher can triangulate the data. Another means to improve dependability is to ensure 
that data collection follows a process and that steps are taken to ensure the artifacts are 
correctly entered into the case database and ascribed to the correct respondent (see Yin, 
2003). In my study, the interviews, COST tool discussion notes and scores, and artifact 
collection followed a protocol (Appendix I) to ensure that the data supplied by each 
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patient was correctly and accurately ascribed to that respondent. Each artifact was labeled 
belonging to the respondent by number and a photograph or scanned electronic image 
was loaded into NVivo data analysis software (Version 11) for analysis and coding.  
Confirmability 
 To enhance confirmability, I used reflectivity. I also ask the patients to review 
their transcripts for their perceptions, comments and accuracy. This helped to ensure that 
the responses recorded were concordant with the patient’s intent. During the data 
gathering, analysis, and coding I used self-reflection to enhance confirmability. I  asked 
questions of myself such as those suggested by (see Patton, 2015). These questions 
included thinking and noting how I mentally approached the study’s knowledge-base, 
how patients knew their experiences, and how the study audience will learn of and 
interpret my findings. The object of reflectivity is to inquire how the researcher and her 
experiences are interacting with the study itself and to note these interactions (see Patton, 
2002).I reduced the four threats of validity, credibility, transferability, dependability and 
confirmability to my research by consistently applying the approaches I described. 
Ethical Procedures 
Ethical procedures are critical to protect the health and well-being of those who 
volunteer to participate in research (Patton, 2015). The IRB is the review process that sets 
standards that must be followed in order to field any research but beyond the IRB there 
are ethical standards and safeguards that must be part of the everyday practice of the 
research process (HHS, n.d.). It is critical to maintain ethical standards for all research 
with human subjects.  
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To recruit subjects, I gained access to patients via a relationship I have with a 
cancer practice in Colorado. I created and obtained signature on a letter of cooperation 
with the president of the practice. Before I started any research, I obtained IRB approvals 
from Walden University and the IRB associated with the cancer center. The IRB of the 
cancer center was the IRB of record.  
To recruit patients, I used several methods including asking the center staff to 
help disseminate fliers to patients about the research. I also disseminated the fliers within 
the center by posting them in the waiting rooms of the center. These fliers described the 
research and asked interested patients to email or call me directly. To recruit the subjects, 
I explained the purpose of the research and the potential benefits of the research. I 
disclosed that the research may ask them about personal subjects such as making 
decisions about cancer care, which may conjure up strong emotions or cause patients to 
relive stress from the past. I disclosed that an honorarium was being offered to 
compensate the patient for their time and travel costs associated with meeting with me. 
Once a patient was screened and agreed to participate, I obtained a signed informed 
consent agreement from the patient. Before starting the interview, I obtained consent to 
record it. Patients were concerned that I may share their feelings with the clinical staff 
and I stressed that their individual findings will not be attributed to them and that date 
will be kept confidential. I explained that I will be seeking to report the cross-case major 
themes and will not disclose identifiable information.  
Keeping the data confidential is a key concern for patients and was maintained by 
removing identifiable information and referring to patients using numbers. All data 
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entered into my database was stripped of names and other key pieces of information 
including addresses and phone numbers. A master key was held separately by the 
researcher and used only for follow-up as needed and permitted by IRB and the patient. 
The transcription service had a signed confidentiality agreement (Appendix F). To help 
ensure that there was no impact on the patients’ care or relationship with the treatment 
center, no individual patient data was shared back with the physicians or the center staff.  
Summary 
This qualitative inquiry used a case study method to research how advanced 
cancer patients who are experiencing FT make decisions about their care and how they 
experience FT within their lives. FTT is a decision-making theory that can be applied to 
this research; it was the theoretical basis for the study. The methods used included in-
depth interviews, collection of artifacts, and a validated measure of FT to gather 
additional insights into the use of gist and verbatim in decisions by patients with FT. The 
study recruited patients from in a community cancer center setting and the sites provided 
me with assistance to identify potential patients to participate.  
I took care to conduct the highest quality research and maintain the validity of the 
study. To improve the trustworthiness of the case study, the research used multiple means 
to improve and maintain construct validity, credibility, external validity, and 
dependability. The research was conducted with the approval of the Walden University 
IRB and the IRB approval from the cancer center.  
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Chapter 4: Results  
This chapter provides a detailed summary of the results of interviews with 
patients with advanced cancer who are experiencing FT stemming from the cost of cancer 
care. This study’s purpose was to understand the experiences of advanced cancer patients 
who are under financial stress to understand its impact on decision-making. There is a 
growing body of quantitative research that has addressed the impact of OOP costs on 
patients and linked these costs to adverse outcomes (Delgado-Guay et al., 2015; 
McDermott, 2017; Zafar, Newcomer, Jusfin McCarthy, Nasso, & Saltz, 2017). However, 
there is little research about how insured advanced cancer patients experience FT and its 
influence on their medical decision-making. In Chapter 4, I describe my research 
instrument, the partner organization that helped to facilitate the research, and the setting 
in which I conducted the study. I also describe the recruitment and data collection 
processes and my data analysis approach.  
I used a qualitative case study method because it provided a means to explore 
patients’ perspectives and gain an in-depth understanding of their thoughts, experiences, 
and considerations in decision-making (see Creswell, 2013).This method also included 
the collection of secondary artifacts (see Creswell, 2008). I used in-person and telephone 
interviews and supplemented these with secondary artifacts that I obtained during the 
interview process.  
I met with 13 patients with advanced cancer from three sites in Colorado during 
the months of August through December of 2017. I included only those patients who had 
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health insurance. Two of the participants preferred to include their family caregiver in the 
interview.  
Research Tools 
Prior to the study, I prepared a research interview guide (Appendix C). The guide 
had basic information questions about the patients including their living situation, cancer 
diagnosis and treatment journey, and history of employment. The rest of the interview 
guide contained questions designed to elicit data to answer my three research questions: 
1. What was the experience of advanced cancer patients who experienced 
financial distress stemming from OOP costs of the disease treatment? 
2. How did financial toxicity manifest in patients’ lives, and how did patients use 
gist and verbatim as they made medical decisions?  
3. How, if at all, did financial toxicity factor into treatment decisions in patients 
with advanced cancer? 
I partnered with a community cancer practice that offers cancer care in locations 
in Colorado. The leadership of this cancer practice allowed me to place fliers in treatment 
waiting rooms in several of their sites and provided private conference room space for my 
interviews in their medical offices. I met with the president of the community cancer 
practice, who signed a letter of cooperation that I included in my IRB application. Before 
I asked to distribute fliers, I made telephone calls and sent emails to each of the 
administrative and patient care teams to explain the purpose of my study and to solicit 
their cooperation.  
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Study Setting 
I conducted the research within three sites of a community cancer practice in 
Colorado After the first month, I expanded the number of sites because of a low number 
of volunteers. 
The three sites where I conducted my research were all part of a larger single 
community cancer practice. Each site offered comprehensive medical oncology services 
including laboratory services, infusion services, outpatient pharmacy services, and cancer 
support services. Two of the sites offered radiation oncology services within the same 
location as the medical oncology services. Financial counseling services and social work 
services were available at each of these sites. 
Each site had a pleasant entry and waiting room with side tables and chairs where 
patients and their family members checked in for appointments, filled out necessary 
paperwork, and waited to be called for their services. This is where I placed recruitment 
fliers. Behind the entry to the examination rooms, there are small desk areas for 
scheduling and other administrative paperwork meetings between staff and patients. 
Beyond these areas are small phlebotomy and laboratory stations where patients’ 
laboratory work is conducted by the staff before treatments. There are interconnected 
hallways with exam rooms for each physician, nursing stations, and sub-waiting rooms 
further back. I placed fliers in the sub-waiting rooms. Each site had an infusion room 
equipped with wide reclining chairs, IV infusion pumps, and a nursing station. There was 
also an enclosed pharmacy where the pharmacy staff did admixture of drugs and 
biological agents. In each site, there was a room for patient education and meetings. In 
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these rooms, there were conference room tables and chairs, relevant patient pamphlets 
and fliers, and boxes of tissues. Each of these rooms had a solid door that could close for 
privacy. 
 There was one patient who preferred that I come to his home that was located 
near the cancer center to conduct the interview because he was having on chemotherapy 
at home using a portable infusion pump and it was uncomfortable for him to travel. I 
accommodated his request and we met for approximately one hour in his living room. 
Sitting for long periods of time was painful for him, and he was more comfortably in his 
own home.  
Data Collection 
I recruited patient volunteers who obtained my information from the cancer 
centers where I left stacks of the fliers in waiting rooms, check-in areas, and sub-waiting 
rooms. The flier had a few details about my study and asked patients to call, email, or text 
me if they were interested in participating. Only two patients connected with me via text; 
all others called or emailed me. I used my mobile phone as the primary number and took 
the calls when I saw a Colorado number. If the patient connected with me by email, I 
responded by email within a few hours and, after several exchanges, I would ask if I 
could call the patient to discuss the study and arrange a convenient time to meet. Because 
I had to travel from my home in Arizona to Colorado for the interviews, this process 
allowed me to group the interviews into a short period and accommodate the preferences 
of the patients. Speaking with the patients in advance let me fully explain the consent 
process, screen the patients for advanced cancer, and ensure that they had health 
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insurance as these were two important inclusion criteria. I emailed the informed consent 
form to each patient and caregiver in advance of the interview. I also explained that I was 
wanting them to share something with me that was representative of their experience with 
the cost of cancer during the interview.  
The process of explaining the study and arranging for consent also enabled me to 
establish a relationship with the patients. I had only one patient cancel on the day of the 
interview. This patient was undergoing chemotherapy treatment and was unwell and 
emailed me to cancel. All others came prepared to meet me and appeared eager for the 
discussions.  
After receiving IRB approval, I arranged to interview several patients via 
telephone. The change in protocol to include telephone interviews was for several 
reasons. Patients were interested in participating, but some were recovering from surgery 
or had limitations for travel and it was more convenient for them to participate by phone. 
It was also helpful for me as I lived in Arizona, and each trip to Colorado was time 
consuming. To ensure security, the IRB requested the use of a code word that I provided 
in advance and arranged to have the patient tell me during the interview as a form of 
secondary verification.  
To ensure each patient had adequate time to consider participation, I emailed or 
mailed the consent form in advance. If the interview was to be in-person, I asked patients 
to bring the artifacts that were representative of cancer costs in their lives. I had consent 
forms ready for them to sign. If the patient preferred a telephone interview, I emailed the 
form and asked the patient to print, sign, and scan it so I could have an electronic copy of 
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the signature. Otherwise, we used mail to send the materials back and forth. I sent a 
packet with a return envelope and asked the patient to mail back the signed copy. These 
processes were successful in obtaining informed consent.  
Participant Selection 
I applied a purposeful sampling approach to recruit each volunteer participant in 
the study. The approach yielded a heterogeneous sample of advanced cancer patients with 
respect to age range, insurance type, severity of FT, employment status, and cancer type. 
Purposeful sampling helped increase the validity of the study by making sure the patients 
were representative of typical community cancer center patients (see Maxwell, 2013).  
Each participant was an adult over 18 years of age and was receiving care from a 
community cancer practice in Colorado where they learned about the study from a flier. I 
screened each participant to ensure that he or she maintained some form of health 
insurance. The COmprehensive Score for financial Toxicity (COST) tool was 
administered with each participant during the interview for discussion purposes (see de 
Souza et al., 2016). With permission, I later scored the patient experience of FT using the 
COST tool.  
Some of the sites had key staff members who handed the fliers out to patients who 
were known to be struggling with costs of cancer care. These patients’ experience was 
known to staff, and this process reflected the power of purposeful sampling because these 
patients represented the experience addressed in the study. Four patients received the flier 
from a staff member of the clinic. There was limited use of snowball or chain 
recruitment. Two patients declared that they would suggest participation to their peers in 
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a cancer support group because they had found the interview to be a pleasant and helpful 
opportunity to verbalize their feelings about cancer costs. Each interview was planned to 
be an hour in duration although some were shorter with the shortest being 31 minutes and 
the longest being 1 hour and 22 minutes. Most were concluded within 50 minutes. After 
each interview, I provided the patient with an $80 honorarium. Several patients did not 
want to accept the payment stating that the research was so important to them that they 
did not feel the need to be paid for their contribution.  
I recorded every interview using my password-secured iPhone. One participant 
did not consent to the recording, so I made detailed notes and met with her after the 
interview to go over the notes I had made. I used field notes and memos after every 
interview to note the situation, nonverbal signals, and facial expressions. I kept memos 
during the fieldwork to observe my reactions and note my potential bias.  
I used a commercial transcription service for the first interview and transcribed 
each recording myself thereafter using a Word document that I secured on an encrypted 
password-protected laptop and cloud backup. I found that the transcription service was 
accurate, but I preferred the process of re-listening to the interview. In addition, I made 
memos after the transcription to capture nonverbal cues that I recalled. I uploaded the 
notes, memos, and transcriptions into NVivo data analysis software (Version 11) for data 
analysis and coding. The protocol called for a photo of each patient to be taken, but this 
seemed to make patients uncomfortable, so I did not take pictures.  
After the interviews, I copied the recorded responses for the COST tool and ran a 
report. I copied and uploaded a screen shot of the report into Nvivo data analysis software 
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(Version 11). The questions and rating scale served as a good source of discussion during 
the interview, and patients stated that the questions on the COST tool are good ones for 
consideration. After each interview, I obtained the patient’s email or home mailing 
address and emailed or mailed a typed copy of the transcript to the member for fact 
checking and to give the patient the option to comment or correct the record. All but two 
patients responded to my mailing or email. Several had small changes such as dates that 
they had trouble recalling during the interview. Most stated that the transcripts were 
accurate. Several patients stated that they were surprised by how much they shared during 
the interview and apologized for the volume of typing that I had to do to capture their 
thoughts. I had proposed to speak with 12 participants in the study, and I found that I 
reached saturation at that number. I included a 13th volunteer who was eager to 
participate in the study, so the total was 13 plus two caregivers.  
Coding Analysis  
To assist with data coding, organization, and storage, I used the 2016 version of 
Nvivo data analysis software (Version 11). This software was a useful tool in my open 
coding method. My two-cycle coding process (Saldana, 2015) followed two passes of 
coding within the data. Pass one used descriptive coding developed by re-reading the 
transcripts multiple times and reviewing the artifacts’ descriptions. I wrote memos and 
notes about the key words and concept nodes. I used the Nvivo data analysis software 
(Version 11) to the create the codes, record my code definitions, and mark portions of 
each interview that contained data pertaining to each code in this first pass of coding (see 
Saldana, 2015). 
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I used a second-cycle method to begin to reassemble the codes into patterns and to 
link to my three research questions (see Saldana, 2015). This work involved re-reading 
the linked materials, grouping them until I recognized themes that were tightly linked to 
the research questions. 
Yin (2003) describes a method that I used in my cross-case analysis. I used a two-
cycle coding process. I first identified themes that transcended each case and then I 
compared and cross connected them to each case. Yin (2003) calls this a cross-case 
analysis method. An important part of this cross-case analysis work was to identify data 
that was in contradiction to most of the cases and to fully explore this. There were several 
examples of data where there was a view presented that others in the sample did not 
share. This analysis will be presented in the next section of this chapter.  
Research Findings  
After discussing the demographic data, I organized the research findings into 
themes in this section of Chapter 4. In the first section, I provide an overview of the 
general background of the study participants including their cancer types, insurance 
status, employment status, living situation, and self-reported score on the COST tool (de 
Souza et al., 2016). I report the themes that I found and use them to answer the three 
research questions.  
Demographic Data 
To begin each interview and establish rapport, I asked each participant 
background questions. I asked about their health insurance since this was a screening 
question and I confirmed their participation eligibility. Thirteen patients with advanced 
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cancer participated and two included their caregivers as active participants in the 
interview. To denote those who had a caregiver in the interview, I added the initials CG 
to the patient number in the demographic tables. All except one of the participants were 
female (see Table 1). Some forms of cancer are extremely rare; I have denoted one 
patient’s cancer in the more general form to provide her with a higher level of anonymity 
(see Table 1).  
All participants had advanced cancer and had undergone several modalities of 
treatment including surgery, radiation, chemotherapy, and immunomodulation therapy. 
By asking about the patient’s cancer journey, I recorded the interval since the initial 
cancer diagnosis and the interview. The time with cancer for patients ranged from being 
in their first year of cancer care, to having fought cancer through active treatments, 
remissions, and recurrences with metastases for over a decade (see Table 1). Participants’ 
living situations ranged from living alone to living with their spouse, partner, family 
member (adult child), or with a spouse and children/stepchildren (see Table 1). Most 
participants were married and living with their spouse or living with a partner (n = 10; see 
Table1). Patients had either commercial insurance, Medicare, or Medicaid coverage. All 
those with Medicare also purchased secondary coverage called Medicare supplemental 
that covers the coinsurance OOP costs for outpatient treatments including intravenous 
infusions (n = 5; see Table 1).  
During the interviews, I asked about the current employment status and at the 
time of the patient’s diagnosis (see Table 2). Of those who were working at the time of 
their diagnosis, eight significantly decreased their level of employment. These changes 
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included retirement, full-time disability, or choosing to leave employment. Two of the 
participants decided to discontinue working once they were diagnosed with cancer 
because this was the only way to qualify for Medicaid insurance. Their jobs did not 
provide insurance.  
Each of the participants took the COST assessment during the interview. The tool 
uses a list of 11 statements for patients to rate their degree of agreement on a Likert scale 
from one to five. The assessment is scored by entering the results of the questions into an 
online web-form that returns an level of FT based on the score (see de Souza et al., 2016). 
I asked the questions and the participants then rated their current state of agreement with 
the COST statements (see Table 2). During and after the taking the COST assessment, we 
discussed their thinking and their answers. 
I used this assessment to generate discussion with the participants. Several 
participants commented that this tool was useful to help them think about how costs 
impacted their lives. The assessment tool asked questions such as the degree to which 
participants felt in control of their financial situation. It asked about their ability to meet 
monthly financial obligations, and their feelings of how their present situation affects 
their future ability to afford costs of living. Several participants indicted that their level of 
FT has been much higher at several points earlier in their treatment when they were 
facing high OOP costs and had no ability work to pay for the care. 
After the interview concluded, I recorded the score and FT severity grade for each 
participant. The tool returns one of four degrees of FT; these include no impact on quality 
of life, mild impact on quality of life, moderate impact, or high impact on quality of life 
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(see Table 2). No impact means that at the time of the assessment, the patient has less FT 
impact on the quality of their life than 95% of cancer patients, and there is no impact on 
daily finances (de Souza et al., 2014, 2016). A mild impact is when FT is present and it is 
impacting quality of life for the patient more than 50% of cancer patients who took the 
instrument. A moderate impact indicates that the patient has a FT quality of life impact 
that is moderate and greater than 75% of patients with cancer. A severe rating for a 
patient indicated that he or she is experiencing a severe degree of FT on quality of life, 
greater than 95% of patients with cancer (see de Souza et al., 2014, 2016).  
Based on the results of the COST tool, most (n=10) of the interviewed patients 
were experiencing a moderate or mild level of FT on their quality of life at the time of the 
interview (see Table 2). Five patients had mild impact and five had moderate impact. The 
patients’ results ranged from two participants currently feeling no impact to one who was 
experiencing a high impact of FT on quality of life.  
Table 1 
Participant Demographics and Background Data 
Participant 
number 
 
Gender 
 
Cancer type 
Time since 
diagnosis 
 
Living situation 
Insurance 
type 
Patient 1 + CG Female CMML 1 yr. Alone Medicare 
Patient 2 Female Breast 14 yrs. Partner  Medicaid 
Patient 3 Female Lung 6 mo. Spouse Commercial 
Patient 4 Female Lung 4 yrs. Son Medicare 
Patient 5 Male Colon 2 yrs. Spouse Medicaid 
Patient 6 
Patient 7 
Patient 8 
Patient 9 
Patient 10 
Patient 11+CG 
Patient 12 
Patient 13 
Female 
Female 
Female 
Female 
Female 
Female 
Female 
Female 
Breast 
Breast 
Breast 
Breast 
Multiple Myeloma 
Lung 
Breast 
Sarcoma 
2 yrs. 
15 yrs. 
1 yr. 
8 yrs. 
1.5 yrs. 
2 yrs. 
4 yrs. 
1.5 yrs. 
Spouse/children 
Spouse 
Spouse 
Spouse/children 
Alone 
Spouse 
Partner 
Spouse/children 
Commercial 
Medicare 
Commercial 
Commercial 
Medicare 
Medicare 
Medicaid 
Commercial 
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Table 2 
Employment Status and FT Severity According to the COST Tool 
 
Participant number 
Employment status at 
diagnosis 
Current employment 
status 
COST tool 
severity rating 
Patient 1 Retired Retired Moderate 
Patient 2 Working FT Disability/unemployed Moderate 
Patient 3 Working FT Medical disability Mild 
Patient 4 Retired Retired Mild 
Patient 5 Working FT Unemployed Moderate 
Patient 6 Working FT Working FT Mild 
Patient 7 Working FT Retired No impact 
Patient 8 Working FT Working PT No impact 
Patient 9 Working FT Medical disability High 
Patient 10 Retired Retired  Mild 
Patient 11+CG Retired Retired Mild 
Patient 12 Working FT Unemployed Moderate 
Patient 13 Working FT Unemployed Moderate 
 
Note. COST tool from: de Souza, J. A., Yap, B. J., Wroblewski, K., Blinder, V., Araújo, F. S., Hlubocky, F. 
J., Cella, D. (2016). Measuring financial toxicity as a clinically relevant patient-reported outcome: 
The validation of the COmprehensive Score for financial Toxicity: Measuring financial toxicity. 
Cancer. https://doi.org/10.1002/cncr.30369 and https://costofcancercare.uchicago.edu 
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Themes 
Every interview participant who responded to my flier indicated that her or she 
was concerned about cancer costs although each had a unique experience and individual 
perspective. Nevertheless, as I conducted the coding, I noted common themes between 
the cases. To help limit the potential biases I may bring to the analysis, I worked to 
ensure that I was capturing the voice of the patient as I coded the interview transcript. By 
comparing themes that were present between the patients, it helped me to recognize the 
emerging themes versus bringing in my personal perspective. I examined the 
commonalities between the cases and looked for any differences between the cases as 
well or those with a different experience.  
In the next section of this chapter, I discuss the way in which patients responded 
to the interview questions, the themes that I noted as I made cross-case comparisons, and 
the answers to the three research questions.  
Research Questions  
In this study, I sought to address three primary research questions. In the 
interview discussion guide, I asked questions that pertained to each of the three research 
questions which were: 
1. What was the experience of advanced cancer patients who experienced 
financial distress stemming from OOP costs of the disease treatment? 
2. How did financial toxicity manifest in patients’ lives, and how did patients use 
gist and verbatim as they made medical decisions?  
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3. How, if at all, did financial toxicity factor into treatment decisions in patients 
with advanced cancer? 
The following section contains the detailed findings for each research question.  
Research Question 1 
To learn about participants’ experiences with OOP costs stemming from their 
advance cancer care, I asked a series of questions (see Appendix C: IQ1-4). First, I asked 
about the patient’s living situation and employment. I asked about the cancer care 
treatments that each participant had and asked each to tell me about the OOP of care and 
how those costs have impacted their lives.  
Employment Status  
Patients experienced an impact on their ability to work outside the home because 
of their cancer diagnosis. Nearly all participants were hospitalized and had surgery within 
a week or two of diagnosis; most followed with chemotherapy. These treatments, 
combined with the impact of the disease on the patient’s overall health reduced most of 
the patients’ ability to work. Nearly all who were working at the time of diagnosis took 
some form of short-term or long- term medical leave to undergo therapy. Several had 
additional follow-on surgery as the disease metastasized and worsened, and these patients 
all discontinued work either by retiring, depleting their medical leave, or quitting their 
jobs. Two patients had to voluntarily abandon their jobs because they were unable to 
afford individual health insurance policies and no insurance was offered at work. The 
income from their jobs made them unable to qualify for Medicaid insurance and so the 
only option was to quit.  
78 
 
 For most who were working at the time of diagnosis, the advanced cancer and 
treatment led to work discontinuation and that resulted in income reduction. Patients who 
tried to work found that it was difficult to manage the dual responsibilities of work and 
demands of active cancer treatment.  
Patient 6: At the very beginning I felt hopeless. The emotional side of it is hard 
because it’s like you are drinking out of a fire hose. You have all this information 
about your diagnosis coming at you! You are being told, not asked, that you need 
to go out and get all these appointments. I remember sitting at work, trying to 
work, and I had 20 missed calls on my phone from people trying to schedule 
appointments with me. On top of that, you have this big disruption in your life, 
and you have the cost of all of it.  
Patient 1 caregiver: I had to take a leave of absence to care for my mom. Before I 
took leave, I missed a lot of work taking care of my mom. I had sick time built up 
to use but I just was not getting my work done. 
 For some, losing a job, or shifting to medical disability was a major source of 
stress and loss of identity. 
Patient 13: I don’t know how to not work. I have not let go of that yet, I think. My 
family and friends, who have been very supportive of this diagnosis, don’t 
understand this pain of losing my job. It does not seem to be as big a deal to them 
that I had to give up my job, but they are concerned about how I am feeling. For 
me, it’s such a huge deal and it seems not to be such a big deal to anybody else. 
So that makes it hard too. 
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Patient 5: I am very much impacted. I cry many days because I cannot work and 
contribute. When I was going (working) I had eight hats; I could do it! I could do 
it all! Now, I cannot even take care of myself.  
Patient 7: Costs are less of an issue for me because my husband has an income 
that supports us. My paycheck was not as significant so to lose it was not a large 
issue from the money side. Quitting my job impacted me in that before even 
though I was only bringing in a small portion of our income, it was the fact that I 
was working. I was happy, and I was good at what I did. This is emotional even 
now for me all these years later. You can imagine how important that was to me. 
 For some, the loss of income compounds the increased OOP costs. Some patients 
moved from full-time to part-time work to accommodate their decline in health. As the 
treatments continue, patients must pay premiums and deductibles for insurance. Two 
patients found the only solution was to quit their jobs to qualify for Medicaid. With no 
income, these patients can obtain Medicaid insurance. They must cope with the lack of 
income as a result.  
Patient 5: I am out of cash totally. I have no income. I used to do well. I mean, I 
wasn’t rich, but I had my own company and we did alright. Cancer has made me 
poor. 
Patient 5: I’m on Medicaid now. It’s embarrassing. At first, I did not want to take 
it because I never believed I would be on Medicaid but, I have to do it for my 
family. 
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Patient 12: I had breast cancer four years ago but six months ago it came back. 
The first time I had cancer I had insurance but recently I had four jobs but no 
insurance. I had a terrible pain in my back; just terrible. I kept going to the doctor 
and they said it was a muscle spasm. Then it went to my arm and they still said it 
was a muscle spasm. I did not have any insurance so they did not go any further. 
They did not do any xrays or anything like that. I was in the emergency room a 
couple of times. I was doubled over in pain. I was crying, “I am in terrible pain. I 
am not here for the pain pills! I want you to find out what’s wrong with me”. So 
finally, I went down to our community health center and they said you don’t 
qualify for Medicaid.  I did not qualify. If I quit my jobs, I can get Medicaid. I got 
to the point where I could not walk but I was still trying to work. Finally, one of 
the doctors did a reflex test and watched me walk and I had zero reflexes. He said 
something is really wrong. He did blood work and found out the cancer had 
metastasized on my bones. I quit my job so I could get Medicaid. Now they can 
do more stuff. All these doctors who told me I had muscle spasms almost let me 
die because I did not have insurance. They would not do anything. I ended up in 
the hospital as soon as they found out by blood work I had cancer. I had 
hypocalcemia. My oncologist said if I had not gotten in there that weekend I 
would have died. It was so crazy.  
Cancer Diagnosis: A Major Life Event that Triggers Downstream Costs 
 Patients shared that their cancer diagnosis had a major impact on them, their 
families, and their lives. First, there was the emotional shock that the pain or cough that 
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they had been experiencing was a serious and life-threatening disease. Treatment became 
the primary focus. At first, costs were not typically discussed but, patients do have them 
on their minds.  
 The initial diagnosis was typically followed by a rapid succession of doctor 
appointments, tests, and scans. All but one patient had surgery. Several had 
chemotherapy treatments prior to surgery, but most were hospitalized and had surgery 
first. Patients expressed that they were scared and disoriented during this time. Some 
patients spoke of their diagnosis using analogies and explained how the diagnosis 
impacted them.  
Patient 2: My diagnosis was like a bomb going off in my life. It was like a total 
shock. My ex-husband took my son while I had surgery and chemo. I couldn’t 
work or take care of him. I had to jump through hoops to see him. He basically 
stole custody of him from me.  
Patient 10: (Leaning of her diagnosis) That was quite a shock! I went into shock. I 
drove past a Costco and went in, and randomly went around the store putting 
things in my cart and eventually, I looked out and it was dark. I went home; I 
called my two children. I had no idea what to do. My heart is pounding just 
thinking about it now. 
Patient 7: It was so serious that they told me over the phone. They said, “I am 
sorry to tell you, but you have cancer and it’s very serious.” It was so serious that 
they said I had to come in very quickly. I was diagnosed with breast cancer. I was 
told on a Friday that I had cancer and that was my last day of work ever because 
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from there I immediately went into all the appointments for surgery and for 
treatment so I never went back to work.  
Patients explained that once they began to recover from their initial whirlwind of 
surgery and treatments, the realities of the disease set in and the bills for treatment began 
to come in the mail. For some, costs were always a concern, but this was the first time 
that they felt stable and well enough to really understand the magnitude of the cost. Also, 
most pointed out that that health care systems failed to tell them how much something 
was going to cost beforehand. For some patients, the costs were always largely unknown. 
The only known costs were those that were expected to be paid directly by the patient. 
The costs began to mount immediately for or a younger breast cancer patient who had 
fertility treatment to store her eggs for the future prior to treatment.  
Patient 6: The fertility clinic told me that they would work with me and they told 
me it would cost me $2,000. They said insurance would cover some. I thought I 
could make that work. But then, after I started hormones, they called me and told 
me the insurance was not covering it and they needed $5,000 right that day. So, as 
you can imagine, I completely freaked out. I just could not deal with it; I had just 
been diagnosed with cancer and the pressure that I may never be able to have a 
kid was too much. Also, I had concern about my body; I mean I had already 
started the hormones and I would not be able to get any cancer care, let alone 
have a fertility procedure. There was a lot of back and forth, and I was able to be 
put on a payment plan and I gave them the $2,000 they had said it would be. 
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Patient 1: I think one of the things that I have seen through all of this,on the 
financial side, it feels like you’re never told. And I feel like, not purposely, but I 
feel like we’re so caught up in the diagnosis side of things or the treatment that 
sometimes the places forget that there’s this other side (cost).  
Patient 4: I did not think that much about the cost until after my second surgery 
and all those bills and receipts for how much they paid started to pour in. I got out 
my computer and started to add up what it cost. I was astounded. I was astounded 
at what I have cost. Not that I am not worth it; I am, but to me, it was just 
horrifying. 
OOP Costs Paid by Patients 
Patients who have insurance and have lower or no OOP costs for routine care 
stated that they generally were not aware of what a covered treatment, surgery, radiation 
therapy, or drug costs. When something has a copay or coinsurance amount associated 
with it, participants stated that the cancer center staff tried to ensure that the patient was 
aware prior to treatment or testing. In addition, many patients who had commercial 
insurance or managed Medicare had to pay a copay for every visit. Sometimes those 
copays are $50 for each visit and it is common that patients have one or two visits a 
week. One patient, living on Social Security income, stated that her copays were too 
much to afford while paying rent and utilities. Patients expressed that these costs add up, 
especially when there is no income or limited income. Those with Medicare and 
supplemental insurance reported that OOP costs were more manageable because the 
insurance paid for nearly everything.  
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Patient 11: The treatment costs are astronomical but fortunately we have been 
able to manage it. In the greater scope of things, the costs are going quite well due 
to insurance. But for me it makes me feel so bad for others who are not as 
fortunate. It’s a shame what things cost for medical care.  
Patient 10: I have concerns and worries but at the moment, it’s not so bad. I am 
financially stressed a bit, somewhat because the costs are always there. I don’t 
feel in control of my financial situation. It scares the hell out of me.  
Patient 8: When I was diagnosed a year ago, I was very concerned about the costs. 
It stressed me a lot. I worry about the cancer coming back and future costs I might 
have. It will always be a concern for me.  
Patient 4: I don’t pay that much except for over $500 a month in premiums but 
my absolute terror is when I watch the news and they talk about cutting Medicare. 
I keep thinking about “what if”. What if I lose my health insurance? Then I will 
be in a lot of trouble.  
Patient 3: I don’t do anything that does not change the course of the disease. I 
don’t do the extras that may be nice because I have to pay extra.  
Financial Assistance and Charity 
When insurance does not cover a medical test or treatment, patients explained that 
the test is offered and the costs are explained. Usually, the test or treatment is declined. 
For example, one patient’s insurance company would cover a CT scan but not a PET scan 
for her lung cancer. She did not have the PET scan. 
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Patient 3: I have finished chemo and I’ve had two CT scans since I finished 
chemo. I am in remission. My doctor wants to get a PET scan but my insurance 
company won’t pay for my PET scan that he wants. Everyone would like to see a 
better picture. But they won’t pay.  
Several patients stated that they cannot afford the costs that are required to be paid 
for the recommended care. In these cases, the cancer center staff work to find financial 
assistance for the patient. There are programs that provide charity funds to patients who 
qualify. Foundations will cover the OOP costs of care that patients may incur including 
fees for infused drug therapy and other treatments. The funds are sometimes called 
foundation grants and these help the patient afford medical OOP costs (see Kaisaeng, 
Harpe, & Carroll, 2014; Rajurkar et al., 2011). There are also copay card programs that 
help with pharmacy costs that patients face. These programs are funded by the 
pharmaceutical company and provide for cost offsets for OOP costs associated with drugs 
(see Fein, 2017; Zafar & Peppercorn, 2017b). Foundations differ from patient assistance 
programs (PAPs) and copay programs. In PAPs, the drug company donates supply of the 
product to patient when the patient applies and meets criteria for not having insurance for 
the product. In this way, the drug is supplied free of charge for those who are without 
coverage. In copay programs, the drug is charged to the insurance and the pharmacy uses 
a copay card to charge the cost of the copay to the pharmaceutical company instead of the 
patient, thereby, reducing the OOP cost for the patient. Often there is a small remaining 
copay that the patient must pay. Because of self-referral laws, Medicare patients are 
largely unable to obtain support from these PAP and copay programs (see Zullig et al., 
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2017). Instead, charitable foundations can make grants to patients to cover their OOP 
costs that the insurance company does not (see Zafar & Peppercorn, 2017a).  
Patient 6: While I was on my chemo my doctor recommended getting Neulasta 
shots to help me prevent infection. Each time, I had to pay like $3,000 a shot or 
something egregious like that. The insurance did not cover them fully – they were 
like $14,000 total a shot and I needed six shots. So, I talked to the financial people 
at the cancer center again but there were no more copay cards available to cover 
me so I was going to go without it. But fortunately, she (the cancer center 
financial counselor) called and said that they were able to get me in and that 
brought my out of pocket cost down to $25. But even with insurance and without 
that card, I would not have been able to have the Neulasta shots. I could not make 
that work.  
In the interviews, patients expressed both deep gratitude and passionate 
frustration with these programs. The processes to enroll and receive benefits are not 
easily understood or transparent for the patient. Patients must complete applications and 
provide detailed financial information. Sometimes staff at the hospital or cancer clinic 
assisted the patients with the paperwork but often it was the patient who completed the 
forms. This caused a great deal of anxiety and stress at a time when the patient was 
unwell. 
Patient 13: Well, I have had to do a lot of asking for charity. My cancer center and 
the hospital that I went to have these charity programs where you can apply for 
financial aid. I did all that, and well, in the case of one hospital – it took five 
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months! Of course, there were back and forth letters. You can never talk to a 
human being on the phone. The people who make the decisions sit in some dark 
back-room somewhere. So, this was constant “give us this piece of information; 
give us this piece of information; send us your bank records; send us your tax 
records.” You know, you swear to this and you swear to that and its stressful 
because you don’t know what is happening. The hospital is sending collection 
notices from the hospital and all of this was during the time that I was on chemo 
and some days I could not even get out of bed. So, it was highly stressful to say 
the least. Every letter the charity sent had a deadline on it that I was supposed to 
respond to but the letters always seemed to come after the deadline had passed. 
For some reason, the mail took two weeks and so I would get a letter that was past 
due to get them information and here I am, lying in bed, puking my brains out. It 
was a lot more stress than I really needed at that time.  
Patient 6: I got a little money from a foundation. So that was helpful, but 
affording all the copays for my treatment was a huge financial stressor. On top of 
that, I had to fully pay up-front for tests and stuff that I did until I met my 
deductible which is $1,500. Some family and friends helped me to piece together 
the money that I needed until I fully met my deductible. 
Patient 1: She (referring to her daughter caregiver) has been working to get some 
help on these things for us.  
Patient 1 caregiver: We did get one grant so far for $5,000. That’ll go on account 
here, so all these copays will go against that. And we’ve got little grants that 
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we’ve done. Well, let’s see. Through the social worker here, I applied to six 
different places. And some of it’s like we got a $100 check. We got a $500 check 
from one place, a $100 from the other. And so, we’re using that to pay for these 
copays. If I was not helping my mom, there is no way she could do it. I think most 
people don’t do it because it so hard and requires a lot of follow-up.  
Patient 4: I feel guilty about getting the money from the foundation because there 
is these other people who have it so much worse than me. And then I say, why are 
they better than me? So, I try to dismiss it, but that we have to even make those 
choices is offensive. 
Research Question 2 
Research question two focused on how FT manifested in patients’ lives, and how 
patients used gist and verbatim as they made medical decisions. To understand how FT 
was present in patients lives, I asked participants to tell me about how their cancer costs 
impacted them. I asked about the experience of having advanced cancer, having 
treatments, and paying for their care. I also asked the participants to tell me about how 
the costs of cancer made them feel. Patients discussed the impact of OOP cost in their 
everyday living, their relationships, and their interactions with their oncologists. They 
discussed the coping mechanisms that they used when the costs were a strain and how, if 
at all, it impacted their decisions to undergo cancer treatments and supportive care. 
Deprivations 
Sometimes the trade-offs and choices that patients made to afford their cancer 
care were harrowing and caused them distress. Patients recounted how they saved money 
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to live and pay for care. To save money while paying for cancer care, most patients 
immediately stopped spending money on things that they viewed as discretionary, such as 
gifts for charities, money to go out to eat, travel, and gifts for family and friends.  
Patient 2: I do everything by hand because it is cheaper. If I want something to 
eat, I have to make it by hand. I cannot afford to eat out. I am back to cleaning to 
keep myself. I clean houses. 
Patient 4: Before cancer, I traveled. I was not a world traveler, but I went back 
and forth to Kansas a lot and saw my friends and family that still lives back there. 
I am guardian for my brother-in-law who is 60 years old and mentally 
handicapped. So, I would go back to Kansas two to three times a year to check on 
him, “yuck it up” with my friends, and see my family. And now, I am lucky if I 
go once a year. Part of the reason is the money, and part has been how I felt 
because of the drug and the fatigue. 
Sometimes it was little things that the patient gave up to save money. For 
example, one patient mentioned that she used to love to knit and was part of a knitting 
group. She no longer buys yarn to knit anymore. Another mentioned that she feels guilty 
forgoing school fund raisers. 
Patient 9: I have worries about money, I do. Like for example, last week I was not 
going to buy my girls’ school pictures because of the price of the pictures and 
because I worry about my cancer costs. They give us a picture at the end of the 
year and because I am a teacher I thought maybe I could just take a picture of the 
picture and enlarge it. I am embarrassed to admit that I was thinking I could “steal 
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it”. And I told my husband, “I am not buying the pictures this year; it’s not an 
expense I can make.” He went ahead and paid. And another example is that last 
night was the deadline to order things to raise money for the school. The girls 
were reminding me to order and spend the money and I just did not want to order. 
I ended up ordering some little mini thing for $22 each. I was aggravated that I 
had to spend the money on something silly. And then I felt terrible because it was 
for a good cause. The school needs the money. Without cancer costs, I would not 
be thinking like that, because all I could think about was those $46 I just spent 
could go into my cancer care. 
Patient 3: I was thinking, “how the hell are we going to do this?” I quit my job 
and I used to make good money. But we worked it out – by not doing anything. 
So, I just spend less and am more contentious. It’s more like when we were young 
and we were broke. It’s kind of disappointing. 
Impact on Friendships and Relationships 
The costs of cancer impacted patients’ friendships and relationships. In many 
discussions, patients became teary and wept while recounting the impact of their cancer 
and cancer costs on their families. Two patients wanted their caregiver to participate in 
the interview because they felt strongly that their caregiver’s perspective on the cost of 
cancer was important for me to capture. Patient 1 said that her relationship with her adult 
daughter caregiver was the reason she is undergoing treatment for her cancer at all. She 
stated she would not have had the ability to do all the paperwork to get help to afford her 
care without help. Two other advanced cancer patients said their husbands always 
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handled the money and their cancer care costs. Both were aware that their care costs a lot 
but neither professed a focus on costs. They have decided to focus on treatment and leave 
the financials to their spouse. These patients depend on their family for this support. 
Patients who lived with a partner found that their family members supported them 
both emotionally and financially which was extremely reassuring for them. It also created 
feelings of guilt for the patient. As one patient puts it, she does not want to spend their 
entire retirement savings only to die and leave her husband without money. This is a 
concern for some patients. For others, there was less concern on the overall impact of the 
costs upon their loved ones and more focus on how cancer has changed their 
relationships.  
One patient stated that fighting cancer together with her husband at her side has 
deepened their relationship. Recently, they had made the decision to stop her treatment 
and look into hospice care. She was comforted by his support and involvement in her 
decision. Another patient spoke about her cancer and the blessing that it has been in her 
life in some ways.  
Patient 9: Actually, the treatment time for my cancer was one of the most 
beautiful experiences of my life; the whole experience of having cancer in 2009 
and 2010. I won’t say that cancer was a gift, but it was the closest I have ever felt 
to God. I just got on my hands and knees and prayed. I just spent time reading the 
Bible and praying. I knew I was in His hands; I was taken care of physically and 
emotionally. So then, I was able to get better. 
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Another patient reported that she has seen her friends change. Some of her old 
friends have become uncomfortable around her. She also reflected that she has less 
interest or empathy for what she deemed to be her friends’ petty complaints about their 
lives. She believes that she makes them uncomfortable because her advanced cancer 
reminds them of their fragility.  
Distrust of the Health Care System Motives 
As patients go through cancer care, some experienced a rapid succession of 
bewildering series of tests, procedures, surgeries, radiation, and infusion treatments. As 
these tests and treatments progressed, some patients expressed concern that the health 
care system was too focused on making money from their cancer care. Patients expressed 
distrust in the motives of the health care systems and sometimes those of their providers. 
One patient stated that she overheard her surgeon asking her medical oncologist if the 
oncologists had convinced her to undergo a full mastectomy versus having a 
lumpectomy. She related that hearing this conversation made her think that the surgeon 
must make more money on the bigger and more invasive surgery and she became worried 
that perhaps her medical needs were not the primary focus. It was too late to change 
surgeons but she was concerned.  
Patient 2: I had a biopsy and a mastectomy. I was poisoned by chemo, but I 
suppose everyone needs a paycheck (laughs). I just hope its legitimate. It seems 
like cancer treatment is a real racket.  
Patient 6: Before my surgery, I was really anxious about the surgery – the costs 
are big concerns. Financial costs impact my every part of my decision-making – I 
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mean, I didn’t go to the doctor much before and I am always a little skeptical – 
am I getting these recommendations because it is what I need and they are the 
best form of care or because they are such a money maker? It all is a bit 
disconcerting to me. 
Patient 11 caregiver: Maybe this is beyond the intent of the interview, but I feel 
like the drug companies are in league with the government. It should not cost 
what it does to treat cancer. I am not angry like, “poor me”, but the excessive 
costs of care are appalling.  
How Cancer Costs Make Patients Feel 
The emotional impact of cancer costs changes as patients progress through cancer 
care. Patients described periods of time in which they felt fear about their ability to afford 
their care. They spoke about how their emotions changed throughout their cancer care. 
Some have had a cancer diagnosis for 15 years while others were in their first year of 
treatment. The most common word that was used was worry.  
Patient 1: I worry – I still worry about it a lot. When I worry, I get sick.  
Patient 8: Cancer treatment monetary costs are hard to put in monetary terms. The 
stress from having this disease interfered with my relationships. I worry about 
being unemployed and having cancer and I could not sleep. I had always been an 
insomniac but now I could not sleep at all. 
Patient 4: Money is the last thing I think about before I fall asleep and the first 
thing I think of when I wake up. I was never like that before cancer.  
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Patient 12: It makes me so angry that it has to cost so much. There is no way to 
tell me that the bag of chemo costs $5,000. There is no way it costs that much, but 
that is what they charge.  
Patient 3: How you feel about the whole thing is, that it takes your self-esteem. 
You know? Where if you were strong – you’re not strong anymore. 
Patient 1: I feel that it is very important to pay my debts and so I worry.  
Patient 13: For me, it has never been a question of doing the treatment that needs 
to be done and I figured I would figure out the money at some point. My mom 
went through this and she wound up passing away in debt to her oncologist. But it 
has been very stressful.  
Cancer Costs Representation in Their Lives 
As part of the interview, patients shared artifacts with me and described what their 
experience has been with cancer care costs. Some patients shared objects while others 
shared or described images. One patient described what her life was like before and after 
cancer and cancer costs. Prior to her cancer diagnosis, this patient felt that her life was 
like a perfect bubble moving along but once cancer struck the bubble began to take on 
cracks and was shattered. The snug bubble was gone for this patient, replaced by 
shattered glass. She feels that reality is harsh.  
Patient 2: This notebook is a reminder of how hard I have to work to keep on top 
of things. I am really obsessed with my cancer. It can be a lot. I write things in 
here that I am thinking about or working on. I am thinking about taking the bus to 
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save money. If my car goes, I cannot afford to fix it – oh my gosh. I need a 
miracle. I mean really. I need a miracle.  
Patient 9: The image to me of cancer costs is the iceberg. The unknown costs are 
all those unknown expenses below the waterline. In the rest of my life, if I go on a 
trip, I can research around and get a comparison of choices. Or if I go to the 
grocery store, I am going buy organic, so I will pay a little more and I know it. I 
know the price before I buy. In cancer, you don’t know. You never know how 
much it will be.  
Patient 8: My image is of a dead flower with the petals and leaves falling off. It’s 
not a good image. It’s losing its leaves. Life is losing its capacity. I pick that 
because of the process. The leaves fall off one by one and is a slow dying process. 
Once it was beautiful. Old age and being sick does that to you. It uses it up. 
Patient 12: The waves catch you in the ocean. It feels like I was on the shore and 
waves keep pulling me further and further out. There is nothing I can do. I am 
drowning. You are downing in debt. Scary! 
 Some patients shared physical artifacts. One participant showed me a satchel 
filled with vitamins that he was taking to complement his cancer treatment. He explained 
that he was following a regime of vitamins and supplements to boost his body’s ability to 
fight the cancer. Even though it was expensive and a large bag of vitamins that he took 
throughout the day, he wanted to do all he could to beat the disease.  
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Use of Gist and Verbatim in Health Care Decisions 
To better understand decisions that patients made about their health care, I asked 
about how they made choices about cancer care options. I probed to hear about the 
information the patients relied on, and what they recalled about these decisions, including 
the use of gist and verbatim.  
The types of decisions that we discussed did vary and some of it was based on the 
types of tumor the patient had, or the circumstances surrounding the decision. I listened 
to how patients included costs in their thinking and in their narratives of their decision-
making. For example, in women with breast cancer, several mentioned that they worked 
with their surgeons to decide about whether to elect a lumpectomy or a full mastectomy. 
Some women indicated that a lumpectomy was not offered as a choice and they only 
found out about that option after having mastectomy. Others indicated that they struggled 
with the decision, recognizing that a less invasive surgery might mean a faster recovery 
which could afford them a chance to start chemotherapy sooner, perhaps offering an 
advantage to them in survival. Others knew a lumpectomy might mean that they could 
return to work faster.  
Several had pre-surgical chemotherapy, which their oncologists recommended to 
the patients. In each of these scenarios, the patients did not recall specific verbatim 
statements or facts that their surgeon or medical oncologist made to them about the 
efficacy or safety of options. Instead, the patients recalled the emotion of their recent 
breast cancer diagnosis, the general gist of the written materials that their doctors 
provided about the surgery, and the feelings of fear of the unknown including the 
97 
 
unknown costs. In no case was the cost of the surgery discussed with the patient in 
advance. The decision was not whether to have surgery; it was a decision about the kind 
of surgery to have and whether chemotherapy should be started prior. 
One patient shared that she wanted to limit the exposure of her body to the toxic 
effects of chemotherapy and she was concerned about the costs. She wanted to have the 
least amount of chemotherapy possible and conveyed this to her doctor who had 
recommended the standard number of cycles of therapy for her tumor and line of 
treatment. In this case, she recalled the exact verbatim of the discussion and chose to 
follow her doctor’s recommendation.  
Patient 6: For example, when I was asking my doctor, what happens if I take four 
treatments instead of six? He said, “we did not really study that; we only know 
that six is the number that works.” I was asking for a couple of reasons. I had 
wanted to have a destination wedding and did not want to get married when I was 
so weak from chemo and the idea of pumping poison into my body and killing off 
all the cells was just…a lot. I wanted to see what the least was that I could do. I 
wanted to see what my body really needed and what would be best for my system. 
And there was a cost worry to that as well.  
In another example, a patient who had been on treatment for her cancer 
intermittently for 10 years was making a decision about treatment for a recurrence. She 
reported her recollection of her recent discussion with her doctor. She did not have an 
OOP cost for her oral medication but was concerned about taking a drug every day and 
the potential side effects on her body. She remembered a vivid combination of verbatim 
98 
 
statements from her doctor about the efficacy of the recommended therapy, and her own 
emotional gist recollection of feelings of distrust of the side effects of the medication. 
She also had gist thinking that she had a desire to extend her chances to live but balanced 
that thinking with a concern of not poisoning her body with chemotherapy.  
Patient 2: I remember feeling very anxious. I was very vulnerable. I don’t want to 
die and my doctor said my cancer was going up – what I mean is my cancer 
treatment was not working anymore and doctor said I have to do something else. I 
was trying to understand what the benefits of my latest drugs are to me, so I asked 
a doctor about it and she said that they are excellent drugs to help women with 
breast cancer to live longer. She said women who took these live two times longer 
than those who don’t take them. People who don’t take them died earlier.  
Some patients explained that they followed the recommendations of their 
physician. Although they received information about their therapy, it was provided to 
help them manage through the treatment and know what to expect rather than part of a 
decision-making process. They were satisfied with following the doctor’s treatment plan 
for them.  
Patient 13: My doctor did a fairly good job of explaining the chemo. She 
explained why I needed it. I was in the hospital post-surgery and it was not a great 
time and I got a little more detail on the therapy from a chemo class later. I 
learned about the specific side effects about the drug and what to expect. I got an 
info sheet and I asked questions. I don’t remember any numbers or statistics – just 
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that there are five protocols that I could choose from but this one had the best 
results.  
Patient 11: With the immunocancer therapy I am on now, we followed the 
doctor’s advice. We did not have any real questions about it. He is terribly 
knowledgeable about cancer care. He told us that “it got very good results” so we 
followed his lead. We did not discuss costs. 
Patient 5: I follow my doctor’s advice on what therapy to take and when to go to 
have it. I would very much like to do the additional holistic therapy that my 
holistic doctor has prescribed but I have not been able to afford it and I cannot ask 
my children to cover it. We are researching the other therapy to see what it will 
cost but those are in addition to what my doctor prescribes.  
Patient 8: I got information about a chemo – they said this is what the drug is. It 
will block things and kill cancer cells. So, I said OK. Let’s do it. I got a ton of 
info – a huge folder about my condition and treatments. I went to her2.com – and 
for my radiation I asked other doctors like my primary care. My doctor was 
wonderful and he explained. On radiation I just went with my doctor’s orders. I 
went with what he said.  
Research Question 3 
The final research question was how did FT factor into treatment decisions in 
patients with advanced cancer? To address this question, I asked patients to talk about 
how costs that they were responsible for factored into their decisions for cancer care.  
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Patients spoke openly about the serious nature of their disease and stated that they 
focused their energy and effort to elect care strategies that put the cancer into remission 
or cure it. Nevertheless, many patients were pragmatic about treatment choices that might 
not be curative but may offer a longer life. Patients said that they followed the 
recommendations of their doctor provided their insurance covered the therapy. Even 
though the copays may accumulate over time, patients believed that they needed to do 
these therapies to live.  
There were two patients who had what each patient believed to be very expensive 
OOP costs associated with oral chemotherapy. In each case, the patient wanted to start on 
the drug that their doctor prescribed but upon learning of their financial responsibility, 
they refused to take the drug until the cancer center helped to arrange for charitable 
assistance for the OOP costs.  
Patient 4: I got information from my oncologist who said this drug was very new. 
He explained what it would do and the risks, and the side effect, and he said it’s 
really expensive. And I said, “well, talk to me about what you mean by really 
expensive”. And he said, “I will let the pharmacist do that – he’s better”. So, the 
pharmacist called me and he told me what it would cost me with my insurance 
and I told him right then and there, “I cannot do that. I cannot. I cannot pay you 
$5,000 or $6,000 a month. I can’t do that”. I can’t sell my home, and I can’t sell 
my body, you know (laughs). So, he said, “whoa, not to worry, this is what we are 
going to do. I need to get you into a foundation to help and I just need some info 
from you and I will call you back”. He called me back and said, “it’s fine, it’s 
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covered”. And so, I was able to get an extra $5,000. But without that, I wouldn’t 
take it for $5,000 a month. It’s never been an option for me that I won’t take the 
drug or do the surgery until it comes to the fact that I will have to live under a 
bridge to afford it. What’s the point? 
Another patient had a similar experience and she obtained financial assistance 
through a foundation but once the grant money was discontinued, she elected to stop 
taking the drug. This was a decision that was not solely based on cost although cost was a 
major determinant. In her case, she had been experiencing significant fatigue on the drug 
and when she combined that feeling with the high OOP cost, she simply did not want to 
continue the drug and pay for the costs herself. 
Patient 10: I have been pretty good with my Medicare insurance and supplemental 
until my doctor wanted me to take a maintenance medication. Then, I found out 
how much the maintenance medication was going to cost – because that is a pill I 
take every day. I have Part D, but that particular prescription was something I 
needed to get from the specialty pharmacy and not even the preferred pharmacy. 
Initially, it was going to be $13,000 a month. So, I would have had to pay some 
ridiculous amount, thousands of dollars a month as my share. I flipped out! I went 
to the financial counsellor here and she was rather useless. So, I got the 
information and made the calls to get my own grant of money because she was 
too slow. I got a grant of $25,000; it covered the rest of the year. Then, I was 
taking the pill and not doing too well on it and at the same time, I got a letter in 
the mail, post-dated mind you, saying “thanks for being one of our grant 
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recipients but we are pulling the money”. I panicked! I thought they might want 
money back I had already spent on the drug. I was so afraid and so freaked out. 
My throat fills up just thinking about it. I called them and the phone people were 
reading from a script and not helpful. They were wonderful, but it was not their 
fault. It was weighing on me and weighing on me. And the quality of life on the 
drug was not good. And what was I going to do next year without a grant? I talked 
to my friends and family who I knew would understand. I decided to stop taking 
the drug. I just decided that I would take the risk of having a shorter life than 
giving one cent of equity in my house to afford my drugs. I was not going to do 
that! I worked really hard for that. I was not going to use the equity in my house 
or the tiny bit of savings that I have to keep me alive. That is ridiculous!  
OOP can be significant for cancer patients who may also have premiums, 
deductibles, copays, and drug coinsurance (Dixon, Cole, & Dusetzina, 2017). Patients 
stated that they must either fund their OOP costs from savings, home equity, debt, or 
charities. The other option is to forgo the care. For example, patient nine was about to 
start chemotherapy for a breast cancer recurrence and was very concerned about costs. 
She wanted to save money and did research and thought an option might be to forgo 
having a central port inserted. She found that venous access was a possibility and she 
wanted to avoid the surgical costs of the port. She knew from having a port placement 
before that there were surgical visit fees, port placement surgery costs, and follow-up 
visits for post-surgery assessments. With a surgeon consult, the copays were a concern to 
patient nine. Nevertheless, the cancer center team urged her to have the port placed. She 
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was upset when she learned she had to pay a $50 copay to have a port maintenance 
learning session with the nurse because she was experienced and knew how to care for 
her port and did not want to pay for that visit. She did not return to the surgeon to have 
her port stitches removed because she thought she would have to pay for a visit copay but 
learned that it was covered as part of the global surgical costs. The patient exclaimed that 
the costs owed by patients are not clear and trying to manage them can be frustrating and 
confusing.  
Patient 9: So, I get my port and surgeon left the plastic stitches not the dissolvable 
ones and I thought, “I am not going to pay $50 to get my stiches out from the 
surgeon. I will get my nurses at the clinic to do it when I am there for chemo and 
only pay one copay.” But they won’t do it. They said that the surgeon does not 
want them to do it and they tell me it can actually infect and I realize something - 
I am being stubborn about money and this could actually hurt me. So, I call the 
surgeon’s office and ask how much it costs to get the stiches out and they say it 
does not cost anything more; it’s part of your surgery. That’s another thing. How 
do we know how much things cost and what things costs?  
Only one patient said she could afford the massage therapy and physical therapy 
that was recommended but not covered by insurance. Several patients said that they 
believed that they would benefit from these therapies but have not elected to do them 
because of the cost. Another example is that patient one did not followed up on 
recommended care with a rheumatologist because she cannot afford the copay for the 
extra specialist visits beyond her cancer care. If the care is not treatment for the cancer 
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itself, it is more likely to be viewed as optional by the patient and not elected. Even with 
therapy meant to prevent recurrence or maintain remission, patients considered or did 
forgo the treatment, and cost was a primary driver in the decision.  
Evidence of Quality  
To be quality research and to make contributions to the study of the impact of FT 
on advanced cancer patients, a study must demonstrate trustworthiness. It was critical that 
I followed processes and procedures that increased the validity and reliability of the 
results or one might question the results (see Maxwell, 2013; Patton, 2015; Yin, 2003). 
The quality and trustworthiness can be tested by evaluating the credibility, transferability, 
and dependability, and confirmability (see Yin, 2003). 
Process for Credibility  
In my study, I was not able to observe patients while they were making health 
care decisions; I had to ask them to recall their thinking and emotions at the time of the 
decision (see Yin, 2003). I improved the credibility of the study by asking the patient to 
explain the full rationale of their thinking in several situations and asked clarifying 
questions to ensure I understood their explanation. In this study, I looked for cross-case 
pattern alternative explanations. To improve the credibility of the study, I tried to identify 
alternative inference when I was examining themes that I saw in my cross-case patterns. I 
looked for alternative explanations in the data analysis. During the interview phase of the 
study, I kept journals and notes about the interviews, including the emotional context that 
the patient displayed. I noted my bias or emotions since I wanted to ensure I was not 
inserting my bias into study. 
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Process for Transferability 
When a study has transferability, its results may be applicable outside of the study 
(see Yin, 2003). To increase my transferability, I worked to use rich and thick 
descriptions which helped provide a deep contextual frame for the study. My descriptions 
included verbatim text from the patients with advanced cancer, describing their thoughts, 
feelings, actions, and beliefs. 
Process for Dependability 
Dependability in case study methods is achieved when a study can be replicated 
in the future and achieve comparable results (see Yin, 2003). To increase the 
dependability of my study, I documented my study patient recruitment and interview 
operations. I followed my detailed steps for data collection and data collection and 
storage. Moreover, I followed the steps for my coding of the data and data analysis.  
This study used four major forms of data. I relied on patient interviews, field 
notes and observations, the validated and published COST tool, and data artifacts 
supplied by the patients. Taken together, these helped me to establish triangulation in the 
patient experiences between the cases. I was careful to increase the dependability by 
ensuring I kept the results attributed to each individual respondent and followed my 
processes for data management (Appendix I) All data was loaded, stored, and managed in 
the software, Nvivo (Version 11). 
Process for Confirmability 
I helped to enhance the confirmability of my study by using reflectivity. Each 
participant was asked to review the typed transcript of their interview to give me 
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feedback on whether I appropriately collected their information. I sent these transcripts to 
them on email and asked for them to either email me back or call with their thoughts and 
comments. I asked them to check the transcripts for accuracy. Several patients made 
small adjustments to facts. Most stated that the notes were more detailed that they 
thought that they would be and appreciated my focus on the accuracy. They were also 
able to give me feedback if there was any area that they wished for me to elaborate on or 
that they did not wish to have included, for any reason. Patton (2015) suggests that 
qualitative researchers use self-reflection to help examine how the researcher interacted 
with the content of the study, and limit bias. In this manner, I increased the confirmability 
of the study.  
Summary 
My study’s purpose was to understand the experiences of advanced cancer 
patients ‘decision-making and experiences while experiencing financial distress and FT. I 
worked to understand how OOP cancer care costs impacted these patients’ experiences 
and decision-making. In Chapter 4, I discussed the study setting, my community partner 
that helped me to facilitate the research, and how I recruited and secured participants. The 
study followed a purposeful sampling method and I obtained informed consent prior to 
the interviews. 
I organized the discussion of the research findings by the three research questions. 
My first question focused on research participants’ OOP costs that stem from their cancer 
care. Some patients discussed reductions in employment and the impact that had on their 
income and mental health. Patients spoke about the significant impact that a cancer 
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diagnosis had upon their life and most shared that costs for care have been worrisome and 
a source of stress throughout their care. The OOP costs can become significant for some 
patients, even with insurance and coverage for procedures, surgeries, and infused drugs. 
Sometimes financial assistance is a helpful way for patients to manage their financial 
obligations. Even with insurance, several stated that their care would be unaffordable 
without charitable care assistance. 
Research question two centered on the manifestations of FT in patients’ lives, and 
their use of gist and verbatim in medical decisions. Patients shared the deprivations that 
they and their families have used to accommodate the extra costs of cancer care. Patients 
reported the impact of cancer and cancer costs on their relationships with friends and 
family. In addition, patients shared how the experience of paying for cancer care made 
them feel and how this increased their distrust of the health care system profit motives. 
Patients make extensive use of gist in their decisions about health care but often have a 
clear verbatim recall of when OOP costs are mentioned. Patients shared exact dollar 
figures about costs that were shared when a therapy was proposed.  
To address research question three, I captured how patients explained the impact 
of FT into treatment decisions. Patients shared that OOP costs can be a major impact in 
their decisions and how the distress that it caused impacted their decisions.  
In the final section of Chapter 4, I discussed the methods and processes that I 
followed to increase the quality of the study including credibility, transferability, and 
dependability, and confirmability. To improve credibility, I worked to fully understand 
patients’ explanations, asking clarifying questions. I also applied a process of cross-case 
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pattern analysis to provide for the emergence of alternative interpretations. Finally, I used 
journaling to decrease my bias. To increase transferability, I employed the use of thick 
and rich descriptions and direct patient quotes. To improve the dependability of my 
study, I followed a written process for my research participant recruitment and interview 
conduct. I used triangulations from several sources of data including interviews, artifacts, 
and the COST tool. The confirmability of study was maintained by my use of reflectivity 
and full participant review of interview transcripts. 
In Chapter 5, I will provide my insight on the interpretation of my results and the 
limitations of the study. I will examine the recommendations stemming from the study, 
the implications for social change, and my experiences as a researcher in this study. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of this qualitative case study was to understand the experiences of 
advanced cancer patients who are under financial stress to understand how OOP cancer 
care costs impacted these patients’ experiences and decision-making. How patients feel 
and think while experiencing FT and making decisions about their care was central to the 
study. There is little published literature about advanced patients’ experiences and health 
care decision-making thought processes while experiencing FT. Findings may help those 
who care for these patients to develop options to mitigate declines in health outcomes and 
decreased quality of life for patients with FT.  
Three questions framed my study: 
1. What was the experience of advanced cancer patients who experienced 
financial distress stemming from OOP costs of the disease costs of the disease 
treatment? 
2. How did financial toxicity manifest in patients’ lives, and how did patients use 
gist and verbatim as they made medical decisions?  
3. How, if at all, did financial toxicity factor into treatment decisions in patients 
with advanced cancer? 
I used a case study method to design and implement my qualitative research. I 
conducted in-depth in-person or telephone interviews with 13 patients with advanced 
cancer. I recorded all but one of the interviews, and I collected responses on a validated 
COST tool that was used to score FT. I also gathered artifacts and representations of the 
cost of cancer in the patients’ lives to triangulate the data. I transcribed the interviews and 
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used NVivo data analysis software (Version 11) to assist in data management and 
analysis. I used a two-cycle coding process and applied a cross-case analysis to identify 
common and explore infrequent themes.  
In Chapter 5, I provide an interpretation of the results using the themes identified 
in Chapter 4. I also relate these themes to FTT, the theory used in my study. In the next 
sections of Chapter 5, I discuss limitations of my study and recommendations for further 
study. The implications for social change are also included, as well as my personal 
insights from conducting the study. 
Interpretation of Findings 
Demographic Information 
This study included advanced cancer patients who self-identified as being 
concerned about the costs of cancer and who volunteered for the research. Participants 
were from three areas of Colorado. I excluded patients without insurance. The time since 
diagnosis ranged from 6 months to 15 years. Most patients (8) had been under treatment 
for less than 2 years. Most patients lived with a spouse or family member; only two lived 
alone. The most common site of tumor was the breast with six of the 13 patients having a 
primary diagnosis of breast cancer. Of the 13 volunteers, 12 were women. I did not 
exclude any men. Women have been shown to participate in equal proportion to men in 
cancer research (Unger et al., 2013). In the United States, the overall incidence of cancer 
in women is only slightly higher at 50.6% of all cases compared to 49.4% in men (Siegel 
et al., 2018).  
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Employment Status and FT COST Scores 
Most of the participants experienced a change in their ability or willingness to 
work after their diagnosis with cancer. No participant increased her or his work hours 
after diagnosis; only one was still working full time after two years of cancer treatment. 
The others reduced their work schedule or remained retired. This was consistent with the 
national experience of cancer patients who reported loss of income and employment 
(Zajacova et al., 2015). 
The self-assessment of FT was another dimension of the demographics of the 
patient group who participated in the study (de Souza et al., 2016). Each participant took 
the COST assessment and discussed her or his feelings associated with FT during the 
interview. At the time of the interview, five participants were feeling moderate levels of 
FT while five were feeling mild levels. Two participants explained that they were feeling 
no symptoms of FT at the time of interview. One participant shared that he felt high 
levels of FT. During the interview, several participants commented that they had resolved 
some of their anxiety and distress and that their FT score had come down over time.  
Certain events triggered greater recollection of FT for participants in the interview 
including unexpected large OOP costs for a necessary and prescribed therapy, sudden 
loss of benefits for care including loss of charitable foundation funds, and surprise bills in 
the mail from hospitals and providers. Participants relayed feelings of loss of control and 
a need to choose between a therapy important to their ongoing battle against a serious 
diagnosis of cancer and financial stability. These feeling of stress and anxiety can 
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contribute to poorer outcomes for patients with cancer and maladaptive coping strategies 
(Chan, Gordon, Zafar, & Miaskowski, 2018; Delgado-Guay et al., 2015).  
Research Question 1  
Employment Status 
Participants described the years of treatment and disabilities they endured 
resulting from treatment for their advanced cancer. Many had multiple surgeries and 
hospitalizations. Most had undergone long periods of chemotherapy or immunotherapy. 
Advanced cancer is a disease that has a high level of mortality, and the treatments for the 
disease typically involve surgical procedures, radiation therapy, and immune and 
chemotherapy regimens designed to attack the active cancer cells (Masters et al., 2015). 
The treatments are resource intensive and costly, and can lead to considerable recovery 
time for the patient. The impact of the disease and its treatment caused nearly all 
participants who were employed at the time of their diagnosis to either quit their jobs or 
take some form of medical leave. This was consistent with the literature on FT and the 
impact of cancer on patients’ incomes (Jagsi et al., 2014; Zajacova et al., 2015). 
The loss of financial security, independence, and self-worth derived from 
employment was an emotional burden to some of the cancer patients in the study. 
Patients described these dimensions of self-confidence and loss of independence as some 
of the most painful aspects of the cancer diagnosis. The loss of employment contributed 
to FT for patients not only from a financial perspective but also from a self-efficacy and 
mental health perspective.  
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Cancer Diagnosis: A Major Life Event that Triggers Downstream Costs 
Cancer for patients was a tipping point in their lives. The diagnosis meant that 
they immediately moved to active treatment, with all but one having surgery within a few 
weeks of the diagnosis or chemotherapy followed by surgery. These events and the 
diagnostic workup triggered the first wave of costs. Typically, patients described an 
initial numbness and lack of focus on costs of care. The costs were on their minds but the 
devastating nature of their diagnosis coupled by the urgent need for intervention to 
prolong their life outweighed the cost focus.  
As patients progressed through care and began to recover from the initial 
treatments, the costs became more a focus and reality. Patients described opening piles of 
mail from their health care providers and being astounded at the total costs paid by their 
insurance. Patents relayed that there were many unknown costs that came to them during 
this time and that their general reactions were to try to pay them as best as they could 
because not receiving the care was choosing not to live.  
OOP Costs Paid by Patients 
Patients’ insurance provided some degree of protection from OOP costs, 
particularly for those with Medicaid and Medicare supplemental insurance. In those 
cases, most of the routine care and copayments were covered by insurance, and the OOP 
costs were for things stemming from cancer care such as supportive care services or 
transportation. In addition, the cost of the insurance premium was considered a necessary 
monthly OOP cost. For those with commercial insurance plans, there was a higher 
likelihood of OOP costs including copayments, coinsurance, and high deductibles. Most 
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of these costs began to hit immediately following initial treatment, and this group of 
patients reported a higher level of anxiety and distress stemming from these costs. This 
was consistent with the literature on the impact of OOP costs, particularly on those who 
are younger and have commercial insurance (Barber et al., 2016; Jagsi et al., 2014). 
Those with Medicaid also have distress because their costs are largely covered but their 
income is so low that affording the basics of daily life is an ongoing struggle (Ramsey et 
al., 2016).  
Financial Assistance and Charity 
Among all participants except one, access to care associated with high OOP costs 
was obtained with the assistance from charity and foundation grants. One patient had 
household income and savings sufficient to afford the costs of care. Hospital and cancer 
center staff typically introduced these options to patients once therapy program costs 
were explained and patients expressed a concern for affordability. These programs have 
become central vehicles to providing bridge coverage of drugs and services that 
otherwise are not affordable for patients because they are not fully covered by insurance 
(see Nicolla et al., 2017; Yezefski, Schwemm, Lentz, Hone, & Shankaran, 2017; Zafar & 
Peppercorn, 2017b).  
Research Question 2 
Deprivations 
Patients and their families make accommodations in their lives to afford cancer 
care. These coping strategies include changing their spending patterns and reducing 
spending on items that are no longer deemed essential. Participants also expressed that 
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they stopped planning for future expenses like travel or retirement activities. This caused 
disappointment and sadness for the participants who felt that they had worked to maintain 
a lifestyle and future security, which had been eroded by health care costs. These findings 
were consistent with those from recent studies of patients with FT in cancer and coping 
mechanisms (see Head et al., 2018). 
Impact on Friendships and Relationships 
Cancer and its costs impact patients and their families. The costs are often carried 
not only by the patient but also by the spouse and family. This can add stress and strain to 
relationships and cause feelings of anxiety and worry for the whole family. Participants 
described the impact of their family and friends supporting them both financially and 
emotionally, including how their relationships changed as they progressed through 
cancer. Several participants credited their family for providing the stability and support to 
make treatment possible; without them the patients would not have had the resources or 
expertise to navigate the system, find help, and access care. 
These relationships formed a stabilizing force for many cancer patients providing 
them with both financial and emotional support necessary to endure the challenges of 
cancer care. This stabilization provided by family and friends became a source of stress 
when patients felt that they had become a burden to their family or friends who were not 
able to cope with the changes that cancer created. One participant shared that she had 
found it more difficult to be around her friends since being diagnosed with cancer. 
Beyond providing financial protection, supportive friends and family have been identified 
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as a factor for increased resiliency and coping with the stress and distress caused by 
cancer (see Carrera et al., 2018; Kim, Han, Shaw, McTavish, & Gustafston, 2010).  
Distrust of Health Care System Motives 
The system for caring for cancer patients can make some feel as if it is set up to 
profit from their misfortune, and some participants expressed concern that some care may 
be not necessary but is recommended because of a profit motive by health care providers 
and pharmaceutical companies. Although patients expressed distrust of the system, nearly 
all spoke of the deep trust that each had with their individual oncologist. Distrust in 
financial motives is one of several dimensions of trust and is part of a concept called 
values distrust (Yang, Matthews, & Hillemeier, 2011). The patient may feel that ethical 
values, financial motives, and transparency are misaligned. Distrust of the health care 
system in cancer screening is well documented, particularly by those of color and lower 
incomes (Armstrong et al., 2013; Yang et al., 2011). Although researchers have 
documented the erosion of trust in the health care system (Ozawa & Sripad, 2013), there 
is a gap in the literature in understanding the dimensions of mistrust and its impact on 
cancer patients who are experiencing FT. This dimension of the patients’ mindset may 
also impact their medical decision-making in terms of choosing therapies, tests, and 
options and in their compliance with oral therapy regimens.  
How Cancer Costs Make Patients Feel 
Participants described a range of emotional reactions to how cancer costs made 
them feel throughout the course of their care. A common theme was a constant nagging 
worry that plagued participants’ everyday lives and thinking. This worry eroded their 
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psychological well-being and was a constant source of stress. The way patients feel about 
cancer costs and the level of stress changes over time depending on the circumstances. 
Participants cited examples of how cancer costs impacted their lives including not being 
able to provide for their child and losing custody as a result, generating large debts, and 
moving in with others to afford to live. These actions had an emotional strain on 
participants, and their reactions included deep sadness, worry, anger, and fear. Some 
cancelled their plans for travel in their retirement, cut all social engagements, ended 
charitable donations, and lived more simply in the moment, not thinking so much about 
the future. Several patients mentioned the positive aspects of cancer costs on their 
relationships because they realized how much their families supported them financially 
and emotionally.  
Cancer Cost Representation in Their Lives 
Patients shared images and artifacts that represented their experience of cancer 
costs in their lives during the interview. These were powerful and complicated 
discussions, often taking the patient some time to explain why they chose the particular 
image or artifact and how it made them feel. The themes of these artifacts ranged from 
harsh images of destruction and debilitation to images of amulets or ammunition and 
means to keep order in life and fight against the cancer. One patient described cancer 
costs as the constant pull and pounding of the ocean waves taking a swimmer from the 
safety of the shore out to deep waters and drowning them. Another spoke of living in a 
happy snug bubble that is shattered and fractured forever more. An iceberg represents the 
danger of the unknown potential future costs for one patient. Another patient described 
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the file drawer full of paperwork, remittances, bills, and correspondence that came like an 
avalanche into her life after cancer costs began. The drawer and the financial 
maintenance of her care requires her energy and focus to help keep track of all her bills, 
costs, and foundation support and is a constant reminder of the stress of this dimension of 
her care.  
Use of Gist and Verbatim in Health Care Decisions 
There was use of gist and verbatim in decision-making. Decisions were often 
infused with emotion around the grave risks that cancer posed to the patient as well as the 
worry and concern about its affordability. The trust in the medical oncologist was an 
important element in the gist decision-making processes for patients. Patients cited that 
they recalled that the therapy or the surgery was what the doctor thought was best for 
them at the time. This gist recollection is aligned with research around patient health care 
decisions making in situations where risks are high and outcomes uncertain (Reyna et al., 
2015). Nevertheless, patients did have specific verbatim recall of costs of care. In these 
cases, patients recalled the quoted costs that they would be responsible for and the 
resultant decision. If the costs were considered unaffordable, then the patients opted to 
not have the recommended therapy. OOP costs of care in cancer produced a high degree 
of verbatim recall in the patients in this study.  
Research Question 3 
Patients focused their decision-making on selecting the therapy recommended by 
their doctor if the OOP costs were reasonably affordable for them. Patients gave many 
examples of recommended supportive and complementary care including physical 
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therapy, acupuncture, and massage therapy that they believed would benefit them, but 
they did not access due to costs. Only one patient paid OOP for these therapies. Patients 
focused on paying for their cost share on services that treat the cancer and extend their 
life. In three separate patient examples, OOP costs were high for prescribed oral drugs or 
supportive care drugs. In each situation, the patient elected to forgo the drug until a 
foundation offset the cost. These findings are fully consistent with literature  correlating 
higher OOP cancer costs and reduced access to therapy (see Dusetzina, Basch, & 
Keating, 2015; NIH, 2007; Parise & Caggiano, 2013; Puts et al., 2015). Multiple studies 
have confirmed the reduction in access to care when OOP costs increase for cancer 
patients, even with the protection of health insurance affords. 
Theoretical Framework 
I applied FTT as the theoretical framework for this study of decision-making of 
advanced cancer patients. This theory holds that cancer patients use conceptually encoded 
blocks of information that they have gathered in the decision-making process to help 
them in selecting an option (see Reyna et al., 2015). In my study, patients described 
making important and risky choices between full mastectomy or lumpectomy, accepting 
an oral chemotherapy regimen, radiation, or undergoing white blood cell growth 
stimulator therapy as supportive care during high risk chemotherapy treatment. Patients 
described the gist of their decision-making, including the information that their physician 
relayed and why they consented to the option. The FTT theory posits that patients use gist 
as an efficient means to accurately recall and process options and select from alternatives 
(Reyna et al., 2015). My findings that confirm the use of gist information as a means by 
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which patients recalled and processed information. Reyna, et al. (2015) advanced the 
theory that patients overlay their emotions, morals, and judgement with makes for the 
fuzzy nature of gist decision-making (Reyna et al., 2015). My study found that the 
advanced cancer patients did have emotional and moral overlays in their decision-making 
processes. In my study, patients use verbatim to recall FT and costs. Patients who had 
large OPP costs associated with their care had vivid verbatim recall of those costs and 
these dimensions of the decision-making dominated. Even the patient who had no FT, 
when she described shopping for hospice centers, she quoted the per day costs and told 
me that it was an important factor in their decision-making. The hospice cost was not 
covered by insurance but would need to be paid by the patient. In the study, when the 
patient was responsible for a significant cost, and was experiencing FT at the time of the 
decision, the verbatim cost trumped all other decision factors including safety, efficacy, 
and trust in their physician’s recommendation. The patients’ verbatim recall was of 
specific costs for which they were to be responsible and were, at the time deemed to be 
unaffordable by the patient. This produced an immediate decision to either discontinue on 
a therapy or to not select a therapy that may have been the best opportunity for survival 
by the patient. The patients describe great emotional anguish in making these decisions 
but pragmatically describe their rationale.  
This is a significant finding that was not part of past research in cancer decision-
making within the FTT framework. Patient responsibility for cost of care had not been a 
part of past evaluations of decision-making. OOP cost is a significant part of advanced 
cancer patients’ experience and should be considered whenever an evaluation of medical 
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decisions making is applied. Patients in my study commented that their doctor did not 
mention exact costs of care and support staff to handle these discussions. Once 
participants understood the cost, patients began to resist accepting the therapy. One 
patient explained that it does her no good to survive longer with cancer only to become 
bankrupt and homeless as a result. The verbatim OOP costs are a significant determinant 
in advance cancer patients’ medical decision-making.  
Limitations of the Study 
This study is limited by several factors that are inherent in its design and scope. 
The study had a small sample size with patients who had different types of cancer. With 
only 13 study respondents, and nearly all of them women, the study may not represent the 
wide variety of experiences and decision-making that thousands of advanced cancer 
patients have. My study focused on participants from Colorado and one may find that the 
experiences and patients’ views are different in other geographies or more rural 
communities. Cancer is a diverse and broad disease covering hundreds of diagnoses, each 
with a different therapy plan. This variance means that by having patients with different 
diseases, there may be a wide variety of decisions and costs and the range of variance is 
not adequately covered by this study. The sampling methodology was not random and 
does not allow one to extrapolate the findings to a larger sample. Patients who responded 
to the recruitment flier self-identified that they felt concern about the costs of cancer care 
and were willing to discuss their experiences and beliefs. Others who did not respond 
may feel differently and therefore, the sample may have inherent selection bias.  
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Recommendations of the Study 
The study was an in-depth review of how FT impacted advanced cancer patients’ 
lives, families, emotional well-being, and medical decision-making. Although it had 
limitations, it produced an understanding of the impact of OOP cost on insured advanced 
cancer patients. There are five compelling recommendations stemming from this study. 
First, cancer care providers need to continue support patient access to foundations, copay 
programs, and PAPs that help patients afford OOP costs. These foundations and 
programs need to continue to be funded with simplified enrollment processes. Additional 
research into the impact that OOP costs and FT have on the use of gist and verbatim in 
FTT is also be important. A third recommendation is to continue research into the 
dimensions of advanced cancer patients’ trust in the health care system and the extent to 
which that trust is eroded by FT and mistrust in financial motivations. Finally, identifying 
ways to increase patient education and health care literacy may improve patient 
understanding of how insurance works and how to navigate OOP costs. This could lead 
to better levels of action and processes for patients that may reduce FT stress and 
improve outcomes. 
The study uncovered the difficult decisions that patients must make while having 
OOP costs and fighting for their lives against a formidable disease. Patients with 
advanced cancer rely on the support of the cancer care community to guide them through 
care, therapy selection, charitable assistance access, and decisions about therapy 
discontinuation and access to hospice care. Advanced cancer patients are particularly 
vulnerable to increases in OOP benefit designs and rely on insurance to afford life-
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extending therapy. The charitable foundations and PAP that offer financial support for 
patients are critical but the processes to access the help can be difficult for cancer center 
staff and patients (Yezefski et al., 2017; Zafar & Peppercorn, 2017a). These programs, 
while imperfect, do improve access to necessary care but their funding mechanisms are 
dependent on pharmaceutical companies and on the government allowing the 
pharmaceutical companies to continue them. This study underscored the importance of 
pharmaceutical companies and governmental officials preserving these important bridges 
to care for underinsured patients. It also highlighted why it is important that community 
cancer care professionals continue to assist patients to access these programs.  
The study confirmed the FTT and that cancer patients make extensive use of gist 
in decision-making. The research further found that for some patients who are 
experiencing FT and have high OOP costs for a proposed therapy, use verbatim recall of 
specific costs. This verbatim recall becomes the dominant decision factor in whether to 
access the therapy. The identification of the importance of verbatim recall of costs for 
cancer patients should be further explored to better understand how it is used in cancer 
treatment decisions by patients. My findings potentially expand FTT to include FT as a 
prominent issue that may drive greater reliance on verbatim recall over gist when OOP 
costs are perceived by patients to be high. Given the growing impact of consumer cost in 
cancer care, it will be important to expand research into FTT and FT in medical decision-
making to include how patients factor costs into medical decisions.  
A third recommendation is to continue research into the dimensions of advanced 
cancer patients’ trust in the health care system and the extent to which that trust is eroded 
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by patients experiencing FT and mistrust in financial motivations of their health system. 
In the study, patients expressed mistrust in the financial motivations of the health care 
system, particularly when the level of FT was more severe. Therefore, it will be 
important to understand the implications of these dimensions of trust upon patient 
decision-making and access to care. Studies of trust have shown that patients with lower 
levels of trust in the health care system access fewer cancer preventive services and that 
cancer patients are less likely to remain compliant with therapy (Armstrong et al., 2012; 
Yang et al., 2011). Further research into the amplifying effect of FT on health care 
system distrust will be important, especially if effective solutions to help patients with the 
impact of FT on their lives and cancer care are to be found.  
A final recommendation comes from a patient who recommends that the health 
care system prepare and educate its patients on cancer costs. The patient recommends that 
cancer centers offer a class on navigating the cancer treatment costs, dealing with 
insurance companies, finding financial assistance, and planning for costs. Patients could 
benefit by feeling more empowered to handle the confusing paperwork and reduce their 
stress and worry if they better understood what the costs were likely to be, how insurance 
works, and what options are available for help.  
Implications for Social Change of the Study 
This study provided insight into the experiences of patients with advanced cancer 
in Colorado with their cancer care, FT, and their experiences of paying for cancer care. 
Many of the patients expressed their gratitude to me for focusing my research on this 
topic; they believe more can be done to support patients through these difficult times. 
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This study can increase knowledge about how patients who are experiencing FT make 
decisions about cancer care. Because the costs of cancer care are increasing, and patients 
are exposed to even greater OOP, this study can help inform providers, health systems, 
pharmaceutical companies, and payers about the need to support patients who are 
struggling to pay for their OOP cancer costs.  
The important role of copay, PAP, and foundation support for patients was a key 
theme in the research. Insight from my study may help lawmakers and insurance 
companies to develop fair policies to allow continued access to these programs by 
qualified cancer patients. This research can help provide the voice of patient to these 
debates, because often their insights are not part of the discussion. Lawmakers and policy 
makers need to be briefed on the patient perspective in addition to that of the insurance 
company or pharmaceutical company. To amplify the impact of this study, I intend to 
disseminate it and its findings.  
I plan to publish the study results and share it with the cooperating sites and 
patients via presentations, summary reviews, and by speaking at regional and national 
professional conferences. I will submit the study for published in a peer-reviewed journal. 
I will seek venues to educate the pharmaceutical and insurance industry on the impact of 
their policies on cancer patients.  
Summary 
In this study I examined how patients with advanced cancer think, feel and make 
health care decisions while experiencing FT. The research examined the experiences of 
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patients with FT and found that there are significant impacts on patients’ lives, work, 
families, lifestyle, and mental well-being when FT increases.  
In research question 2, I reviewed how FT impacted patients and their use of gist 
and verbatim in medical decision-making. I found that FT had a profound impact on 
patients, especially at certain periods of their lives. I identified that FT impacted patients’ 
trust in the health care system. The impact of FT created a constant worry for many 
advanced cancer patients. I examined how FT could be a key determinant in patients’ 
decisions about cancer care. Using FTT, I confirmed the use of gist in cancer decision-
making and extended my findings to include a strong use of verbatim cost representations 
in decision-making. 
My third research question focused on how FT factored into treatment decisions 
about their cancer treatments. I found that for nearly all the patients in the study, FT had a 
significant impact as OOP increased. The patients did believe that they were fighting for 
their survival and sincerely wanted to access the treatments recommended by their 
doctor, but the treatments needed to be affordable. When the costs of cancer began to 
threaten their everyday living budget, patients began to make decisions to not access the 
care. 
FTT was the theoretical framework that I used to help guide and anchor the 
research. In FTT in cancer, Reyna et al. (2015) found that patients make extensive use of 
gist representations to make decisions involving risks and reward trade-offs for cancer 
care. My research found that patients use gist predominantly in cancer decisions except 
when patients had high OOP and were experiencing FT. In these instances, the patients 
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rely on the verbatim costs associated with the choice and these became the clear 
determinants for selection of care.  
In Chapter 5, I provided a discussion of the recommendation and implications for 
social change from this study. This research provides guidance for additional research 
and helps health care providers, payers, pharmaceutical companies, governmental 
leaders, patients, and families to find ways to cope with the challenges of FT. The study 
will help providers and the cancer community develop effective and meaningful solutions 
to support advanced cancer patients during some of the most stressful times of their lives.  
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Appendix A: Informed Consent Form 
Study #17071  
Protocol Title: Understanding Cancer Patients’ Medical Decision-Making While 
Experiencing Financial Toxicity 
 
Patient Name: 
 
DOB: OR Medical Record/Account #: 
 
 
INFORMED CONSENT PROCESS 
NOTE:  If any of the pre-study assessments are not part of normal patient care, 
INFORMED CONSENT
 
 must be obtained before proceeding with the assessments. 
Informed consent was obtained on (MMDDYY) ______________with version # 
_______ prior to initiating any study procedures on this protocol.  The patient (legal guardian) 
had the opportunity to review the consent and ask questions, and a signed copy was provided to 
him/her. 
 
This version of the consent signed by the patient was  initial or  re-consent.  If re-
consent, does this version replace any versions that have been skipped? 
 NO     YES   If yes, which version? # ________  Please explain why: 
 
 _____________________________________________________________________________  
Additional details regarding the informed consent form process can be documented 
below. (For example, any researcher/participant date differences, any witnesses present, 
the use of a legally authorized representative, etc.): 
 
 _____________________________________________________________________________  
  
NOTE:  Include this form with the source documents. 
 
 
Signature:        Date: 
152 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
Protocol Title: Understanding Cancer Patients’ Medical Decision-Making While 
Experiencing Financial Toxicity 
 
STUDY RESEARCHER: Heather Morel 
 
RESEARCH PARTICIPANT’S NAME:         
 
Introduction: 
You are invited to take part in a research study about how costs of cancer care impact 
cancer patients and their health care decision-making. Patients to be included in the study 
are adult advanced cancer patients who have insurance. This form is part of a process 
called “informed consent” to allow you to understand this study before deciding whether 
to take part. 
 
This study is being conducted by a researcher named Heather Morel. She is a doctoral 
student (studying to obtain a PhD) at Walden University.  
 
Background Information: 
The purpose of this study is to better understand how cancer patients who pay for part of 
their care believe those costs to impact them in their lives and their health care decision-
making. 
 
Number of Participants: 
This study is being conducted at one oncology practice and will enroll approximately 12 
patients. 
 
Procedures: 
If you agree to be in this study, you will be asked to:  
• Participate in a one hour face-to-face interview with the researcher.  This is a one-
time interview.  This will complete your participation in the research study. 
o The researcher will also be making observations and taking notes during 
the interview so the researcher can capture not only what you say, but also 
how you say it with “body language”. 
o The researcher will ask your permission to photograph you. If you agree, 
this photograph will be used by the researcher only to recall the interview 
once all personal information that identifies you has been removed from 
the study data. 
• To the extent that you wish to, share examples of things or paperwork that 
exemplifies your experience with costs of cancer care.  
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o Examples that may be helpful include Explanation of Benefit forms from 
insurance companies, a photograph that represents your experience with 
cancer costs, or other items you feel to be relevant.  
o Original items will be returned and with your permission, copies or 
photographs will be made for the research.  
• If the session can be audio recorded and transcribed to capture all of your 
comments. 
• You will have the opportunity to review the transcription to assure that your 
comments are accurately captured. 
 
Here are some sample questions:  
• How have the costs of care that you have had to pay for (those costs not covered 
by your insurance) impacted you? How has it made you feel? 
• As you know, I am researching the important topic of the affordability of cancer 
care for patients like you, who have a serious diagnosis of cancer and are 
experiencing concern regarding affording their care.  Please tell me about your 
care and the cost associated with care?  
• How have the costs of care that you have had to pay for (those costs not covered 
by your insurance) impacted you? How has it made you feel? 
• What other costs related to your cancer diagnosis, besides the bills that you get for 
your care, are impacting you financially? 
• While making a health care decision, to what extent, if at all, have costs of care 
made you consider not undergoing a treatment, or discontinuing treatment? 
• What was the decision that you were making about your care in which cancer 
costs were a factor?  
o Where did you get information about your choices?  
o Do you recall what you were thinking about in terms of your choice or the 
thoughts you were having while you were making these decisions?  
 
Voluntary Nature of the Study: 
This study is voluntary. You are free to accept or turn down the invitation. No one at your 
doctor’s office will treat you differently if you decide not to be in the study. If you decide 
to be in the study now, you can still change your mind later. You may stop at any time. 
  
Risks and Benefits of Being in the Study: 
Being in this type of study involves some risk of the minor discomforts that can be 
encountered in daily life, such as becoming sad or distressed from discussing these 
topics. Being in this study would not pose risk to your safety or wellbeing. 
 
By participating in this study, you will be helping to provide more information on how 
patients like you experience costs associated with cancer, and the impact on health care 
decision-making. This may help develop future programs and ways to help patients in the 
future. 
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Payment: 
You will receive $80 at the conclusion of the interview to compensate you for your time 
and travel costs.  
 
Confidentiality: 
Agreeing to be in this study gives the researcher your permission to obtain, use, and share 
information about you for this study, and is required in order for you to take part in the 
study. Reports coming out of this study will not share the identities of individual 
participants. Details that might identify participants, such as the location of the study, 
also will not be shared.  The study data collected by the researcher does not include your 
name, address, social security number, phone number or other information that directly 
identifies you.  Instead, upon entry into the study, the researcher will assign a code to 
your study file.  Any data submitted will only identify you by this code and may use your 
initials.  The researcher will not use your personal information for any purpose outside of 
this research project.  
 
Data will be kept secure by using computer security with encryption, password 
protection, use of codes instead of patient names in the report and database, and locked 
file cabinets. Data will be kept for a period of at least 2 years.  
 
Your health and personal information will not be disclosed without your written 
authorization except where permitted by state and federal laws or required by law.  If you 
sign this form, it will provide that authorization.  The form is intended to inform you 
about how your information will be used or disclosed in the study.  Your information will 
only be used in accordance with this authorization and as required or allowed by law. 
Results of this study may be published, or used in discussions after all identifying data 
has been removed.  
 
Your information collected as part of this research, even if identifiers are removed, will 
not be used or distributed for future research studies without your prior written 
permission. 
 
Organizations that may review your information for quality assurance and data analysis, 
as required under the guidelines of the Health Insurance Portability and Accountability 
Act (HIPAA) are this Institutional Review Board, and regulatory agencies, such as U.S. 
Food and Drug Administration (FDA).  These groups will be permitted to review 
information contained in your record that includes your name, inspect and/or copy 
records kept prior to and related to your participation in this study and any of the data 
generated by the study.   
 
Authorization for the uses and disclosures described in this document does not expire 
until the conclusion of any regulatory assessments of the study that may be conducted by 
the United States or any other country. However, California law requires that participants 
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who reside in California be informed that the disclosure of their information has a 
specific end date; this date has been defined as fifty years after the date of this 
authorization. 
 
You may cancel this authorization at any time by providing a written notice to the 
researcher. If you cancel this authorization after you have started in the study, the 
researcher will take all necessary steps to comply with this revocation and no longer use 
or disclose your information in connection with this study.  However, the researcher will 
continue to use information which has already been obtained.  
 
If you cancel this authorization, or do not sign this authorization, you will no longer be 
able to participate in the study.  This is because the researcher would not be able to 
collect the information needed to evaluate how costs of cancer care impact cancer 
patients and their health care decision-making. 
 
Contacts and Questions: 
You may ask any questions you have now. Or if you have questions later, you may 
contact the researcher via 602-697-9255 or via email heather.morel@gmail.com.   
For questions about your rights as a research participant, contact the Institutional Review 
Board which is a group of people of various backgrounds who review research to protect 
your rights at 1-800-381-2637 or 281-863-2406 (ask the receptionist for the IRB 
Coordinator; collect calls will be accepted). The IRB Coordinator will assist you. 
 
The researcher will give you a copy of this form to keep.  
 
Obtaining Your Consent 
 
If you feel you understand the study well enough to make a decision about it, please 
indicate your consent by signing below.  
 
 
Printed Name of Participant  
Date of consent  
Participant’s Signature  
Researcher’s Signature  
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Appendix B: Patient Recruitment Flier 
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Appendix C: Interview Discussion Guide 
Interview opening: 
The researcher will introduce herself and the purpose for the interview. She will thank the 
participant and will review the informed consent document and answer any questions that 
the participant may have. The researcher will obtain consent to audio record the interview 
and audio recording will begin. The researcher will begin to conduct the interview.  
a. Begin with a series of questions to gather some background data on the 
patient, their disease, and their life 
i. What is your full name? 
ii. What city do you live in now? 
iii. Do you live alone or with family? 
iv. Are you currently working outside the home? 
v. Has your employment status changed since you were diagnosed 
with cancer? 
vi. Tell me a bit about your cancer journey? What kind of cancer do 
you have? How long have you been fighting it? 
2. Can you describe the treatments that you’ve had for your cancer? 
3. As you know, I am researching the important topic of the affordability of cancer 
care for patients like you, who have a serious diagnosis of cancer and how those costs 
impact your health care decision-making and your life.  How have the costs of care 
that you have had to pay for (those costs not covered by your insurance) impacted 
you? How has it made you feel? 
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4. What other costs related to your cancer diagnosis, besides the bills that you get for 
your care, are impacting you financially?  
5. Let’s take this COST tool score together and see how you rate your current 
feelings related to cancer costs.  
a. To what extent, if at all, does the score surprise you? Why or why not? 
b. Which of those questions in the COST tool seem to fit with your personal 
experience? Why? 
6. I would like to explore how these feeling about paying for cancer care may impact 
your decisions around your health care choices. Please think back to a recent time 
when you were faced with a choice about your cancer care, or your doctor was 
recommending a treatment for you. Alternatively, if you are making a health care 
decision now, please tell me how, if at all, the concern for paying for your part of care 
impacted your decisions to proceed?  
7. While making a health care decision, to what extent, if at all, have costs of care 
made you considered not undergoing a treatment, or discontinuing treatment? 
8. What was the decision that you were making about your care in which cancer 
costs were a factor?  
a. Where did you get information about your choices?  
b. Do you recall what you were thinking about in terms of your choice or the 
thoughts you were having while you were making these decisions? 
c. Please describe in your own words what were the main concepts or central 
ideas that were the focus of your decision? Do you recall any specific 
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thoughts, numbers, or phrases that helped you in making your decision? If 
so, what were they and why do you think you remember them? 
9. You have brought along some documents to share with me. In setting up our 
interview, I asked you to consider bringing along anything that I might copy and use 
in my research to help me understand what your experience has been in paying for 
and experiencing the cost of cancer on you and your family. Please tell me about what 
you have brought along to share with me.  
a. Why is this significant to you? 
b. What does it represent to you and what should I know about it? 
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Appendix D: COST Tool and Permission for Use 
 
 
Email Permission for Use of COST Tool from Dr. de Souza 
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Appendix E: Protocol for Cancer Center Staff to Disseminate Fliers 
 There is a completely optional research study that is being conducted by a student 
here in this center. The study involves an interview with the researcher and will gather 
your experience with paying for cancer care, the impact of the cost of care on your life, 
and your health care decisions. This research does not involve any drug therapy. This 
study is completely optional.  
To learn more, please contact the researcher with information on this flier.  Hand 
over the flier.  
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Appendix F: Agreement for Transcription Services: TranscribeMe 
IMPORTANT! PLEASE CAREFULLY READ THESE TERMS OF USE AS 
THEY AFFECT YOUR LEGAL RIGHTS AND OBLIGATIONS. 
Please read carefully the following provisions of these Terms of Use (the 
“Agreement” or “Terms of Use”). This is a legal agreement between you and 
TranscribeMe, Inc. (“TranscribeMe”, “we”, or “us) regarding the use of our online 
and/or mobile services, website, and software provided by us (collectively known 
as the “TranscribeMe Service”). By accessing or using the TranscribeMe Service, 
you agree that you have read, understood, and agree to be bound by these 
Terms of Use, whether or not you are a registered user of the TranscribeMe 
Service. 
We reserve the right to amend this Agreement at any time by notifying you as 
provided in this Agreement, provided that no notice shall be required or given for 
non-substantive changes to the Agreement. If we substantively amend This 
Agreement, we will give you at least seven (7) days notice before the changes 
take effect, during which period of time you may reject the changes by 
terminating your account. Your continued use of the TranscribeMe Service after 
any such change takes effect constitutes your acceptance of the new Terms of 
Use. If you do not agree to any of these terms or any future Terms of Use, your 
only remedy shall be to not use or access (or continue to access) the 
TranscribeMe Service. This Agreement applies to all visitors, users, and others 
who access the TranscribeMe Service (“Users”). 
USE OF OUR SERVICE 
1. ELIGIBILITY 
You may use the TranscribeMe Service only if you can form a binding contract 
with TranscribeMe, and only in compliance with this Agreement and all applicable 
local, state, national, and international laws, rules and regulations. If you are 
under 18, your parent or guardian must enter into this Agreement on your behalf, 
and will be responsible for your use of and access to the TranscribeMe Service. 
Any use or access to the TranscribeMe Service by anyone under 13 is prohibited 
and in violation of this Agreement. If you are under 13, please do not attempt to 
register for the TranscribeMe Service or send any information about yourself to 
us, including your name, address, telephone number, or email address. If we 
learn that we have collected personal information from anyone under age 13 
without verification of parental consent, we will delete that information as quickly 
as possible. TranscribeMe reserves all rights not expressly granted under this 
Agreement. Any attempt by you to transfer any of the rights, duties or obligations 
hereunder, except as expressly provided for in this Agreement, is void. 
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2. TRANSCRIBEME ACCOUNT 
You must create an account in order to gain access to the services and 
functionality that we may establish and maintain from time to time and in our sole 
discretion. You may never use another User’s account without permission. You 
are solely responsible for the activity that occurs on your account, and you must 
keep your account password secure. You must notify TranscribeMe immediately 
of any breach of security or unauthorized use of your account. TranscribeMe will 
not be liable for any losses caused by any unauthorized use of your account. 
The TranscribeMe Service is available through Facebook’s “Facebook Connect” 
service, which requires an active Facebook account, and you hereby represent 
and warrant that you have read and agreed to be bound by all applicable 
Facebook policies and will act in accordance with those policies, in addition to 
your obligations under this Agreement. If you access the TranscribeMe Service 
through Facebook Connect, TranscribeMe may require that your TranscribeMe 
user ID be the same as your user name for Facebook. If you sign into 
TranscribeMe through Facebook Connect, you will provide your Facebook 
account credentials to TranscribeMe, and you are consenting to have the 
information in that account transmitted into your TranscribeMe account, and you 
agree that you shall only use Facebook accounts owned by you, and not by any 
other person or entity. 
By providing TranscribeMe your email address, you consent to our using that 
email address to send you TranscribeMe Service-related notices, including any 
notices required by law, in lieu of communication by snail mail. We may also use 
your email address to send you other messages, such as changes to features of 
the TranscribeMe Service and special offers. If you do not want to receive such 
email messages, you may opt out by sending us a request at 
optout@transcribeme.com. Opting out may prevent you from receiving email 
messages regarding updates, improvements, or offers. Please note that if you do 
not want to receive legal notices from us, including without limitation a notice that 
this Agreement has changed, those legal notices will still govern your use of the 
TranscribeMe Service. We will post legal notices to the TranscribeMe Service, 
and you are responsible for reviewing such legal notices for changes. Please see 
our Privacy Policy for more details. 
3. SERVICE RULES 
You agree not to engage in any of the following prohibited activities in connection 
with the TranscribeMe Service: (i) copying, distributing, or disclosing any part of 
the TranscribeMe Service in any medium, including without limitation by any 
automated or non-automated “scraping”; (ii) using any automated system, 
including without limitation “robots,” “spiders,” “offline readers,” etc., to access the 
TranscribeMe Service in a manner that sends more request messages to the 
TranscribeMe servers than a human can reasonably produce in the same period 
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of time by using a conventional on-line web browser; (iii) transmitting spam, chain 
letters, or other unsolicited email; (iv) attempting to interfere with, compromise 
the system integrity or security or decipher any transmissions to or from the 
servers running the TranscribeMe Service; (v) taking any action that imposes, or 
may impose at our sole discretion an unreasonable or disproportionately large 
load on our infrastructure; (vi) uploading invalid data, viruses, worms, or other 
software agents through the TranscribeMe Service; (vii) collecting or harvesting 
any personally identifiable information, including account names, from the 
TranscribeMe Service; (viii) using the TranscribeMe Service for any commercial 
purposes; (ix) impersonating another person or otherwise misrepresenting your 
affiliation with a person or entity, conducting fraud, hiding or attempting to hide 
your identity; (x) interfering with the proper working of the TranscribeMe Service; 
(xi) accessing any content on the TranscribeMe Service through any technology 
or means other than those provided or authorized by the TranscribeMe Service; 
(xii) bypassing the measures we may use to prevent or restrict access to the 
TranscribeMe Service, including without limitation features that prevent or restrict 
use or copying of any content or enforce limitations on use of the TranscribeMe 
Service or the content therein, or (xiii) decompiling, reverse engineering, or 
otherwise attempting to obtain the source code of the TranscribeMe Service. 
You may not access or use the TranscribeMe Service if you work with or for a 
competitor, except with TranscribeMe’s prior written consent. In addition, you 
may not use or access the TranscribeMe Service for purposes of monitoring the 
performance or functionality for a competitor or for any third party, or for any 
other benchmarking or competitive purposes and you may not share any 
benchmarking data regarding the TranscribeMe Service usage with any third 
party without TranscribeMe’s prior written consent. 
We may, without prior notice, change the TranscribeMe Service, stop providing 
the TranscribeMe Service or features of the TranscribeMe Service (to you or 
generally), or create usage limits for the TranscribeMe Service. You agree that 
TranscribeMe has no responsibility or liability for the deletion or failure to store 
any documents, data or other content maintained or uploaded by you to the 
TranscribeMe Service. We may permanently or temporarily terminate or suspend 
your access to the TranscribeMe Service without notice or liability to 
TranscribeMe, for any reason or for no reason, including if in our sole 
determination you violate any provision of this Agreement. Upon termination of 
this Agreement or your access to the TranscribeMe Service for any reason or no 
reason, you will continue to be bound by the terms of this Agreement which, by 
their nature, should survive termination, including without limitation ownership 
provisions, warranty disclaimers, indemnity, and limitations of liability. 
4. USER CONTENT 
You are solely responsible for all audio and other data (“User Content”) that you 
upload, post, publish or display (hereinafter, “upload”) or email or otherwise use 
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via the Service. 
You agree not to upload User Content that: (i) may create a risk of harm, loss, 
physical or mental injury, emotional distress, death, disability, disfigurement, or 
physical or mental illness to you, to any other person; (ii) may create a risk of any 
other loss or damage to any person or property; (iii) seeks to harm or exploit 
children by exposing them to inappropriate content, asking for personally 
identifiable details or otherwise; (iv) may constitute or contribute to a crime or 
tort; (v) contains any information or content that we deem to be unlawful, harmful, 
abusive, racially or ethnically offensive, defamatory, infringing, invasive of 
personal privacy or publicity rights, harassing, humiliating to other people 
(publicly or otherwise), libelous, threatening, profane, obscene, pornographic, or 
otherwise objectionable; (vi) contains any information or content that is illegal 
(including, without limitation, the disclosure of insider information under securities 
law or of another party’s trade secrets); (vii) contains any information or content 
that you do not have a right to make available under any law or under contractual 
or fiduciary relationships; or (viii) contains any information or content that you 
know is not correct and current. You agree that any User Content that you upload 
does not and will not violate third-party rights of any kind, including without 
limitation any Intellectual Property Rights (as defined below) or rights of privacy. 
For the purposes of this Agreement, “Intellectual Property Rights” means all 
patent rights, copyright rights, mask work rights, moral rights, rights of publicity, 
trademark, trade dress and service mark rights, goodwill, trade secret rights and 
other intellectual property rights as may now exist or hereafter come into 
existence, and all applications therefore and registrations, renewals and 
extensions thereof, under the laws of any state, country, territory or other 
jurisdiction. 
In connection with your User Content, you affirm, represent and warrant that your 
User Content and TranscribeMe’s use thereof as contemplated by this 
Agreement and the TranscribeMe Service will not violate any law or infringe any 
rights of any third party, including but not limited to any Intellectual Property 
Rights and privacy rights. 
TranscribeMe takes no responsibility and assumes no liability for any User 
Content that you or any other User or third party posts or sends over the 
TranscribeMe Service. You acknowledge and agree that Transcribme may 
preserve your User Content and may also disclose content if required to do so by 
law or in the good faith belief that such preservation or disclosure is reasonably 
necessary to: (a) comply with legal process, applicable laws or government 
requests; (b) enforce this Agreement; (c) respond to claims that any content 
violates the rights of third parties; or (d) protect the rights, property, or personal 
safety of TranscribeMe, its users and the public. You understand that the 
technical processing and transmission of the TranscribeMe Service, including 
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your content, may involve (a) transmissions over various networks; and (b) 
changes to conform and adapt to technical requirements of connecting networks 
or devices 
By uploading any User Content you hereby grant and will grant TranscribeMe 
and its affiliated companies a nonexclusive, worldwide, royalty free, fully paid up, 
transferable, sublicenseable, perpetual, irrevocable license to copy, display, 
upload, perform, distribute, store, modify and otherwise use your User Content in 
connection with the operation of the TranscribeMe Service, in any form, medium 
or technology now known or later developed. 
5. Digital Millennium Copyright Act 
DMCA Notification. We comply with the provisions of the Digital Millennium 
Copyright Act applicable to Internet service providers (17 U.S.C. §512, as 
amended). If you have an intellectual property rights-related complaint about 
material posted on the TranscribeMe Service, you may contact our Designated 
Agent at the following address: 
TranscribeMe, Inc. 
ATTN: Copyright Notification 
2150 Shattuck Ave, Suite 250 
Berkeley CA 94705, USA 
Email: copyright@transcribeme.com 
Any notice alleging that materials hosted by or distributed through the 
TranscribeMe Service infringe intellectual property rights must include the 
following information: 
a. an electronic or physical signature of the person authorized to act on 
behalf of the owner of the copyright or other right being infringed; 
b. a description of the copyright-protected work or other intellectual property 
right that you claim has been infringed; 
c. a description of the material that you claim is infringing and where it is 
located on the TranscribeMe Service; 
d. your address, telephone number, and email address; 
167 
 
e. a statement by you that you have a good faith belief that the use of those 
materials on the TranscribeMe Service is not authorized by the copyright 
owner, its agent, or the law; and 
f. a statement by you that the above information in your notice is accurate 
and that, under penalty of perjury, you are the copyright or intellectual 
property owner or authorized to act on the copyright or intellectual property 
owner’s behalf. 
Repeat Infringers. TranscribeMe will promptly terminate without notice the 
accounts of users that are determined by TranscribeMe to be “Repeat Infringers.” 
A Repeat Infringer is a user who has been notified of infringing activity or has had 
User Content removed from the TranscribeMe Service at least twice. 
6. CONFIDENTIALITY 
Any materials or data that you provide to TranscribeMe for the purpose of 
providing the TranscribeMe Service will be your “Confidential Information,” 
except to the extent such documents (a) are known to TranscribeMe prior to 
receipt from you from a source other than one having an obligation of 
confidentiality to you; (b) become known (independently of disclosure by you) to 
TranscribeMe directly or indirectly from a source other than one having an 
obligation of confidentiality to you; or (c) become publicly known or otherwise 
cease to be secret or confidential, except through a breach of this Section by 
TranscribeMe. TranscribeMe will use the Confidential Information solely for the 
purpose of providing the TranscribeMe Service to you (the “Permitted Purpose”). 
TranscribeMe will not, without your prior consent, disclose to any third party your 
Confidential Information, other than furnishing such Confidential Information to 
our directors, officers, employees, agents, consultants, contractors, 
representatives or affiliated entities (collectively, “Associated Persons”) who need 
to have access to such Confidential Information in connection with the Permitted 
Purpose. TranscribeMe will use at least reasonable care to protect the 
confidentiality of your Confidential Information. In the event that TranscribeMe is 
required by law to make any disclosure of any of your Confidential Information, 
by subpoena, judicial or administrative order or otherwise, TranscribeMe will use 
commercially reasonable efforts to give you notice of such requirement (to the 
extent legally permissible) and will permit you to intervene in any relevant 
proceedings to protect your interests in your Confidential Information 
7. FEES 
To use the TranscribeMe Service, you will be required to make one or more 
payments and provide us with information regarding your credit card. You 
represent and warrant to TranscribeMe that such information is true and that you 
are authorized to use the payment instrument. You will promptly update your 
account information with any changes (for example, a change in your billing 
address or credit card expiration date) that may occur. You agree to pay 
TranscribeMe the amount that is specified by the TranscribeMe Service in 
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accordance with the terms therein and this Agreement. TranscribeMe reserves 
the right to change our prices. If we change our prices, we will provide notice of 
the change on the TranscribeMe web site or in email to you, at our option. Your 
continued use of the TranscribeMe Service after the price change becomes 
effective constitutes your agreement to pay the changed amount. 
If TranscribeMe agrees, in its sole discretion, to invoice you for your receipt of the 
TranscribeMe Service (rather than requiring you to pay all fees by credit card), 
you must nevertheless provide TranscribeMe with your credit card information 
(as reasonably requested by TranscribeMe) and promptly update such 
information with any changes that may occur. If you fail to pay any invoices within 
30 days of the date of the invoice, TranscribeMe will notify you by email of the 
overdue charge and, if the invoice remains unpaid, TranscribeMe will charge 
your credit card the full amount owing under the invoice on the 35th day following 
the date of the invoice. You hereby authorize us to charge any such overdue 
amounts to your credit card on file and acknowledge that TranscribeMe may 
suspend its provision to you of the TranscribeMe Service if any amounts remain 
unpaid. You may be required to pay all subsequent fees by credit card if you fail 
to pay an invoice within 35 days of the invoice date. TranscribeMe will only 
remove a credit card on file at your request if your account balance is $0 and 
there are no TranscribeMe Services pending for you. 
END USER LICENSE GRANT 
8. TRANSCRIBEME SERVICE 
Subject to the terms and conditions of this Agreement, you are hereby granted a 
non-exclusive, limited, non-transferable, freely revocable license to use the 
TranscribeMe Service for your personal, non-commercial use, as permitted by 
the features of the TranscribeMe Service. TranscribeMe reserves all rights not 
expressly granted herein in the TranscribeMe Service and the TranscribeMe 
Content (as defined below). TranscribeMe may terminate this license at any time 
for any reason or no reason. 
9. MOBILE SOFTWARE 
We may make available software to access the TranscribeMe Service via a 
mobile device (“Mobile Software”). To use the Mobile Software you must have a 
mobile device that is compatible with the Mobile TranscribeMe Service. 
TranscribeMe does not warrant that the Mobile Software will be compatible with 
your mobile device. TranscribeMe hereby grants you a non-exclusive, non-
transferable, revocable license to use a compiled code copy of the Mobile 
Software for one TranscribeMe account on one mobile device owned or leased 
solely by you, for your personal, non-commercial use. You may not: (i) modify, 
disassemble, decompile or reverse engineer the Mobile Software, except to the 
extent that such restriction is expressly prohibited by law; (ii) rent, lease, loan, 
resell, sublicense, distribute or otherwise transfer the Mobile Software to any 
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third party or use the Mobile Software to provide time sharing or similar services 
for any third party; (iii) make any copies of the Mobile Software; (iv) remove, 
circumvent, disable, damage or otherwise interfere with security-related features 
of the Mobile Software, features that prevent or restrict use or copying of any 
content accessible through the Mobile Software, or features that enforce 
limitations on use of the Mobile Software; or (v) delete the copyright and/or other 
proprietary rights notices on the Mobile Software. You acknowledge that 
TranscribeMe may from time to time issue upgraded versions of the Mobile 
Software, and may automatically electronically upgrade the version of the Mobile 
Software that you are using on your mobile device. You consent to such 
automatic upgrading on your mobile device, and agree that the terms and 
conditions of this Agreement will apply to all such upgrades. Any third-party code 
that may be incorporated in the Mobile Software is covered by the applicable 
open source or third-party license EULA, if any, authorizing use of such code. 
The foregoing license grant is not a sale of the Mobile Software or any copy 
thereof, and TranscribeMe or its third party partners or suppliers retain all right, 
title, and interest in the Mobile Software (and any copy thereof). 
10. MOBILE SOFTWARE FROM APPLE APP STORE 
This paragraph is intended to apply to you if you have downloaded the Mobile 
Software from the Apple App Store. TranscribeMe and you acknowledge that this 
Agreement is concluded between TranscribeMe and you only, and not with Apple 
Inc. (“Apple”), and as between TranscribeMe and Apple, TranscribeMe, not 
Apple, is solely responsible for the Software and TranscribeMe Services and the 
content thereof. You acknowledge that Apple, Inc. has no obligation whatsoever 
to furnish any maintenance and support services with respect to the Mobile 
Software. You acknowledge that you have reviewed the App Store Terms and 
Conditions (located online 
at http://www.apple.com/legal/itunes/us/terms.html#APPS). You represent and 
warrant that (i) you are not located in a country that is subject to a U.S. 
Government embargo, or that has been designated by the U.S. Government as a 
“terrorist supporting” country; and (ii) You are not listed on any U.S. Government 
“watch list” of prohibited or restricted parties, including the Specially Designated 
Nationals list published by the Office of Foreign Assets Control of the U.S. 
Treasury or the Denied Persons List published by the U.S. Department of 
Commerce. 
This Agreement incorporates by reference the Licensed Application End User 
License Agreement (the “LAEULA”) published by Apple, Inc. (located online 
at http://www.apple.com/legal/itunes/appstore/dev/stdeula/). For purposes of this 
Agreement, the “Mobile Software” is considered the “Licensed Application” as 
defined in the LAEULA and “TranscribeMe” is considered the “Application 
Provider” as defined in the LAEULA. If any terms of this Agreement conflict with 
the terms of the LAEULA, the terms of this Agreement shall control. 
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11. MOBILE SOFTWARE FROM GOOGLE ANDROID MARKET 
This paragraph is intended to apply to you if you have downloaded the Mobile 
Software on a device powered by the Android operating system. TranscribeMe 
and you, the end‐user of the Mobile Software and TranscribeMe Services, 
acknowledge that the Agreement is entered into by and between TranscribeMe 
and you. TranscribeMe is solely responsible for the Software and TranscribeMe 
Services. Should you have downloaded the Software from the Google Android 
Market located online at https://play.google.com/store. You acknowledge that you 
have reviewed the Android Market Terms of Service (located online 
at https://play.google.com/about/play-terms.html) and the Android Market 
Business and Program Policies (located online 
at http://play.google.com/about/play-terms.html). You represent and warrant that 
(i) you are not located in a country that is subject to a U.S. Government embargo, 
or that has been designated by the U.S. Government as a “terrorist supporting” 
country; and (ii) you are not listed on any U.S. Government “watch list” of 
prohibited or restricted parties, including the Specially Designated Nationals list 
published by the Office of Foreign Assets Control of the U.S. Treasury or the 
Denied Persons List published by the U.S. Department of Commerce. 
12. TRANSCRIBEME PROPRIETARY RIGHTS 
Except for your User Content, the TranscribeMe Service and all materials therein 
or transferred thereby, including, without limitation, software, images, text, 
graphics, illustrations, logos, patents, trademarks, service marks, copyrights, 
photographs, audio, videos, music, and User Content (the “TranscribeMe 
Content”), and all Intellectual Property Rights related thereto, are the exclusive 
property of TranscribeMe and its licensors. Except as explicitly provided herein, 
nothing in this Agreement shall be deemed to create a license in or under any 
such Intellectual Property Rights, and you agree not to sell, license, rent, modify, 
distribute, copy, reproduce, transmit, publicly display, publicly perform, publish, 
adapt, edit or create derivative works from any materials or content accessible on 
the TranscribeMe Service. Use of the TranscribeMe Content or materials on the 
TranscribeMe Service for any purpose not expressly permitted by this Agreement 
is strictly prohibited. 
13. PREMIUM SERVICES 
From time to time, TranscribeMe may provide additional features and/or 
TranscribeMe Services that you pay for (“Premium TranscribeMe Services”). 
TranscribeMe may also offer from time to time in its sole discretion, certain 
Premium TranscribeMe Services for free, whether for a trial period or otherwise. 
Unless expressly stated otherwise, references in this Agreement to the 
TranscribeMe Service include the Premium TranscribeMe Services. 
14. PRIVACY 
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For information about how TranscribeMe protects your privacy, please read 
the TranscribeMe Privacy Policy. This policy explains how TranscribeMe treats 
your personal information, and protects your privacy, when you use the 
TranscribeMe Service. 
 
15. DELIVERY TERMS OF SERVICE 
TranscribeMe will undertake service delivery to complete the assigned work in 
the shortest amount of time possible. Where time commitments are explicitly 
agreed on, the time indicated is confined to business days only in the Pacific 
Standard Timezone. For example, 24 hour delivery equates to 1 business day, 
48 hour delivery equates to 2 business days and so forth. Our standard hours of 
service are 8am to 6pm Monday-Friday, Pacific Standard time. Additional support 
hours and after-hour service is available by inquiry. Transcripts will be returned 
back to the users 
16. TRANSCRIPTION OUTPUT STYLE 
TranscribeMe provides output in “clean verbatim”, “full verbatim”, and “edited 
text” transcriptions. The “clean verbatim” is the default style choice, and 
automatically removes “umms”, “ahhs”, “likes”, “you knows”, and other filler word 
in addition to stuttering from the final transcript. The “edited text” transcripts go 
beyond clean verbatim transcripts and improve on grammar to make a transcript 
more readable. We consider these transcripts as publishable and this option is 
frequently used by bloggers, podcasters and conference speakers. Full verbatim 
transcripts capture speech exactly how it sounds, including all filler words and 
speech errors. 
17. SECURITY 
TranscribeMe cares about the integrity and security of your personal information. 
However, we cannot guarantee that unauthorized third parties will never be able 
to defeat our security measures or use your personal information for improper 
purposes. You acknowledge that you provide your personal information at your 
own risk. 
18. THIRD PARTY LINKS 
The TranscribeMe Service may contain links to third-party websites, advertisers, 
services, special offers, or other events or activities that are not owned or 
controlled by TranscribeMe. TranscribeMe does not endorse or assume any 
responsibility for any such third-party sites, information, materials, products, or 
services. If you access a third party website from the TranscribeMe Service, such 
as through Facebook Connect, you do so at your own risk, and you understand 
that this Agreement and TranscribeMe’s Privacy Policy do not apply to your use 
of such sites. You expressly relieve TranscribeMe from any and all liability arising 
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from your use of any third-party website, service, or content. Additionally, your 
dealings with or participation in promotions of advertisers found on the 
TranscribeMe Service, including payment and delivery of goods, and any other 
terms (such as warranties) are solely between you and such third parties. You 
agree that TranscribeMe shall not be responsible for any loss or damage of any 
sort relating to your dealings with such third parties. 
19. INDEMNITY 
You agree to defend, indemnify and hold harmless TranscribeMe and its 
subsidiaries, agents, licensors, managers, and other affiliated companies, and 
their employees, contractors, agents, officers and directors (collectively, the 
“TranscribeMe Parties”), from and against any and all claims, damages, 
obligations, losses, liabilities, costs or debt, and expenses (including but not 
limited to attorney’s fees) arising from: (i) your use of and access to the 
TranscribeMe Service, including any data or content transmitted or received by 
you; (ii) your violation of any term of this Agreement, including without limitation 
your breach of any of the representations and warranties you make in this 
Agreement; (iii) your violation of any third-party right, including without limitation 
any right of privacy or Intellectual Property Rights; (iv) your violation of any 
applicable law, rule or regulation; (v) any claim or damages that arise as a result 
of any of your User Content or any that is submitted via your account; or (vi) any 
other party’s access and use of the TranscribeMe Service with your username, 
password or other appropriate security code. 
20. NO WARRANTY 
THE TRANSCRIBEME SERVICE AND ANY PRODUCT OR SERVICE YOU 
PURCHASE THROUGH THE TRANSCRIBEME SERVICE (“PRODUCT”) ARE 
PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. USE OF THE 
SERVICE IS AT YOUR OWN RISK. TO THE MAXIMUM EXTENT PERMITTED 
BY APPLICABLE LAW, THE TRANSCRIBEME SERVICE AND THE 
PRODUCTS ARE PROVIDED WITHOUT WARRANTIES OF ANY KIND, 
WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, 
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A 
PARTICULAR PURPOSE, OR NON-INFRINGEMENT. WITHOUT LIMITING 
THE FOREGOING, TRANSCRIBEME, ITS SUBSIDIARIES, AND ITS 
LICENSORS DO NOT WARRANT THAT THE CONTENT IS ACCURATE, 
RELIABLE OR CORRECT; THAT THE TRANSCRIBEME SERVICE OR THE 
PRODUCTS WILL MEET YOUR REQUIREMENTS; THAT THE SERVICE WILL 
BE AVAILABLE AT ANY PARTICULAR TIME OR LOCATION, 
UNINTERRUPTED OR SECURE; THAT ANY DEFECTS OR ERRORS WILL BE 
CORRECTED; OR THAT THE SERVICE IS FREE OF VIRUSES OR OTHER 
HARMFUL COMPONENTS. ANY CONTENT DOWNLOADED OR OTHERWISE 
OBTAINED THROUGH THE USE OF THE TRANSCRIBEME SERVICE IS 
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DOWNLOADED AT YOUR OWN RISK AND YOU WILL BE SOLELY 
RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER SYSTEM OR 
LOSS OF DATA THAT RESULTS FROM SUCH DOWNLOAD OR YOUR USE 
OF THE TRANSCRIBEME SERVICE. 
TRANSCRIBEME DOES NOT WARRANT, ENDORSE, GUARANTEE, OR 
ASSUME RESPONSIBILITY FOR ANY PRODUCT OR SERVICE ADVERTISED 
OR OFFERED BY A THIRD PARTY THROUGH THE TRANSCRIBEME 
SERVICE OR ANY HYPERLINKED WEBSITE OR SERVICE, AND 
TRANSCRIBEME WILL NOT BE A PARTY TO OR IN ANY WAY MONITOR 
ANY TRANSACTION BETWEEN YOU AND THIRD-PARTY PROVIDERS OF 
PRODUCTS OR SERVICES. 
IF YOU DOWNLOADED THE MOBILE SOFTWARE FROM THE APPLE APP 
STORE, YOU FURTHER ACKNOWLEDGE THAT APPLE HAS NO 
RESPONSIBILITY FOR ADDRESSING ANY CLAIMS RELATING TO THE 
SOFTWARE OR TRANSCRIBEME SERVICES OR YOUR POSSESSION 
AND/OR USE OF THE SOFTWARE OR TRANSCRIBEME SERVICES, 
INCLUDING, BUT NOT LIMITED TO: (I) PRODUCT LIABILITY CLAIMS; (II) 
ANY CLAIM THAT THE SOFTWARE OR TRANSCRIBEME SERVICES FAIL TO 
CONFORM TO ANY APPLICABLE LEGAL OR REGULATORY REQUIREMENT; 
AND (III) CLAIMS ARISING UNDER CONSUMER PROTECTION OR SIMILAR 
LEGISLATION. 
21. LIMITATION OF LIABILITY 
IN NO EVENT SHALL THE TRANSCRIBEME PARTIES BE LIABLE, WHETHER 
BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR ANY OTHER 
LEGAL THEORY, FOR ANY LOSSES, LIABILITIES, CLAIMS OR DAMAGES 
OF ANY KIND, WHETHER DIRECT, INDIRECT, INCIDENTAL, 
CONSEQUENTIAL, SPECIAL OR PUNITIVE, OR FOR LOSS OF REVENUE OR 
PROFITS, LOSS OF BUSINESS, OR ANY OTHER DAMAGES, ARISING OUT 
OF OR IN CONNECTION WITH THE SOFTWARE AND/OR ANY OF THE 
TRANSCRIBEME SERVICES, THESE TERMS OF USE OR THE 
PERFORMANCE, SUSPENSION, TERMINATION OR BREACH HEREOF, 
EVEN IF TRANSCRIBEME OR ANY OTHER TRANSCRIBEME PARTY HAS 
BEEN ADVISED OF THE POSSIBILITY THEREOF. THE TRANSCRIBEME 
PARTIES SHALL HAVE NO LIABILITY IN CONNECTION WITH OR ARISING 
FROM THESE TERMS OF USE OR USE OF THE SOFTWARE OR ANY OF 
THE TRANSCRIBEME SERVICES. SOME JURISDICTIONS DO NOT ALLOW 
THE LIMITATION OF LIABILITY FOR PERSONAL INJURY, OR OF 
INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THIS LIMITATION MAY 
NOT APPLY TO YOU. IN NO EVENT SHALL TRANSCRIBEME’S (OR APPLE’S 
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IF YOU DOWNLOADED THE SOFTWARE FROM THE APPLE APP STORE) 
TOTAL LIABILITY TO YOU FOR ALL DAMAGES (OTHER THAN AS MAY BE 
REQUIRED BY APPLICABLE LAW IN CASES INVOLVING PERSONAL 
INJURY) EXCEED THE AMOUNT YOU HAD PAID TO TRANSCRIBEME OVER 
THE PRECEDING THREE MONTHS PERIOD. 
THE FOREGOING LIMITATIONS WILL APPLY EVEN IF THE ABOVE STATED 
REMEDY FAILS OF ITS ESSENTIAL PURPOSE. THESE LIMITATIONS OF 
LIABILITY ALSO APPLY WITH RESPECT TO DAMAGES INCURRED BY YOU 
BY REASON OF ANY PRODUCTS OR TRANSCRIBEME SERVICES SOLD OR 
PROVIDED BY THIRD PARTIES OTHER THAN TRANSCRIBEME AND 
RECEIVED THROUGH OR ADVERTISED ON ANY OF THE TRANSCRIBEME 
SERVICES. YOU AGREE THAT IN THE EVENT YOU INCUR ANY DAMAGES, 
LOSSES OR INJURIES THAT ARISE OUT OF TRANSCRIBEME ACTS OR 
OMISSIONS, THE DAMAGES, IF ANY, CAUSED TO YOU ARE NOT 
IRREPARABLE OR SUFFICIENT TO ENTITLE YOU TO AN INJUNCTION 
PREVENTING ANY EXPLOITATION OF ANY WEB SITE, PROPERTY, 
PRODUCT, SERVICE, OR OTHER MATERIALS OWNED OR CONTROLLED 
BY THE TRANSCRIBEME PARTIES, AND YOU WILL HAVE NO RIGHTS TO 
ENJOIN OR RESTRAIN THE DEVELOPMENT, PRODUCTION, 
DISTRIBUTION, ADVERTISING, EXHIBITION OR EXPLOITATION OF ANY 
WEB SITE, PROPERTY, PRODUCT, SERVICE, OR OTHER MATERIALS 
OWNED OR CONTROLLED BY THE TRANSCRIBEME PARTIES. 
SOME COUNTRIES DO NOT ALLOW THE LIMITATION OR EXCLUSION OF 
LIABILITY IN CONTRACTS WITH CONSUMERS AND AS A RESULT THE 
CONTENTS OF THIS SECTION MAY NOT APPLY TO YOU. 
GENERAL 
22. GOVERNING LAW AND JURISDICTION 
This Agreement shall be governed by and construed under the laws of the State 
of California, excluding that body of law related to choice of laws, and of the 
United States of America. If a lawsuit or court proceeding is permitted under 
these Terms of Use, any such lawsuit or court proceeding shall be brought in the 
County of Santa Clara, State of California (if under State law) or the Northern 
District of California (if under Federal law), and each of the parties hereby 
submits itself to the exclusive jurisdiction and venue of such courts for purposes 
of any such action, and waives any jurisdictional, venue, or inconvenient forum 
objections to such courts. If you refuse or otherwise fail to fulfill any of your 
material obligations pursuant to this Agreement, including, without limitation, any 
indemnity obligation hereunder, TranscribeMe shall be entitled, in addition to any 
other rights and remedies available to it hereunder or otherwise at law or in 
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equity, to reimbursement for its costs and expenses (including court costs and 
reasonable fees for attorneys and expert witnesses) incurred with respect to 
bringing and maintaining any legal action regarding any such matter; and (iii) any 
claim or legal action initiated by you must be brought individually and shall not be 
consolidated as part of a group or class action lawsuit. 
23. Dispute Resolution and Arbitration 
a. Generally. In the interest of resolving disputes between you and 
TranscribeMe in the most expedient and cost effective manner, you and 
TranscribeMe agree that every dispute arising in connection with these 
Terms of Use will be resolved by binding arbitration. Arbitration is less 
formal than a lawsuit in court. Arbitration uses a neutral arbitrator instead of 
a judge or jury, may allow for more limited discovery than in court, and can 
be subject to very limited review by courts. Arbitrators can award the same 
damages and relief that a court can award. This agreement to arbitrate 
disputes includes all claims arising out of or relating to any aspect of these 
Terms of Use, whether based in contract, tort, statute, fraud, 
misrepresentation, or any other legal theory, and regardless of whether a 
claim arises during or after the termination of these Terms of Use. YOU 
UNDERSTAND AND AGREE THAT, BY ENTERING INTO THESE 
TERMS, YOU AND KABUNI ARE EACH WAIVING THE RIGHT TO A 
TRIAL BY JURY OR TO PARTICIPATE IN A CLASS ACTION. 
b. Exceptions. Despite the provisions of Section 23.a., nothing in these 
Terms of Use will be deemed to waive, preclude, or otherwise limit the right 
of either party to: (a) bring an individual action in small claims court; (b) 
pursue an enforcement action through the applicable federal, state, or local 
agency if that action is available; (c) seek injunctive relief in a court of law; 
or (d) to file suit in a court of law to address an intellectual property 
infringement claim. 
c. Arbitrator. Any arbitration between you and TranscribeMe will be settled 
under the Federal Arbitration Act, and governed by the Commercial Dispute 
Resolution Procedures and the Supplementary Procedures for Consumer 
Related Disputes (collectively, “AAA Rules”) of the American Arbitration 
Association (“AAA”), as modified by these Terms of Use, and will be 
administered by the AAA. The AAA Rules and filing forms are available 
online at www.adr.org, by calling the AAA at 1-800-778-7879, or by 
contacting TranscribeMe. 
d. Notice; Process. A party who intends to seek arbitration must first send a 
written notice of the dispute to the other party by certified U.S. Mail or by 
Federal Express (signature required) or, only if such other party has not 
provided a current physical address, then by electronic mail (“Notice”). 
TranscribeMe’s address for Notice is: TranscribeMe, Inc., 2150 Shattuck 
Ave, Suite 250, Berkeley CA 94705, USA. The Notice must: (a) describe 
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the nature and basis of the claim or dispute; and (b) set forth the specific 
relief sought (“Demand”). The parties will make good faith efforts to resolve 
the claim directly, but if the parties do not reach an agreement to do so 
within 30 days after the Notice is received, you or TranscribeMe may 
commence an arbitration proceeding. During the arbitration, the amount of 
any settlement offer made by you or TranscribeMe must not be disclosed to 
the arbitrator until after the arbitrator makes a final decision and award, if 
any. If the dispute is finally resolved through arbitration in your favor, 
TranscribeMe will pay you the highest of the following: (i) the amount 
awarded by the arbitrator, if any; (ii) the last written settlement amount 
offered by TranscribeMe in settlement of the dispute prior to the arbitrator’s 
award; or (iii) $1,000. 
e. Fees. If you commence arbitration in accordance with these Terms of 
Use, TranscribeMe will reimburse you for your payment of the filing fee, 
unless your claim is for more than $10,000, in which case the payment of 
any fees will be decided by the AAA Rules. Any arbitration hearing will take 
place at a location to be agreed upon in Newcastle County, Delaware, but if 
the claim is for $10,000 or less, you may choose whether the arbitration will 
be conducted: (a) solely on the basis of documents submitted to the 
arbitrator; (b) through a non-appearance based telephone hearing; or (c) by 
an in-person hearing as established by the AAA Rules in the county (or 
parish) of your billing address. If the arbitrator finds that either the 
substance of your claim or the relief sought in the Demand is frivolous or 
brought for an improper purpose (as measured by the standards set forth in 
Federal Rule of Civil Procedure 11(b)), then the payment of all fees will be 
governed by the AAA Rules. In that case, you agree to reimburse 
TranscribeMe for all monies previously disbursed by it that are otherwise 
your obligation to pay under the AAA Rules. Regardless of the manner in 
which the arbitration is conducted, the arbitrator must issue a reasoned 
written decision sufficient to explain the essential findings and conclusions 
on which the decision and award, if any, are based. The arbitrator may 
make rulings and resolve disputes as to the payment and reimbursement of 
fees or expenses at any time during the proceeding and upon request from 
either party made within 14 days of the arbitrator’s ruling on the merits. 
f. No Class Actions. YOU AND TRANSCRIBEME AGREE THAT EACH 
MAY BRING CLAIMS AGAINST THE OTHER ONLY IN YOUR OR ITS 
INDIVIDUAL CAPACITY AND NOT AS A PLAINTIFF OR CLASS 
MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE 
PROCEEDING. Further, unless both you and TranscribeMe agree 
otherwise, the arbitrator may not consolidate more than one person’s 
claims, and may not otherwise preside over any form of a representative or 
class proceeding. 
g. Modifications to this Arbitration Provision. If TranscribeMe makes any 
future change to this arbitration provision, other than a change to 
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TranscribeMe’s address for Notice, you may reject the change by sending 
us written notice within 30 days of the change to TranscribeMe’s address 
for Notice, in which case your account with TranscribeMe will be 
immediately terminated and this arbitration provision, as in effect 
immediately prior to the changes you rejected will survive. 
h. Enforceability. If Section 23.f. is found to be unenforceable or if the 
entirety of this Section 23 is found to be unenforceable, then the entirety of 
this Section 23 will be null and void and, in that case, the parties agree that 
the exclusive jurisdiction and venue described in Section 22 will govern any 
action arising out of or related to these Terms of Use. 
24. NOTICE TO CALIFORNIA USERS 
Pursuant to California Civil Code Section 1789.3, California users of 
TranscribeMe Service are entitled to the following specific consumer rights 
notice: The Complaint Assistance Unit of the Division of Consumer Services of 
the California Department of Consumer Affairs may be contacted in writing at 
1625 North Market Blvd., Suite N 112, Sacramento, CA 95834, or by telephone 
at (800) 952-5210. TranscribeMe’s mailing address and email address can be 
found in the Contact Us section of this Agreement. 
25. ENTIRE AGREEMENT / SEVERABILITY 
This Agreement, together with any amendments and any additional agreements 
you may enter into with TranscribeMe in connection with the TranscribeMe 
Service, shall constitute the entire agreement between you and TranscribeMe 
concerning the TranscribeMe Service. If any provision of this Agreement is 
deemed invalid by a court of competent jurisdiction, the invalidity of such 
provision shall not affect the validity of the remaining provisions of this 
Agreement, which shall remain in full force and effect. 
26. NO WAIVER 
No waiver of any term of this Agreement shall be deemed a further or continuing 
waiver of such term or any other term, and TranscribeMe’s failure to assert any 
right or provision under this Agreement shall not constitute a waiver of such right 
or provision. 
27. THIRD PARTY BENEFICIARIES AND AGREEMENTS 
If you downloaded the Mobile Software from the Apple App Store, you 
acknowledge and agree that Apple, and Apple’s subsidiaries, are third party 
beneficiaries of this Agreement, and that, upon your acceptance of the terms and 
conditions of this Agreement, Apple will have the right (and will be deemed to 
have accepted the right) to enforce this Agreement against you as a third party 
beneficiary hereof. You agree to comply with, and your license to use the Mobile 
Software and TranscribeMe Service is conditioned upon your compliance with, all 
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applicable third-party terms of agreement, as may be applicable, when using the 
Mobile Software and/or TranscribeMe Service. 
28. ASSIGNMENT 
This Agreement, and any rights and licenses granted hereunder, may not be 
transferred or assigned by you, but may be assigned by TranscribeMe without 
restriction or notice. 
29. NOTICES 
We may provide notices, whether such notices are required by law or are for 
marketing or other business related purposes, to you via email notice, written or 
hard copy notice, or through posting of such notice on our website, Apple App 
Store or Google Android Marketplace, as determined by us in our sole discretion. 
We reserve the right to determine the form and means of providing notifications 
to our Users, provided that you may opt out of certain means of notification as 
described in this Agreement. 
30. CONTACT US 
Should you wish to contact us with any questions, complaints or claims with 
respect to the TranscribeMe Service, you should visit the TranscribeMe website 
at www.transcribeme.com, by mail at 2150 Shattuck Ave, Suite 250, Berkeley CA 
94705, USA or email at support@transcribeme.com. 
These terms of service were last amended on May 26, 2016. 
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Appendix G: Honoraria Receipt 
I, _________________________ have received an Honoraria of $80.00 for participation 
in research conducted by Heather Morel, Student at Walden University. 
 
_______________________________________ Date: _________________________ 
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Appendix H: Interview Protocol 
1) Interview Set Up Procedures 
a) Meet with center staff to explain study purpose and methodology, and procedures 
for flier dissemination – either by email, mail, or in-person dissemination (See 
Appendix E) 
b) Researcher returns emails and /or calls potential participant, discusses the study 
and purpose, commitment and answers any questions. Sets up interview if 
participant is able and willing. 
c) Send consent form to participant by email or mail.  
d) Most interviews will be conducted in a private room at the cancer center although 
some may be completed in a quiet corner of the infusion room while a patient has 
therapy, if more convenient.  
e) Researcher explains to patient to bring any artifacts representative of the patient’s 
experience with FT and how they think about its impact on their lives and health 
care decision-making. 
2) On site interview procedures for the procedure 
a) Researcher will arrive early and make observations on the interview setting.  
b) Greet patient, welcome them to the interview and introduce myself. 
c) Describe the process of the interview, how I will safeguard their private and 
confidential information.  
d) Show them the informed consent and ask them to sign it. 
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e) Ask if I can audio record the interview so I can concentrate on the conversation 
and not trying to write all their words down. 
f) Ask if I may take a photograph of them.  
g) Transition to discussion guide (Appendix A.) questions 
3) Interview close down procedures 
a) In a few days, I would like to get your feedback on the transcript that I will make 
from our interview today. Could I email it to you to read over and if you find that 
there are things you would like to further explain or that I may not have captured 
accurately, you can call me or email me we can adjust it?  
b) Thank you very much for taking time with me today. I am providing you an $80 
honorarium for your time and travel expenses. Do you mind signing a receipt for 
the honoraria? 
 
